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The most recent projections in the growing obesity rates across the nation show an
increase to 60% by the year 2030. These growing rates of obesity are paralleled by an
increased rates of depressive conditions, anxiety, and sleep loss, often with environmental
factors at the root of the cause. Stress and the stress response is a dynamic system that
reflects one’s ability to cope with events, behaviorally or physiologically, as stressors
occur over a lifetime. While many key players mediate the effects of stress exposure on
disease outcomes including the sympathetic nervous system, parasympathetic,
inflammatory cytokines and metabolic hormones, this dissertation focuses on
glucocorticoids because of the extensive regulatory role they play in mounting the
adaptative response to stress. Additionally, glucocorticoids act to regulate feeding and
energy balance, and when not properly regulated, they can lead to increased weight gain,
particularly the development of abdominal visceral fat. Independent from their role in the
stress response, glucocorticoids are also secreted in a diurnal fashion as regulated by the
master circadian (daily) clock in the suprachiasmatic nuclei (SCN). Signaling in this
regard is at least partially responsible for entraining circadian clocks outside of the SCN.
Just as shifts in glucocorticoid exposure are associated with metabolic disturbances,
disruption of circadian rhythms has also been linked to the development of obesity.
However, it remains unclear how the two systems independently and/or collectively
regulate energy balance.

The first aim of this dissertation was to determine how disruptions in the
environmental photoperiod impacts clock gene expression and if this environmental
exposure affects circulating glucocorticoid levels. The second aim was to determine if
increased exposure to a rhythmic corticosterone (CORT) disrupted circadian rhythms.
Given that CORT imbalances result in circadian disruption and weight gain in both
models, the third aim was to determine a mediator in the two systems that regulates
CORT synthesis and affects metabolism.

Recent studies have demonstrated that

glucocorticoids possess the ability to increase the production and release of
endocannabinoid molecules. Additionally, endocannabinoids are potent regulators of
appetite, energy balance and metabolic processes through both central and peripheral
regulation of feeding and metabolism, making the system an ideal candidate.
Mice lacking the cannabinoid CB1 receptor were protected against all of these
changes in metabolic function in both mouse models, indicating that endocannabinoid
signaling is required for circadian disruption to promote obesity and metabolic syndrome
through glucocorticoid regulation. These alterations are prevented by blocking the CB1
receptor, not only globally, but also through targeted peripheral inhibition, suggesting
that the endocannabinoid system mediates glucocorticoid induced metabolic syndrome
through a predominantly peripheral mechanism. These data build upon previous findings
that indicate the endocannabinoid system is required for diet-induced obesity. They
further suggest that this system plays a much broader role in the regulation of metabolic
processes, as well as acting as a mediator of changes in metabolic function in response to
an array of stimuli, including environmental exposure, and not just diet composition.

Research presented also aims to highlight the importance of studying different stresslike exposures in mouse models in order to fully characterize the human condition.
Chronic environmental stressors, as in chronic disruption of the-light-dark-cycle, provide
one such mean to study the impact of stress on a population.

The environmental

experience has been identified as a potential pathway linking neighborhood disadvantage
and poor health, through the dysregulation of stress-related biological pathways.
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Chapter 1: Introduction
Obesity is one of the most profound health problems in the United States with more than
two-thirds of adults and more than 9 million children aged 6-16 years considered
overweight.1 Although much has been learned about the regulation of body weight and
adiposity, the prevalence of obesity continues to rise. Obesity is of particular concern, as not
only a disease in and of itself, but also a major risk factor in the metabolic syndrome, which
is generally described as a series of physiological markers that put an individual at greater
risk of negative cardiovascular outcomes associated with obesity, including diabetes.2,3
Current explanations of such diseases based on nutritional over consumption, poor diet,
and/or lack of physical activity, are inadequate to explain their sudden rise and increased
prevalence. Furthermore, most current treatments for the metabolic syndrome have proved
unsuccessful, and while some weight can be lost with moderate diet and exercise, the altered
hormonal levels after weight gain make it more difficult for weight loss and maintenance of
weight once lost.4 Thus prevention of obesity or diabetes is an essential component of any
successful weight loss program.
Obesity is a growing health concern throughout the world, and those with a lower
socioeconomic status (SES) are more likely to experience chronic diseases like obesity and
high blood pressure, weakened immune system, mental illness and decline of physical
strength.5 When the impact of SES on the development of cardiovascular and metabolic
disease is considered, it is crucial to study the social-biological interface, and understand
exactly how SES affects the biological factors involved in disease etiology. Lower SES is
associated with a range of biological risk factors, including adverse lipoprotein profiles,
increased central obesity, impaired glucose tolerance, insulin resistance, raised levels of
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fibrogen, abnormalities of cardiac rhythm, and procoagulant blood clotting profiles.6
Unfortunately, the pathways through which lower SES causes these changes are still not well
understood. While lifestyle and health behaviors such as smoking, lack of physical activity,
and alcohol consumption contribute to health outcomes, biological risk persists after social
gradient is taken into account. It has, therefore, been argued that low SES may activate
psychobiological processes, or neuroendocrine, autonomic and immune responses that in turn
promote the development of high-risk profiles.7
The role of stress, particularly chronic everyday stressors compared to traumatic but
rare events, in the development of negative health outcomes, is often overlooked by health
professionals when considering the cause of a disease.8 This, despite a growing body of
research which suggest that it is the inundation of these everyday burdens that strongly affect
well-being. These chronic stressors even at a low level may cause an individual to be
anxious or depressed, to lose sleep at night, to increase the intake of comfort foods, to smoke
and/or drink, and to become more susceptible to infection.
One major issue preventing health professionals from considering a patient’s everyday
experiences and environment on their health outcome, apart from discrimination and
stereotypes (large issues plaguing low SES communities but covered extensively by
Williams et al., 2010) is the discrepancy in both human and animal literature describing the
effects and possible mechanisms that would link chronic stress and health
outcomes.9 Further, both social and biological scientists think in a specific mindset and see
stress to only mean a particular set of effectors. In this introduction, I aim to outline the
etiology of the stress response and how many systems of the body including metabolic,
cardiovascular, and immune, are directed to mediate this response. In particular, I highlight
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the endocannabinoid system, which has gained attention over the last decade for its
regulatory role in multiple processes, ranging from feeding to cognition to pain to emotional
behavior in response to stressful environments. I further discuss how environmental
experiences, sleep and circadian disruption and an individual’s behavioral and physiological
response whether health-promoting or health-damaging, aid in adaptation but which also can,
when overused and out of balance, lead to pathophysiology. Herein I discuss how
nontraditional animal models of stress, such as those of sleep and circadian disruption, have
attempted to answer these questions, including my own recent studies.

Stress, cortisol and HPA dysfunction
Stress, defined as a state of threatened homeostasis following exposure to extrinsic or
intrinsic adverse forces, mobilizes a vast number of physiologic and behavioral responses
that constitute the adaptive stress response that aim to restore disturbed equilibrium.10 Apart
from the key systems hypothesized to mediate the effects of stress exposure on disease
outcomes: the sympathetic nervous system (SNS), which stimulates release of epinephrine
(more commonly known as adrenaline) from the adrenal gland, and the hypothalamic
pituitary adrenal (HPA) axis, which produces glucocorticoids (GCs) and several other
mediators, including the parasympathetic nervous system, and pro- and anti-inflammatory
cytokines, and metabolic hormones, have been described in a dynamic nonlinear network of
allostasis.11,12
Allostasis refers to the active process by which the body responds to daily events as they
vary across the day in response to external and internal demands.13 Biomediators (HPA,
autonomic, metabolic, and immune) act to down- and up-regulate each other depending on
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the body’s internal concentrations, location, and sequential temporal patterning. Allostasis,
unlike homeostasis, which acts to keep physiological parameters in a narrow range, is a
dynamic and adaptive process necessitating the need for adjustments of the mentioned
biological systems. This adaptative ability comes at a cost termed allostatic load or overload,
which refers to the wear and tear that results from either too much stress or from inefficient
management of allostasis.12 Allostatic load can have detrimental effects on health and can
manifest in a number of ways, as in repeated hits from multiple stressors, not turning off the
stress response when it is no longer needed, not turning on an adequate response at onset, or
not habituating to the recurrence of the same stressor, and thus dampening the allostatic
response.12
The stress hormones, primarily the glucocorticoids (GCs ;cortisol in primates,
corticosterone in rodents), are of particular interest because of the extensive regulatory role
they play in the central nervous system, the metabolic system and the immune system.14 GCs
are the final mediators of the HPA-axis, and play a crucial role in mounting the adaptive
response to stress. The central components of the stress system are located in the
hypothalamus and the brain stem, and primarily include the parvocellular corticotropinreleasing hormone (CRH) and arginine-vasopressin (AVP) neurons of the paraventricular
nuclei of the hypothalamus, and the locus coeruleus-norepinephrine system.15 The
hypothalamus in turn regulates the secretion of adrenocorticotropin hormone (ACTH) from
the anterior pituitary via CRH and AVP both of which are secreted in a synchronized mode,
which can be disrupted by imposed stressors.16 Upon ACTH stimulation the adrenal cortex
secretes GCs, which act via their widespread receptors to respectively activate or repress
numerous genes, many of which are directly related to metabolic pathways.17 The primary
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means of HPA-axis regulation occurs through a well-characterized negative feedback loop
where GCs suppress ongoing HPA activity at the hypothalamic and pituitary levels. Despite
the clear importance of GCs in feedback regulation, it is important to note that the HPA-axis
is also susceptible to GC-independent inhibition as evident from adrenalectomized rats with
corticosterone replacement in the form of a pellet, thus maintaining a constant circulating
level of corticosterone, but inability to execute a stress response.18 Nonetheless, these rats
maintained the ability to inhibit ACTH responses, arguing for the existence of neuronal
inhibitory pathways working in parallel with steroid feedback. Additionally, forebrain and
hindbrain regions, which communicate with the PVN, have shown to regulate the HPA-axis
under both basal and stress conditions.19, 20
GCs have several important functions, such as increasing access to energy stores,
increasing protein and fat mobilization, as well as regulating the magnitude and duration of
inflammatory responses.21 Thus, without sensitivity to this feedback system or when the
activity of the system becomes dysregulated, excessive or unchecked, secretion of GCs can
have deleterious consequences on one’s health. The alterations of GC release are a key
component of the vital systems that lead to allostatic load, in conjunction with sympathetic
activity, proinflammatory cytokines, and a compensatory response in parasympathetic
activity. This state leads to increased susceptibility of an organism to an array of disease
states, ranging from mood disorders to Type 2 diabetes and cardiovascular disease.

Measurement of Glucocorticoids
Increases in plasma or salivary cortisol levels are used as biochemical markers of stress;
however, apart from the observed diurnal pattern (discussed in detail below), GC secretion is
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also subject to considerable variation across individuals as well as within individuals across
different days.22 This variation makes measurement of active free GCs difficult. As a result,
a number of different approaches to modeling cortisol in humans have been examined,
including: slope from highest to lowest point (diurnal slope), size of the cortisol awakening
response (CAR), morning or evening levels, and total cortisol concentration over the day
measured as area under the curve (AUC) of the diurnal pattern.23 Waking levels of cortisol
and the slope of decline across the day are generally correlated with the CAR and likely
capture related features of the diurnal pattern. A flatter or ‘blunted’ cortisol pattern is
thought to indicate HPA-axis dysfunction with a steeper decline believed to indicate a normal
rhythm.24, 25
To make the story more complicated, cortisol levels can vary depending on the selected
assay. Cortisol can be assayed from saliva, plasma, urine, feces and hair. Salivary cortisol is
most frequently used at present given the ease of collection over the day. Further, it
represents free cortisol that has passively diffused into the salivary glands. Free cortisol
represents the fraction of cortisol not bound to binding proteins, including corticosteroidbinding globulin (CBG). While cortisol in the saliva is not bound to CBG, 30-50% has been
converted to cortisone (the inactive form of cortisol) by the enzyme 11beta-hydroxysteroid
dehydrogenase (11 beta-HSD) type 2, leading to overall lower levels of cortisol in saliva.26
Urine collections of 12 or 24 h are still often used to provide an integrated measure of HPA
activity over a longer period of time. However, it is important to note that urinary free
cortisol is a measure of not only cortisol production, but also cortisol metabolism by the liver
and clearance by the kidneys. Hair analysis is increasingly more common as they reflect
cortisol changes that can occur over weeks and months. 26 While each of these
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measurements has advantages and limitations, hair analysis, avoids the requirement of
multiple samples taken a specific times of day, making it suitable for population analysis.

Hypercortisolism
The association between stress and increased cortisol has been well documented over the
past few decades to the point where stress and increased GC secretion have become
synonyms in the literature.27 Obesity has indeed been associated with increased cortisol
excretion that correlated with BMI.28-30 Anecdotally this comes to no surprise to many who
note increased stress is accompanied by increased food intake and weight gain. Further,
endocrinologists have noted the striking resemblance between Cushing’s syndrome and the
metabolic syndrome, thus suggesting a common underlying mechanism.31 However, while
both are characterized by insulin resistance, hypertension, visceral obesity, hyperlipidaemia,
and glucose intolerance, circulating GC concentrations are commonly not increased in
obesity or Type 2 diabetes, stressing the need to look beyond high circulating GCs.
In addition to global action, GCs also have tissue-specific affects. Visceral adipocytes
are particularly responsive to GCs. They not only express higher numbers of GC receptors
but are also a key site for the local interconversion of inactive GC precursors into active GCs,
a reaction catalyzed by 11β-hydroxysteroid dehydrogenase Type 1 (11βHSD1), which
converts cortisone to cortisol.32
The role of binding proteins to regulate the availability of free GCs levels is also often
overlooked. During the diurnal nadir, only about 5% of GCs circulate unbound in an active
thermodynamically “free” form, where they are able to bind to receptors, whereas most are
bound to corticosteroid-biding globulin (CBG) or albumin in blood plasma.33 CBG proteins
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are saturated by high-physiological concentrations. For this reason they are subject to large
variations of plasma concentrations of free plasma cortisol that occur during diurnal changes.
The inactive GCs do not have a pronounced diurnal variation and are rarely protein-bound,
which results in a higher inactive GC storage pool in circulating plasma.34 This inactive
storage pool is constantly available to 11β-HSD1 reductase to maintain local active GC
concentrations even in periods of low plasma cortisol concentrations, such as during the
diurnal nadir. In this way, by expressing 11βHSD1, the target tissue, such as white adipose
tissue, is equipped to regulate its own GC concentration and subsequently its GC
responsiveness on the receptor level by adjusting the rate of local GC activation.35
Use of genetically altered mice further solidified the role of 11β-HSD1 reductase in
promoting obesity. 11β-HSD1 knockout mice, show impaired induction of hepatic
gluconeogenic enzymes during fasting and a mitigated glycaemic response to stress or
induction of obesity.36 Additionally, they show improved glucose tolerance, increased
hepatic insulin sensitivity, and an exaggerated hepatic induction of genes for lipogenic
enzymes.37 In humans, dysregulation of tissue-specific 11β-HSD1 activity also seems to
play a role in the development of obesity in that activity in adipose tissue is increased.38 To
this extent, mice over expressing 11β-HSD1 in fat tissue show an increase in enzyme activity
to a similar degree to that seen in obese humans, accompanied by visceral obesity with
insulin resistance and dyslipidemia;39 overexpression in hepatic cells of mice produces
symptoms of the metabolic syndrome without obesity.40
Hypercortisolism has also been linked to depression and it was subsequently proposed
that chronic stress causes depression and successive poor health habits that can lead to the
metabolic syndrome and ensuing coronary heart disease.41 Studies examining mood states,
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depressive symptoms, and stress levels found that trait anxiety and depression, but not
perceived stress, were associated with small but statistically significant cortisol elevation.
However, stressful daily events were associated with increased cortisol secretion, the
magnitude of the effect depending on whether the event was still ongoing and on how
frequently a similar kind of event had occurred previously.42 Similarly, Pruessner et al. found
higher levels of depressive symptomatology were associated with a greater cortisol response
after awakening. In that study, cortisol levels and depressive symptomatology were
significantly positively correlated with measures of chronic and acute stress perception.43
Biologically, this has been attributed to dysregulation of the HPA axis, particularly
hyperactivity.44 Consistent with this hypothesis, a study looking at 45 postmenopausal
women found that hypercortisolemic depression, compared to normocortisolemic depression,
was associated with increased visceral fat, suggesting that associations with metabolic
abnormalities may be especially powerful for hypercortisolemic depression.45 A study in an
older population confirmed these findings suggesting again that when both depression and
high cortisol levels are present, the odds of the metabolic syndrome is increased.46 Despite
convincing evidence that would suggest increased circulation of cortisol leads to weight gain
in depressed patients, the mechanism linking the two remains elusive.
In order to obtain a better understanding on how disruption of the HPA-axis function
may increase the incidence of the metabolic syndrome, our group recently developed a
noninvasive approach to deliver a high dose of corticosterone in the drinking water of mice.
In this way, the adrenal glands remain intact and animals are able to retain some integrity in
the diurnal rhythm present in normal animals. This approach has allowed us to avoid
confounding variables such as daily injections and surgery for implantation of corticosterone
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pellets which could provide additional stress. We are also able to minimize handling with
only one weekly cage change and simultaneous weight measurement, procedures that have
also been described elsewhere to alter the stress response.47, 48 A 4-wk exposure to
corticosterone (100 µg/ml) in the drinking water resulted in rapid and dramatic increases in
weight gain, increased adiposity, elevated plasma leptin, insulin, and triglyceride levels,
hyperphagia, glucose intolerance, and decreased home-cage locomotion. A lower dose of
corticosterone in the drinking water (25 µg/ml) resulted in an intermediate phenotype in
some of these measures with no effect in others. Interestingly, when challenged with a highfat diet (HFD), mice receiving a high dose of corticosterone gained less weight compared to
high dose mice on standard chow (SC), and no significant difference from mice on HFD
alone. Whereas low treatment of corticosterone with HFD resulted in significant weight gain
compared to both mice on corticosterone or HFD alone. When looking at insulin, leptin, and
triglyceride levels the effects of corticosterone in both low and high dose groups are additive,
while low corticosterone does not impair glucose tolerance (unpublished). These findings
are similar to those from Shpilberg et al. who looked at the impact of a corticosterone pellet
implanted in male Sprague-dawley rats and simultaneously placed on a HFD for 16 days.
Again animals receiving corticosterone and HFD had a lower body weight, but increased
epididymal mass compared to rats given a wax pellet on and placed on a standard diet. These
rats also displayed serve fasting hyperglycemia, hyperinsulinemia, insulin resistance, and
impaired β-cell response to oral glucose load when compared to control rats.49 Both models
provide suitable means to study the metabolic syndrome and type 2 diabetes and the role that
GCs play in mediating these diseases both independently and in conjunction with HFD.
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Hypocortisolism
Hypocortisolism, characterized by a hyporesponsiveness on different levels of the HPAaxis, is a phenomenon that occurs in 20-25% of patients suffering from stress-related
diseases.50 Although reports of hypocortisolism in healthy individuals who lived under
conditions of ongoing stress go back to the 1960s and 1970s, they were not taken seriously
until similar results were seen in sufferers of post-traumatic stress disorder (PTSD).51-54 More
recently, hypocortisolism has also been reported for patients suffering from disorders such as
burnout, chronic fatigue syndrome, fibromyalgia, chronic pelvic pain and asthma.50 Studies
over the last few years act as a further indicator that hypocortisolism does not seem to be an
exclusive correlate of stress-related pathology, but is also present in healthy subjects living
under ongoing stress such as those highlighted by Juster et al. In this study, it was
demonstrated that increased allostatic load, the process by which chronic stress causes stress
hormones to strain many biological systems, is associated with lower morning and stress
reactive cortisol levels in comparison to individuals in the “Low” allostatic load group.55 In
an effort to determine cross-sectional and longitudinal associations between body
composition and serum cortisol concentrations in a group of community-dwelling men, a
negative association between cortisol concentrations and all body composition parameters
was revealed.56 The impact of neighborhood-level stressors and lack of social support also
resulted in an overall decrease in cortisol levels in higher stress, lower support
neighborhoods, with a flatter rate of cortisol decline throughout the day.57, 58 While the
presence and specific cause of hypocortisolism is still up for debate, it has been suggested to
be a result of a) reduced adrenocortical secretion, at least temporarily during the circadian
cycle; b) reduced adrenocortical reactivity; or c) enhanced negative feedback inhibition of the
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HPA axis.27
Although there is some controversy in clinical studies about the presence and impact of
hypocortisolism, research from animal studies provides mechanistic evidence to support its
presence under chronic stress. Fries et al. make note of a reported rodent model of
hypocortisolism in which rats exposed to 3 wks of restraint stress exhibit a hyperactive HPAaxis with significantly elevated corticosterone levels. However, 2 wks post termination of
the stressor the animals show a blunted corticosterone response/hypocortisolism compared to
non-stressed control rats.50 In an alternative model, using morphine withdrawal as a stressor,
prolonged elevated levels of ACTH and corticosterone were followed by a continuous drop
of corticosterone levels.59-61 In monkeys, the use of maternal separation as a stressor to mimic
early life adversity has been shown to significantly lower basal hair cortisol levels in peerreared monkeys compared to the mother-reared monkeys 1.5 and 3 years after early
separation. Plasma cortisol assessed in the monkeys after 1.5 years of normal social life also
indicated that the peak in the peer-reared cortisol response to acute stressors was
substantially delayed.62
In recent years there have been a growing number of studies looking at the relationship
between the impact of obesity and food intake and hypocortisolism. In rodent models this
has been studied through the chronic stress response network model, in which rats exposed to
repeated chronic restraint stress are then given lard or sucrose and subsequently demonstrate
an attenuated stress response compared to those given chow.63 Similarly, a palatable cafeteria
high-fat diet normalized the effects of prolonged maternal separation in rats, reversing
increases in anxiety and depressive behaviors, increased corticosterone, increased
hypothalamic CRH, and increased hippocampal GC receptor expression.64 Chronically
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stressed rats, over time, develop greater mesenteric fat, which has been shown to inversely
correlate with CRH mRNA expression in the paraventricular nucleus.65 This response is one
hypothesized mechanism explaining how, over time, chronically stressed humans appear to
have hypocortisolism.
This effect seems to be preserved across species as evident by the chronic stress response
network in rhesus monkeys, in which subordinate females consumed more calories, gained
more weight, and subsequently showed lower diurnal cortisol responses and dampened
cortisol responses to an acute social separation stressor.66 Findings were analogous in a
human study looking at the relation between “comfort food” and HPA-axis response in a
group of “highly stressed” women. As with the animal models, it was shown that highly
stressed women reported greater emotional eating, greater abdominal fat, and showed blunted
output in response to acute stress, as well as signs of a heightened sensitivity to cortisol
including lower diurnal cortisol, and an enhanced negative feedback loop as indicated by a
dexamethasone response.67 The biological determinates of decreased circulating GCs, and
the link between circulating levels to weight gain, whether dependently through food intake
or through an independent mechanism remain to be determined.

Circadian rhythm of glucocorticoids
In addition to being a vital product of the stress response and feedback regulation, GCs
follow a normal diurnal rhythm necessary for proper functioning. The vital role of GCs here
was highlighted by Mary Dallman’s group, which showed that a diurnal exposure to
corticosterone in the drinking water of rats was sufficient to normalize ACTH levels in
adrenalectomized rats, perhaps priming neural mechanism subserving a shut-off of the HPA-
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axis.18 This, in contrast to constant but flat GCs in circulation, blunt the turn-on and shut-off
of the HPA ACTH response to an acute stressor in ADX rats.68 Normal cortisol levels have
been shown to have a maximum level in the morning, characterized by an acute increase
during the first hour after awakening.69,70 Levels typically drop rapidly for the next couple of
hours and then continue to decline slowly throughout the day and night reaching a low point
around midnight (rodents as nocturnal animals show the reverse effect with circulating
corticosterone).71

The direct glucocorticoid contribution to obesity
Persistent exposure to stress, and the concomitant increase in circulating GCs, is accepted
as one of the mediators of the ever-growing epidemic of obesity and metabolic syndrome.72-74
However, until recently, few models were able to recapitulate the weight gain that
accompanies stress exposure in many humans. More common, models of chronic stress
including certain models of chronic subordination and chronic restraint stress, have
repeatedly been associated with a reduction in body weight and a generalized catabolic
state.75-77 While these models are well suited for studying anhedonia and depression that
some stressed individuals display, they shed no light on the other side of the coin.
More recently models of chronic psychosocial stress such as social hierarchy disruption
and intruder aggression have shown increases in body mass and adiposity in subordinate
mice with a negative energy balance in dominant mice79-81 and increased vulnerability to diet
induced obesity.81,83,47 Although increased food intake is accompanied by stress in many of
these studies, weight gain is more often attributable to decreased energy expenditure.
Interestingly, increased weight gain and circulating corticosterone in this model is not
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accompanied by increased fat pad, the hallmark of GC-induced obesity. Bartolomucci et al.
argue that this effect could be attributed to upregulation of the HPA-axis in subordinate mice
compared to dominate mice.84
In order to model the effects of early life chronic stressors and their potential to
dysregulate metabolism, Loizzo et al. developed a paradigm combining psychological and
nociceptive manipulations in neonatal life. Neonatal manipulations (10 min of maternal
separation plus s.c. sham injection, daily for the first 21 d of life) resulted in increased
weight-gain after onset of maturity, showing increased fat tissue and hypertrophic epididymal
adipocytes along with increased levels of leptin, triglycerides, and plasma corticosterone.
Overweight mice do not present consistent variations in daily spontaneous locomotor
activity and show a slight increase in food intake, but only in adulthood. Total life food
intake is considered, it accounts for only 20% of the total body weight increase over
controls.85 The above studies all support the concept that stressors early in life can cause
obesity in a way that does not involve major increases in food intake.
The effect of chronic GC exposure on obesity is seen predominantly in the visceral area
as briefly discussed earlier in this review.86,87 Additionally, GC exposure leads to increased
intake of sweet, fattening, nutrient dense foods87-89 and when an acute stress is juxtaposed
with a chronic stressor, stress eating is increased,91,92 all of which adds to increased weight
gain and obesity. However, as described above, decreases in circulating GCs, whether due to
an under-active HPA axis or adjustments in alternative pathways acting to regulate the
system and maintain allostasis, can also result in weight gain and the precise role of GCs here
needs to be explored. The compensatory role of increased food intake, particularly that of
high-calorie, nutrient-sparse foods is clearly a health-damaging behavior, which in the long-
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term can lead to allostatic load and, thus not the best coping device for an extended measure
of time. Recent work from James Jackson suggests that in certain populations the
engagement of such health-damaging behaviors while decreasing life span is able to prevent
depression.93 The latter example provides a great display of the complexity of the stress
response and how individuals adapt to and cope with a challenge while also contributing to
allostatic load.
In terms of appetite, GCs are noted to have an anorexigenic affect by suppressing hunger
centrally through a CRH-mediated mechanism, likely through an acute post-stress inhibition
of neuropeptide Y (NPY)-stimulated food intake.94-96 Long-term GC release acts to stimulate
feeding, perhaps as an adaptative response to replenish energy sources lost during the
stressful event or to stockpile in the event of a future stressor.97-99 In the modern world where
food, particularly high-energy foods are in abundance and stress can come from more of a
psychosocial versus physical form, this adaptation can be particularly harmful.
As stated above, stress and GCs tend to stimulate appetite, particularly for nutrient
dense foods, with insulin having a key role in this regard.63 The preference for calorically
dense foods in stressed animals seems to have a beneficial role by dampening HPA-axis
response to further stress.64 The rewarding nature of this cycle led to the research on the role
of dopaminergic, opioid and glutamatergic transmission within the nucleus accumbens, given
their role in mediating responses to drugs of addiction.100-102 This reward circuitry has long
been known to be activated by eating, and has been shown to be involved with the propensity
to ingest highly palatable food.103
Beyond appetite, GCs are known to play a vital role in lipid homeostasis, from adipose
tissue mobilization to fat deposition and storage. Much evidence here comes from
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accumulating visceral fat seen in humans and primates as described above; however, the
precise mechanism underlying this relationship is not fully understood. From in vivo studies,
the general story suggests that infusion of GCs enhances lipolysis by stimulating the release
of nonesterified fatty acids from adipocytes through the activation of hormone-sensitive
lipase (HSL), an enzyme responsible for enhancing fatty acid mobilization.104,105 It has been
argued that this increase in circulating free fatty acids restricts glucose utilization and
encourages insulin resistance.106 Further it appears that GCs enhance fat storage by
increasing LPL activity and in this way affect lipid metabolism by increasing both turnover
and uptake of fatty acids in adipose tissue.107-108
GCs are also important for the differentiation of preadipocytes into mature
adipocytes.109-110 The role here, in conjunction with their ability to upregulate the NPY Y2
receptor in abdominal fat, subsequently leading to stimulation of proliferation and
differentiation of adipocytes, further accentuate the accumulation of fat.111, 83 Further, GCs
seem to play a role in fatty liver through dysregulation of SREBP1c, a transcription factor
that regulates lipid-related processes.112 While it is clear that GCs promote adiposity, a
distinct mechanism remains unclear particularly in the case where hypocortisolism may be to
blame.

Nonclassical mediators between glucocorticoids and obesity: The Endocannabinoid
System
The Endocannabinoid (eCB) System has a well established role in mediating the stress
response; inversely, GCs have the ability to increase the production and release of eCB
molecules.113-115 The eCB system was originally characterized as the neuronal system to
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which the psychoactive constituent of cannabis ∆-9-tetrahydrocannabinol (THC) interacted
to exert its effects on physiology and behavior. The endocannabinoids, Narachidonylethanolamine (anandamide; AEA) and 2-arachidonoylglycerol (2-AG) are lipid
mediators derived from membrane phospholipids or triglycerides. The endocannabinoids are
not stored or released vesicularly, but are synthesized and/or released in response to altered
activity. The syntheses of AEA and 2-AG occur via separate enzymatic cascades and are
evoked by cellular stress, tissue damage, or metabolic challenges.116,117 2-AG is degraded by
monoacylglycerol lipase (MAGL) and diacylglycerol lipase (DAGL). In contrast, AEA is
degraded by an intracellular serine hydrolase, fatty acid amide hydrolase (FAAH).118 The
system is comprised of the cannabinoid CB type 1 and type 2 (CB1 and CB2) receptors. The
CB1 receptor is expressed in the central nervous system as well as metabolically active
organs including the liver, adipose tissue, pancreas, and intestine. The CB2 receptor is
predominately expressed in tissue of the immune system.119
Accumulating evidence has demonstrated that the eCB system is responsive to
modulation by both stress and GCs within the hypothalamus and limbic structures. In vitro
work demonstrates that glucocorticoids within the PVN can evoke a rapid induction of eCB
synthesis, which in turn acts to suppress incoming excitatory neurotransmission to CRH
neurosecretory cells.114 In vivo work demonstrated that a single administration of CORT
increased AEA content within the amygdala, hippocampus and hypothalamus at only 10 minfollowing administration.120 2-AG was also found to be elevated 10 min post injection, but
only in the hypothalamus. These effects subsided at 1 hour following administration of
corticosterone.113 Functional studies have shown that mice lacking the CB1 receptor exhibit
potentiated secretion of both ACTH and corticosterone following exposure to an array of
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psychological stressors. Such data suggest that eCB signaling is engaged by stress to
constrain activation of the HPA-axis, when disrupted an exaggerated response occurs.115
Overall, studies to date suggest that eCB signaling appears to regulate both the activation and
termination of the HPA axis in response to stress through a reduction in AEA and an increase
in 2-AG, respectively.113
Additionally, eCBs are potent regulators of appetite, energy balance and metabolic
processes through both central and peripheral regulation of feeding and metabolism.121-125
Research over the last decade showed genetic deletion of the CB1 receptor in mice results in
decreased body weight and reduced fat mass. This reduction in weight loss led to the
development of a drug for the treatment of obesity: rimonabant (SR141716), a selective CB1
receptor antagonist.122
Given the unique regulatory role of eCBs in stress and energy metabolism, we sought
to examine the role of eCB regulation in our hypercortisolism model of metabolic
dysregulation. Endocannabinoid mediation also suggested by data presented by Valenzuela,
who showed that an overactive liver and epididymal fat CB1R due to early life stress may be
involved in metabolic alterations in adulthood, which were attenuated by chronic treatment
with the CB1R antagonist SR141716A.119

Circadian control

Daily rhythms in gene expression, physiology, and behavior persist under constant
conditions in-spite of seasonal changes of light and dark and, therefore, must be driven by
self-sustained biological oscillators called circadian clocks.126 These clocks are adjusted daily
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by the light-dark-cycle in order to be in harmony with the outside environment. In mammals,
light signals from the outside world are transmitted directly to the suprachiasmatic nuclei
(SCN) of the ventral hypothalamus via the retino-hypothalamic tract.127 Given its ability to
synchronize all overt rhythms, the SCN is referred to as the “master clock.”128 In order to
synchronize physiology with external time, the SCN clock emits timed signals through
hormonal and neuronal pathways to a series of peripheral circadian clocks found in most
organs.129, 130 Peripheral clocks translate clock time into physiologically meaningful signals
through rhythmic activation of clock-controlled genes.131,132 The clock mechanism in the
brain and peripheral tissues consists of two interlocking, regulatory feedback loops. In the
first loop, CLOCK and BMAL1 heterodimerize and bind to E-box sequences to mediate
transcription of a large number of genes, including Periods (Per1-3) and Cryptochromes
(Crys). Pers and Crys constitute part of the negative feedback loop and inhibit
CLOCK:BMAL1-mediated transcription.133 In a second loop, BMAL1 transcription is
regulated by reverse erythroblastosis virus a (REV-ERBa), retinoic acid receptor-related
orphan receptor a (RORa), and peroxisome proliferator-activated receptor a (PPARa), all of
which regulate lipogenesis and lipid metabolism. Subsequently, the CLOCK:BMAL1
heterodimer regulates the expression of Rev-erba, Rora, and PPara.133-136 Protein expression
of the clock genes has been shown to be important for regulation of metabolism as evident by
alterations in rhythmic expression in models of high fat feeding and diabetes.136,137
Additionally, clock gene mutation or knockout has led to not only circadian dysregulation but
also metabolic disturbances of lipid and glucose homeostasis.138-142 Understanding the
precise mechanism by which the SCN is able to reset peripheral clocks and how such
regulation is able to affect downstream pathways, such as glucose and lipid metabolism, has
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been a major focus over the last decade.
GCs have been a particularly attractive candidate in peripheral regulation, because they
are secreted in daily cycles and the GC receptor is expressed in most peripheral cell types,
but not in the neurons of the SCN.143,144 In this way, GCs could act as entraining signals as
suggested by Balsalobra who demonstrated that adrenal GCs have the ability to reset the
clock of subordinated oscillators in the periphery.145 The adrenal circadian clock was further
shown to regulate the rhythmic release of GCs into the blood, which likely controls
metabolic rhythms in many other organs, including liver, kidney, and brain.146-149
GCs are also interesting as a regulatory signal because of their role in the feeding
response. Again, work by Mary Dallman and others has given light to the role of GCs in
feeding driven behavior, particularly in regards to weight gain and the desire to eat “comfort
foods”, such as sweet and high-fat foods. Studies looking at the relationships between acute
and chronic stressors, the brain and the HPA axis show that stress and GCs, in the presence
of insulin, increase the relative intake of “comfort foods” and reduce HPA activity. Further,
apart from the direct role in the brain to both excite and inhibit CRH and ACTH secretion,
GCs act in the periphery to provide an indirect secondary inhibitory feedback signal that
limits the degree of chronic stress perceived by an organism.87
In the case of circadian rhythms, recent studies have shown that a high-fat diet leads to
rapid alterations in both the period of locomotor activity in constant darkness and to
increased food intake during the normal rest period under light-dark conditions.151 These
behavioral changes to rhythmicity are accompanied by disrupted circadian gene expression
within hypothalamus, liver, and adipose tissue and with altered cycling of hormones and
nuclear hormone receptors involved in fuel utilization, such as leptin, thyroid-stimulating
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hormone, and testosterone in mice, rats, and humans.152-155 Similarly a decrease in calorie
intake through daytime restricted feeding, results in an uncoupling of circadian clocks in
peripheral tissues, such as liver, kidney, heart, and pancreas from the central pacemaker in
the SCN.156,157 Long-term daytime restricted feeding (18 wk) is sufficient to increase the
amplitude of clock gene expression and catabolic factors and in this way reduce levels of
disease markers.158-160 When determining the impact of restricted feeding on the harmful
effects of high fat feeding, studies found that compared to mice fed an ad lib high-fat diet,
restricted mice on a high-fat diet were able to restore the expression phase of the clock genes
and a reduction in weight and improved insulin sensitivity despite equivalent food
consumption.161 Further, mice on a restricted high-fat diet had decreased circulating
corticosterone compared to the restricted low fat chow group.162 Work here hints to the
complex regulatory role of GCs with increases from restricted feeding having beneficial
metabolic effects even in the face of inhibition through high-fat feeding, suggesting the role
of an alternative upstream mediator.
Work showing that rhythmicity of GCs influences photic entrainment of locomotor
activity, led to the elegant studies by Kiessling, who demonstrated that genetic ablation of the
adrenal clock accelerated the rate of re-entrainment.164,165 Further, timed application of
metyrapone, an inhibitor of adrenal GC synthesis, elicited a shift in GC rhythmicity, either
prolonging or shortening jet lag, depending on the time of administration. Jet lag, is best
described in this review as a set of physiological and psychological perturbations experienced
when internal circadian rhythms and external times are out of synchrony. This work suggests
that the adrenal clock coordinates circadian entrainment during jet lag by gradually adjusting
GC rhythm.165 Studies originally looking at the impact of jet lag, on salivary cortisol found
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higher levels in cabin crew versus ground crew across the working day. This increase in
cortisol was higher for international transmeridian flying and observed across four different
career cohorts suggesting that employees are unable to adapt to the effect of transmeridian
flight.165
Thesis Rationale and objectives
Rationale
Incidence of the metabolic syndrome, the presence of a range of metabolic dysregularities
that lead to type 2 diabetes or cardiovascular disease, is increasing not only in the United
States, but also around the world. Several recent studies suggest that metabolic
abnormalities are associated with the settings of the circadian clock system,147,148 and,
moreover, that alterations in these settings are among the possible causes of metabolic
syndrome. Organisms have developed behavioral and physiological adaptations to not only
strong diurnal cues, but also to unforeseen, random stress stimuli such as predator attack or
serve weather changes. Moreover, these responses communicate with one another at
different signaling levels, resulting in interrelated regulatory networks, and dysregulation of
either system can lead to the development of metabolic disorders.149,150 Indeed,
glucocorticoids, which are well known to affect metabolic conditions, entrain the circadian
rhythm by phase-shifting the expressions of several core clock genes in peripheral organs,
including the liver, kidneys, and heart.146 Recently, two mouse models were developed in the
lab that would allow further investigation into the interaction between glucocorticoid
signaling and the core clock and how both may lead to the development of obesity through a
common pathway-one a chronic disruption in normal light cues,166 the other an exogenous
administration of corticosterone (CORT) in the drinking water.47 In addition, the
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endocannabinoid system emerged as a possible variable here given its recent and thorough
characterization as a moderator of the adaptive stress response113,114,124,151 as well as its role
in regulating energy homeostasis.121 Therefore, the central goal of the studies presented in
this dissertation is to elucidate a novel pathway that can integrate altered glucocorticoid
signals and metabolic functions.

Hypothesis
Both increases and decreases in GCs in circulation lead to alterations in clock gene
expression and subsequent disturbances in metabolic pathways. These alterations are
prevented by blocking the CB1 receptor not only globally but also through targeted peripheral
inhibition suggesting that the endocannabinoid system mediates GC induced metabolic
syndrome through a predominantly peripheral mechanism.

Objectives
1. To determine whether exposure to alterations in external light cues result in changed
clock gene expression in the white adipose tissue, liver, and hippocampus of wildtype male mice, and if so determine the role glucocorticoid signaling may have on
adjusted patterns of expression and subsequent weight gain (Chapter 3).
2. To demonstrate whether chronically increased circulating levels of glucocorticoids
result in impaired circadian (daily) rhythms and altered clock and metabolic gene
expression in the white adipose tissue and liver of wild-type male mice (Chapter 4).
3. To establish the endocannabinoid system as a mediator in glucocorticoid mediated
metabolic abnormalities with the use of CB1 receptor knockout mice (Chapter 5).
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4. To determine the primary source of endocannabinoid and glucocorticoid interaction
through characterization of system parameters (Chapter 6) and by specifically
targeting the peripheral signaling pathway using pharmacological and genetic
approaches (Chapter 7).
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Chapter 2: Materials and Methods
Animals and protocols
General procedure for corticosterone treated mice
All animal procedures were undertaken with approval of The Rockefeller University IACUC.
Adult male mice (C57/BL6; 19–21 g at receiving) from Charles River Laboratories
(Kingston, NY) were group housed (n=5/cage) in standard cages (28.5 x 17 x 13 cm), on a
12-h light, 12-h dark cycle (lights off at 1800 h). A 2 lux red light allowed for animal
maintenance in the dark phase. Temperature in the room was maintained at 21 ± 2 C. Mice
were allowed to acclimate to the facility for 7 days prior to the beginning of all
experimentation. After the acclimation phase, water was replaced with a solution containing
25 or 100 µg/ml free corticosterone (CORT; Sigma, St. Louis, MO) or 1% EtOH vehicle
alone as described previously.47 Animals were weighed once a week during cage change, at
which time solutions were replaced, and otherwise left undisturbed.

General procedure for shifted mice
Male C57BL/6 mice (Charles River, Inc.) were group housed (n = 5 per cage) and allowed 1
week to acclimate to the facility. Food and water were available ad libitum for the duration
of the experiment. For circadian manipulation, one group of animals was maintained in a 20h LD cycle, with 10 h of light and 10 h of dark. The control group remained in a 12:12 LD
cycle. Animals were weighed weekly during cage change and otherwise left undisturbed for
8 weeks. For the time course shift study mice were euthanized at ZT 0, 6, 12, 18 (n=810/group).
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CORT time course study
This study was conducted at Washington State University’s College of Veterinary Medicine
in Pullman, WA. All procedures with animals were undertaken with the approval of the
WSU Institutional Animal Care and Use Committee. In this study one cohort of animals was
group housed (n=4/cage) and placed on either vehicle, 25 or 100 µg/mL as described above.
After 4 weeks of treatment animals were euthanized at ZT 6, 12, or 18 (n=4-6/group). Mice
from the second cohort were individually housed. Body temperature and activity was
continuously recorded using temperature data-loggers implanted into the peritoneal cavity
(SubCue, Inc.), programmed to record body temperature every 30 min, with a resolution of
0.0625 °C. Following implant, animals were allowed 1 week to recover. Body temperature
and activity levels were collected using MiniMitter battery-less telemeter system
(Respironics, Inc). Data were collected using VitalView software (Respironics), and
analyzed in ClockLab for MatLab or ActogramJ for Image J. Following recovery mice were
placed on vehicle, 25 or 100 µg/mL CORT. Three days before mice were euthanized, the
animals were placed in constant darkness to measure free running circadian rhythmicity.
Mice were then euthanized at CT 12 or 18, CT time for each animal based on their individual
actogram and thus kill times were staggered.

Mouse shift with exogenous CORT replacement
In this experiment mice were placed in circadian disruption chambers of LD10:10 or
control chambers of LD12:12 as described above; however, mice were simultaneously placed
on either 25 µg/mL of CORT or vehicle solution as described above. After 8 weeks of
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circadian disruption and CORT treatment, mice were euthanized at ZT 6, 12, or 18 (n=45/group).
Genetic manipulations
The CB1R–/– global and liver specific mice used in this study were originally generated
and backcrossed to a C57/Bl6J background167 and were provided by the National Institute of
Mental Health. CB1R–/– mice and their wild-type littermates were bred from heterozygote
mother and CB1R–/– father and wild type breeding pairs, respectively. LCB1–/– mice were
generated by crossing mice homozygous for the CB1-floxed allele (CB1f/f), which were on a
predominantly C57BL/6N background (7-8 crossings), with mice expressing the bacterial
Cre recombinase driven by the mouse albumin promoter (TG[Alb-cre]21 Mgn) that had been
backcrossed 7 times to a C57BL/6J background, from Jackson Laboratory,168 to obtain
CB1f/fx CB1f/fAlbCre breeding pairs. The littermates obtained were on a mixed C57BL/6JxN
background. In each experimental paradigm, littermates were used as controls. In each
studying knockout mice were euthanized at ZT 4-6, unless otherwise stated. Genotyping of
CB1-/- mice was carried out using Transnetyx, Inc. LCB1-/- mice were genotyped by PCR
for the Cre transgene, Cre3- 5’ cactcatggaaaatagcgatc 3’, Cre4- 5’ atctccggtattgaaactccagcgc
3’. Briefly, genomic DNA was obtained from ear punches using Viagen DirectPCR® DNA
Extraction System (Los Angeles, CA). 1-2 µL of genomic DNA was run with .2µM of Cre3
and Cre4, .2µM dNTPs, 1.5 mM MgCl2, 1xPCR buffer, 2u Taq DNA polymerase, and water
to a volume of 25µL. PCR cycle was as follows 95°C 2 minutes, 34 cycles of 95°C for 45
seconds, 60°C for 1 minute, 72°C for 1 minute, and a final stage of 72° for 7 minutes.
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Tissue Collection
After treatment animals were euthanized by rapid decapitation. Trunk blood was collected
in BD Vacutainer K3 EDTA coated glass tubes (VWR, West Chester, PA), placed on ice,
and centrifuged at 1500 rpm for 15 min at 4 C. Plasma was removed and stored at -80 C
until used for analyses. Spleen, adrenals, liver, and gonadal fat pads from each animal were
collected and weighed. A portion of the liver and fat pad along with the entire brain were
flash frozen for further analysis. Remaining fat pad, liver, and pancreas were fixed with 4%
PFA/PBS overnight for histology.

Pharmacological Manipulations
AM251
Adult male mice (C57/BL6)) were group housed (n=5/cage) and placed on a solution
containing 100µg/ml free CORT (Sigma, St. Louis, MO) dissolved in 100% ethanol, and
then diluted in regular tap water to a final EtOH concentration of 1%. Control mice received
a 1% EtOH solution alone. Mice were given free access to drinking water and fed ad
libitum, for 4 weeks, at the end of which markers of obesity and metabolic markers were
examined (see below). Chronic treatment with AM251 (Tocris) commenced concurrently
with CORT in drinking water. AM251 was dissolved in 2% DMSO and >1% Tween 80. 1 h
prior to lights off, mice were injected intraperitoneally with vehicle (2% DMSO and >1%
Tween 80) or AM251 at 2 mg/kg body. All mice were allowed chow ad libitum. Animals
and chow were weighed daily, at the time of injection. Animals were otherwise left
undisturbed. Tissues were collected and processed as described below.
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AM6545
CORT and animal treatment followed as above. In tandem with CORT mice received
chronic intraperitoneal injections of vehicle or AM6545, a generous gift from Dr. Alex
Makriyannis’ group at Northeastern, (2% DMSO and >1% Tween 80 with gentle heating) at
10mg/kg 1 h prior to lights off.

Histology
Oil Red O
Frozen sections of the liver (10 μm) were stained with Oil Red O and counterstained with
hematoxylin for histology. Staining was done on five samples per experimental group.

H&E
Paraffin embedded samples were sectioned at 8 μm thickness with a microtome
(Microtom). Sections were floated in a water bath at 42 °C, placed on poly-L-lysine-coated
Polysine microscope slides (Erie Scientific Company) and allowed to air dry. For
hematoxylin and eosin (H&E) staining, sections were dewaxed in xylenes and rehydrated in
ethanol baths. Nuclei were stained with Gill no. 2 hematoxylin stain for 8 min and eosin for
10 dips. Sections were then covered with permount and cover slipped. H&E staining was
done on five samples per experimental group. Adipocyte length was determined from
images at a 10X magnification. 20 randomly selected droplets were measured using NisElements AR software, and averaged per animal.
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Immunohistochemistry of F4/80 in WAT
Paraffin embedded samples, cut at 8µM and dried on slides, rehydrated through changes
of xylenes and dilutions of ethanol. Slides were pretreated with a citrate buffer for antigen
retrieval (10 mM Citric Acid, 0.05% Tween 20, pH 6.0). Sections were incubated in
blocking solution (2% BSA, 50mM glycine, 0.1% Triton X-100, 10% normal goat serum) for
1 h at room temperature and then incubated in a rat antibody solution (1:100; abcam,
Cambridge, MA) overnight at 4C. F4/80-immunopositive macrophage cells were detected
by biotinylated goat antirat secondary antibody (1:300; Vector Laboratories, Burlingmae,
CA) and avidin-biotin-peroxidase (ABC, 1:300; Vector), followed by diaminobenzidine
staining. Digital images were captured using a bright-field light microscope and camera
(Nikon) and analyzed using Nis-Elements AR software.

Immunohistochemistry of CBG in the liver
Fresh frozen liver samples, cut at 14µM in the cryostat were fixed in 10% formide for 10
minutes. Slides were then dried and rinses in 2 changes of PBS (5 minutes each). Slides were
incubated in 0.3% H2O2 solution in PBS at room temperature for 10 minutes, followed by 2
additional PBS rinses. Sections were incubated in blocking solution (2% BSA, 50mM
glycine, 0.1% Triton X-100, 10% normal goat serum) for 1 h at room temperature and then
incubated in a rabbit antihuman CBG primary antibody solution (1:300; Affiland) for 72h at
4C. CBG-immunopostivite liver cells were detected by biotinylated goat antirabbit
secondary antibody (1:300; Vector Laboratories, Burlingmae, CA) and avidin-biotinperoxidase (ABC, 1:300; Vector), followed by diaminobenzidine staining. Digital images
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were captured using a bright-field light microscope and camera (Nikon) and analyzed using
Nis-Elements AR software.

Measurements of blood hormones
Plasma leptin, adiponectin and insulin levels were assayed using ELISAs (Millipore,
Billerica, MA), as was plasma CBG (USCN Life Science, Houston, TX) and plasma glucose
and triglyceride levels were assayed using colormetric assays (Cayman Chemicals, Ann
Arbor, MI), all using manufacturer's instructions. (Plasma CORT concentrations were
measured using a commercially available radioimmunoassay (MP Biomedicals, Inc., Solon,
OH). Samples were analyzed in duplicate and results are reported as ng/ml. The assay
provided an intra-assay coefficient of variation of 8%, with a lower limit of detectability of
15.9 ng/ml.

Pair Feeding
The amount of food eaten and body weight were recorded daily. For pair feeding, mice
receiving CORT were fed the same amount of regular chow as age matched vehicle group.

Quantitative reverse transcription (RT)-PCR
In initial studies, looking gene transcription large PCR arrays were used to look at
numerous genes known to affect the pathways of obesity and insulin resistance. For these
initial studies, mRNA from WAT and brain punches was isolated using the Rneasy Lipid
Tissue Mini Kit (Qiagen) and the RT2 First Strand Kit (SABiosciences) was used to create
cDNA. Resultant cDNA was used to perform qPCR on RT2Obesity Pathway and insulin
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resistant PCR Arrays (SABiosciences). Plates were read on the Roche LightCycler 480 with
1 cycle of 10 min at 95°C followed by 45 cycles of 15s at 95°C and 1 min at 60°C. SYBER
Green fluorescence was monitored at the annealing step of each cycle and analyzed with
LightCycler Software.
In subsequent studies looking at gene expression, mRNA from liver was extracted using
Qiagen’s RNeasy Mini kit, and mRNA from WAT and brain punches (in Chapter 4) or
dissected hippocampus and amygdala brain regions (from vehicle and CORT treated mice in
Chapter 6) were separately homogenized in 1 mL of QIAzol (Qiagen). For the latter, total
RNA was extracted using a RNAeasy Mini Kit (Qiagen,Valencia, CA, USA) according to
manufacturer’s recommendations. For all samples, DNAse digestion, to remove
contaminating genomic DNA, was also completed using the kit and manufacturer’s protocol.
Following extraction and digestion, the purity and concentration of RNA were determined by
NanoDrop 260/280 ratios (NanoDrop Technologies, Wilmington, DE). All samples tested
had a purity of 1.7-2.0. Two micrograms of total RNA, as evaluated by NanoDrop, was
reverse transcribed using High Capacity cDNA Reverse Transcription Kits (Applied
Biosystems, Foster City, CA) using the manufacturer’s recommendations. Target gene
expression was quantified with gene-specific primers and Power SYBR Green master mix
(ABI) using Applied Biosystems 7900HT Sequence Detection System at 95°C for 10 min,
followed by 35 cycles of 95°C for 15 sec, 60°C for 15 sec, and 72°C for 30 sec. Each sample
was done in triplicate, and each reaction was repeated at least once to ensure reproducibility.
Raw threshold-cycle (Ct) values were obtained from the Sequence Detection Systems 2.0
software (Applied Biosystems). An average cycle threshold value (Ct) was calculated from
triplicate results for each gene. Threshold values were normalized to the housekeeping gene
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GAPDH or β-actin, to provide ∆Ct values. Fold change for each gene was then calculated
using the formula 2-∆Ct. Forward and reverse primers were as described in Table 1.

In Situ
To determine CRH mRNA containing cells, fresh frozen brains were cut at 20µM in the
cryostat. We constructed a CRH riboprobe, a pBluescript SK vector containing a 1.2-kb
fragment of the rat CRH cDNA was linerized with XhoI and SacI to make antisense and
sense cRNA probes, respectively. Labeled RNA probes were synthesized by in vitro
transcription of lineraized, gel-purified DNA templates using the appropriate T3 and T7
polymerases with S35-labeled UTP. Full-length probes were separated from labeling
reactions via size-exclusion columns before being mixed with hybridization buffer and
measured for specific activity.
Only a random subset of animals (n = 4-5 per group) were processed for in situ
hybridization histochemistry; remaining brains were punched for qRT-PCR. In brief, slidemounted sections were thawed and fixed in 3.8% formaldehyde for 10 min. Sections were
then processed with proteinase K [1 mg/ml, 0.1 m Tris buffer (pH 8.0); 50 mm EDTA; 10
min] at 37 C and 0.25% acetic anhydride in 0.1 m triethanolamine for 10 min. Before
hybridization, slides were rapidly dehydrated in a graded series of ethanols (70, 95, and
100%). Sections were incubated in hybridization buffer [60% formamide; 10% dextran
sulfate; 10 mm Tris-HCl (pH 8.0); 1 mm EDTA (pH 8.0); 0.6 m NaCl; 0.2% Nlaurylsarcosine, 500 mg/ml; 200 mg/ml tRNA; 1× Denhardt’s; 0.25% sodium dodecyl sulfate
(SDS); and 10 mm dithiothreitol] containing DIG-labeled CRH antisense cRNA probes for
16 h at 60 C. After a high-stringency posthybridization wash, sections were treated with
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RNase A and were then further processed for immunodetection with a nucleic acid detection
kit (Roche Molecular Biochemicals, Indianapolis, IN). Sections were incubated in 1.0%
blocking reagent in buffer 1 [100 mm Tris-HCl buffer, 150 mm NaCl (pH 7.5)] for 1 h at
room temperature and then incubated at 4C in an alkaline phosphatase-conjugated DIG
antibody (Roche Applied Science, Indianapolis, IN) diluted 1:3500 in buffer 1 for 3 d. On the
following day, sections were washed in buffer 1 twice (5 min each) and incubated in buffer 3
[100 mm Tris-HCl buffer (pH 9.5), containing 100 mm NaCl and 50 mm MgCl2] for 5 min.
They were then incubated in a solution containing nitroblue tetrazolium salt (0.34 mg/ml)
and 5-bromo-4-chrolo-3-indolyl phosphate toluidinium salt (0.18 mg/ml; Roche Applied
Science) for 8 h. The colorimetric reaction was halted by immersing the sections in buffer 4
[10 mm Tris-HCl containing 1 mm EDTA (pH 8.0)]. Tissue hybridized with the sense probe
resulted in no specific labeling.

Metabolic Phenotyping of CB1-/- mice on chronic CORT
Body composition was determined using NMR technology (EchoMRI, Waco, TX), which
reports fat, lean tissue, and water content of the animal. To determine energy expenditure,
mice were adapted to individual metabolic chambers. Metabolic measurements (oxygen
consumption, carbon dioxide production, food intake, and locomotor activity) were obtained
continuously using a CLAMS (Columbus Instruments) open-circuit indirect calorimetry
system for 5 consecutive days. RQ was calculated as CO2 (VCO2) production/O2(VO2)
consumption, with the values of 1 or 0.7 indicating 100% CHO or 100% fat oxidation (FO),
respectively. FO and CHO were calculated as FO=1.69*VO2-1.69*VO2 and
CHO=4.57*VCO2-3.23*VO2 and expresses as ml/kg/hr. 169
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Insulin sensitivity was assessed using a .75 U intraperitoneal insulin challenge after a 6 h
dark (feeding period) fast with tail blood sampling before and after injection. Blood glucose
was analyzed using the OneTouch Ultra Blood Glucose Monitoring System (LifeScan, Inc,
Milpitas, CA). Circulating leptin, insulin, triglycerides, and adiponectin were measured as
described above. Additional blood parameters including cholesterol and ALT levels were
measured and carried out by the Tri-Institutional core facility.

Measurement of hepatic lipids and VLDL secretion
In both wild type and CB1-/- mice on chronic CORT, total liver lipids were extracted with
Folch extractions. Briefly, snap-frozen liver tissues (∼100 mg) were homogenized and
extracted twice with chloroform/methanol (v/v = 2:1) solution. The organic layer was dried
under nitrogen gas and resolubilized in chloroform containing 2% Triton X-100. This extract
was dried again and resuspended in water and then assayed for triglyceride concentration
using commercial kits as described above.
VLDL-TG secretion rates were determined in mice fasted for 4h and intraperitoneally
injected with 400µl of Pluronic-407 (1mg/g body weight) resuspended in PBS. Blood was
collected in silastic tubes pretreated with heparin prior to injection and at indicated
timepoints (1h, 2h, 4h after injection). Plasma triglyceride levels were measured
enzymatically, as described above. The TG production rate (µmol/kg/h) was calculated from
the difference in plasma TG levels over a given interval following detergent injection. TG
production rates were then expressed as relative changes compared to respective controls.
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Characterization of Endocannabinoid System in CORT treated mice
Membrane Preparation
Brains were removed and the hippocampus, amygdala, and hypothalamus were dissected
over dry ice and stored at − 80 °C until analysis. Liver samples were also collected in this
manner. Membranes were collected from isolated brain regions and liver samples by
homogenization of frozen tissue in 10 volumes of TME buffer (50 mM Tris HCl, pH 7.4; 1
mM EDTA and 3 mM MgCl2). Homogenates were centrifuged at 18,000 x g for 20 min and
the resulting pellet, which contains a crude membrane fraction, was re-suspended in 10
volumes of TME buffer. Protein concentrations were determined by the Bradford method
(Bio-Rad, Hercules, CA, USA).

CB1 Receptor Radioligand Binding Assay
CB1 receptor agonist binding parameters were determined through radioligand
binding using a Multiscreen Filtration System with Durapore 1.2-µM filters (Millipore,
Bedford, MA). Incubations (total volume = 0.2 mL) were carried out using TME buffer
containing 1 mg/mL bovine serum albumin (TME/BSA). Membranes (10 µg protein per
incubate) were added to the wells containing 0.1, 0.25, 0.5, 1.0, 1.5 or 2.5 nM [3H]CP
55,940, a cannabinoid CB1 receptor agonist. Ten µM ∆9-tetrahydrocannabinol was used to
determine non-specific binding. KD and Bmax values were determined by nonlinear curve
fitting of specific binding data to the single site binding equation using GraphPad Prism (San
Diego, CA, USA).
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Fatty Acid Amide Hydrolase (FAAH) Activity Assay
FAAH activity was measured as the conversion of AEA labeled with [3H] in the
ethanolamine portion of the molecule ([3H]AEA)7 to [3H]ethanolamine as reported
previously.170 Membranes were incubated in a final volume of 0.5 ml of TME buffer (50
mM Tris-HCl, 3.0 mM MgCl2, and 1.0 mM EDTA, pH 7.4) containing 1.0 mg/ml fatty acidfree bovine serum albumin and 0.2 nM [3H]AEA. Isotherms were constructed using eight
concentrations of AEA between 10 nM and 10 µM. Incubations were carried out at 37°C and
were stopped with the addition of 2 ml of chloroform/methanol (1:2). After standing at
ambient temperature for 30 min, 0.67 ml of chloroform and 0.6 ml of water were added.
Aqueous and organic phases were separated by centrifugation at 1,000 rpm for 10 min. The
amount of [3H] in 1 ml of the aqueous phase was determined by liquid scintillation counting
and the conversion of [3H]AEA to [3H]ethanolamine was calculated. The binding affinity of
AEA for FAAH (Km) and maximal hydrolytic activity of FAAH (Vmax) values for this
conversion were determined by fitting the data to the Michaelis-Menton equation using
Prism.

Endocannabinoid Extraction and Analysis
Brain regions and liver samples were subjected to a lipid extraction process as
described previously.171 Briefly, tissue samples were weighed and placed into borosilicate
glass culture tubes containing two ml of acetonitrile with 84 pmol of [2H8]anandamide and
186 pmol of [2H8]2-AG. Tissue was homogenized with a glass rod and sonicated for 30 min.
Samples were incubated overnight at -20°C to precipitate proteins, then centrifuged at 1,500 x
g to remove particulates. The supernatants were removed to a new glass tube and evaporated
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to dryness under N2 gas. The samples were resuspended in 300 µl of methanol to recapture
any lipids adhering to the glass tube, and dried again under N2 gas. Final lipid extracts were
suspended in 20 µl of methanol, and stored at –80oC until analysis. The contents of the two
primary endocannabinoids, AEA and 2-AG within lipid extracts in methanol from brain
tissue, were determined using isotope-dilution, liquid chromatography-mass spectrometry as
described previously.173

Endocannabinoid analysis in blood
All extractions were performed using Bond Elut C18 solid-phase extraction columns (1
mL; Varian Inc, Lake Forest, CA). Serum samples (0.5mL each) were thawed and made up
to 15% ethanol, to which the internal standards (Cayman Chemicals, Ann Arbor, MI) were
added. Samples were then vortexed and centrifuged at 1000xg for 4 min. The supernatant
was loaded on C18 columbs which had been conditioned with 1 mL redistilled ethanol and
3mL of double distilled water (ddH2O). The remaining pellet was washed with 100 µL of
15% ethanol and centrifuged again for 3 minutes. The resulting supernatant was also loaded
onto the C18 column. Columns were washed with 5mL ddH2O and eluted with 1mL of ethyl
acetate. The ethy acetate layer in the resulting elute was removed and dried under N2. Lipids
in the residual ddH2O phase were extracted by mixing with an additional 1 mL of ethyl
acetate, which was added to the original ethyl acetate solution. Once dried, samples were
resuspended in 20 µL of methanol and stored at -80°C. Endocannabinoids were quantified
using isotope-dilution, atmospheric pressure, chemical ionization liquid
chromatography/mass spectrometry (LC-APCI-MS) as described elsewhere.172
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Endocannabinoid analysis of adipose tissue
Extensive method development was needed at Northeastern University to accomplish this
task, as a fatty oil results from the liquid-liquid phase extraction of fat. Solid phase
extraction created usable samples that did not completely dirty the mass spectrometer. After
performing reproducibility studies, the samples sent from Rockefeller University have finally
been analyzed.
Mixtures of the dried endocannabinoids and their deuterated analogs that had been stored
at -80°C were reconstituted in ethanol for further dilution in a 20 mg/mL solution of fatty
acid free bovine serum albumin (BSA) to simulate analyte-free tissue and in ethanol to make
the calibration standards, and quality control (QC) samples, as previously described.174 The
calibration curves were constructed from the ratios of the peak areas of the analytes versus
the internal standard.
The extraction procedure for the calibration standards, and quality control started with
protein precipitation with ice cold PBS, pH 7.4, acetonitrile and the internal standard mixture
followed by centrifugation at 14,000 g for 5 minutes at 4°C. Tissue samples were weighed
and homogenized in the same solvents prior to centrifugation. The resulting supernatants
were diluted in 5% phosphoric acid in water, followed by solid phase extraction. OASIS
HLB cartridges (30 mg, 1 mL cartridges) were rinsed with methanol and water prior to
loading the diluted samples. The loaded samples were washed with 40% methanol in water,
eluted with acetonitrile and evaporated to dryness under nitrogen. Samples were
reconstituted in ethanol, vortexed and sonicated briefly and centrifuged prior to immediate
analysis for the endocannabinoids.
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Chromatographic separation was achieved using an Agilent Zorbax SB-CN column
(2.1x50 mm, 5 mm) on a Finnigan TSQ Quantum Ultra triple quad mass spectrometer
(Thermo Electron, San Jose CA) with an Agilent 1100 HPLC on the front end (Agilent
Technologies, Wilmington DE) as previously described9. The mobile phase consisted of 10
mM ammonium acetate, pH 7.3 (A) and methanol (B) in a flow rate of 0.5 ml/min; the
autosampler was kept at 4°C to prevent analyte degradation. Eluted peaks were ionized via
atmospheric pressure chemical ionization (APCI) in MRM mode. Deuterated internal
standards were used for each analyte’s standard curves and their levels per gram tissue were
determined.

Statistical analysis
Data analyses were accomplished using Prism 5 (GraphPad Software, Inc.). T-test, One-way
or Two-way analysis of variance or repeated-measures (RM) ANOVAs were undertaken
where appropriate. Our a priori hypothesis is that the CB1R–/– mice will be resistant to the
effects of CD and glucocorticoid administration, so regardless of significance of the
interactions, Bonferroni posttests were used to examine differences in all variables among
treatment conditions. In all cases, results were considered significant at P < 0.05. One-way
ANOVAs and two-tailed t-tests were conducted to identify significant daily rhythms as
indicated with significant levels at P <0.05.
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Table 2.1 Forward and reverse primers for qRT-PCR.
βActin

Forward

TGTTCCCTTCCACAGGGTGT

βActin

Reverse

TCCCAGTTGGTAACAATGCCA

GAPDH

Forward

ATGACATCAAGAAGGTGGTG

GAPDH

Reverse

CATACCAGGAAATGAGCTTG

CB1R

Forward

GGTTCTGATCCTGGTGGTGTTGAT

CB1R

Reverse

CCGATGAGACAACAGACTTCT

FAAH

Forward

TGTGTGGTGGTGCAGGTACT

FAAH

Reverse

CTGCACTGCTGTCTGTCCAT

MAGL

Forward

CCTGTGTGGCGTGCCGATGAC

MAGL

Reverse

GCTGGAGTCAATGCGCCCCAA

DAGL

Forward

TGGAAACCCCCGCCCATTGC

DAGL

Reverse

CTGCTTGCCTGCACACCCCA

NAPE-PLD Forward

GCTGGGACATGCGACGCTGA

NAPE-PLD Reverse

GCGAAACCGCTTCGGACCCA

SREBP1c

Forward

GGAGCCATGGATTGCACATT

SREBP1c

Reverse

GGCCCGGGAAGTCACTGT

FAS

Forward

CATGACCTCGTGATGAACGTGT

FAS

Reverse

TCGGGTGAGGACGTTTACAAA

ACC-1

Forward

GCGGGAGGAGTTCCTAATTC

ACC-1

Reverse

GGTTGGCATTGTGGATTTTC

PPARα

Forward

GGCTCGGAGGGCTCTGTCATC

PPARα

Reverse

ACATGCACTGGCAGCAGTGGA

PPARγ

Forward

CGGGCTGAGAAGTCACGTT

PPARγ

Reverse

TGCGAGTGGTCTTCCATCAC

HNF4α

Forward

CCGGTTGACTCTTGATGGCT

HNF4α

Reverse

GCTTGTACTTGGTCCCGTCA

G6P

Forward

CCTCCTCAGCCTATGTCTGC

G6P

Reverse

GAGAGCTCTTGGATGGCTTG
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Table 2.1 Continued
Forward
PCG1α

GGAGCC GTGACCACTGACA

PCG1α

Reverse

TGGTTTGCTGCATGGTTCTG

TFAM

Forward

GCTTCCAGGAGGCTAAGGAT

TFAM

Reverse

CCCAATCCCAATGACAACTC

NRF-1

Forward

GGTGCCTAGTGAGAGTGAGTCCCCC

NRF-1

Reverse

TCGGGGCTGAAGAGGGAGAAGTC

Per1

Forward

CAAGTGGCAATGAGTCCAACG

Per1

Reverse

CGAAGTTTGAGCTCCCGAAGT

Per2

Forward

CAGACTCATGATGACAGAGG

Per2

Reverse

GAGATGTACAGGATCTTCCC

Per3

Forward

GTGTACACAGTGTGCAAGCAAACA

Per3

Reverse

ACGGCCGCGAAGGTATCT

Cry1

Forward

CCTCTGTCTGATGACCATGATGA

Cry1

Reverse

CCCAGGCCTTTCTTTCCAA

Cry2

Forward

AGGGCTGCCAAGTGCATCAT

Cry2

Reverse

AGGAAGGGACAGATGCCAATAG

11βHSD1

Forward

AAGGAGCCGCACTTATCTGAAGCCT

11βHSD1

Reverse

GCCCATGAGCTTTCCCGCCTT

11βHSD2

Forward

GGCCTCCTGCCACTCTTGCG

11βHSD2

Reverse

GTGCCGTAGGCTGCCAAGCA
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Chapter 3: Chronic circadian disruption alters body weight, signal regulation, and
glucocorticoid signaling
Abstract
Environmental stressors have consistently been linked to increased rates of morbidity and
mortality, but the specific mechanisms by which such stressors get “under the skin” remain
elusive. Here we look at the impact of disrupted lighting cues as a potential environmental
stressor and means to disrupt circadian rhythms. Similar effects can be caused when
wakefulness occurs at inappropriate biological times due to environmental pressures (i.e.,
early school start times, long work hours that include work at night, shift work, jet lag) or the
occurrence of circadian rhythm sleep disorders. Previous work from the lab demonstrated
that disruption of the light-dark cycle in mice resulted in altered body temperature rhythms
(suggesting a disruption in circadian rhythms), changes in neural function, as well as an
obese phenotype. Here we looked to extend these findings and determine the consequences
of chronic circadian disruption on core clock gene expression, altered hypothalamicpituitary-adrenal (HPA) axis activity as measured through glucocorticoid, particularly
corticosteroid (CORT) signaling, and how the two systems act to induce obesity in this
mouse model on the level of white adipose tissue (WAT) and liver metabolism. We report
here that male C57BL/6 mice exposed to a 10 h light: 10 h dark circadian cycle (LD10)
compared to a normal 12 h light: 12 h dark cycle (LD12) have decreased and blunted diurnal
expression of clock genes in WAT and liver tissue associated with a similar pattern in CORT
secretion. Decreased signaling acted to increase liver lipid content in the absence of
increased food intake, while also decreasing the expression levels and rhythmicity of hepatic
gluconeogenic regulatory genes. Adiposity and adipocyte size are increased in LD10 mice,
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but we were unable to determine direct clock regulation based on measured end points.
Findings in this study provide not only a link between metabolic disorders and environmental
light-dark cycles in non-genetically altered animals, but also suggest altered exogenous light,
as a chronic stressor. Furthermore, it adds to the growing evidence of hypocortisolism as an
outcome of chronic stress and suggests that at least in the case of environment stress
hypocortisolism, rather than hypercorisolism as a potential mechanism linking stress to poor
health.
Rationale
Disruption of normal circadian cycles is a growing problem in modern society, with shift
work and artificial lighting at night being a major contributor.175 The relationship between
circadian disruption (CD) and metabolic dysregulation is becoming appreciated as studies
show that shift work, sleep deprivation and circadian misalignment in humans alter insulin
sensitivity, increase weight gain and promote obesity.176-178 Genetic manipulation in mouse
models has also demonstrated the vital regulatory role clock genes play in energy
balance.166,179-181 As these factors may be significant contributors to the rise in obesity,
understanding the mechanisms’ driving changes in metabolic function caused by CD are of
immediate concern.
Glucocorticoids (GC) especially the corticosteroids (CORT), which are well known to
affect metabolic conditions, entrain circadian rhythms by phase-shifting the expressions of
several core clock genes in peripheral organs, including the liver, kidneys, and heart.145
Therefore, we hypothesized that chronic alterations of the light-dark cycle results in altered
circadian rhythms and CORT levels followed by alterations in metabolic function.
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Experimental Design
For long-term effects of circadian disruption, a total of 80 animals were used (40 exposed
to a 24-h day-12 h light, 12 h dark (LD12); 40 exposed to shortened 20-h day-10 h light, 10 h
dark (LD10)). After 8 weeks in designated light cycle, mice were euthanized at Zeitgeber
time (ZT, ZT12=lights OFF) 0, 6, 12, or 18. Blood, brain, gonadal fat pad (white adipose
tissue (WAT), and liver were collected and processed from each animal.
Results
In order to determine if disruptions of environmental light cues affected the rhythm of
circadian clocks in peripheral tissues, we investigated clock gene expression in WAT and
liver at 4 time points across the circadian cycle. Clock genes showed rhythmic expression in
WAT and liver in LD 12 mice; however, the rhythmic expression of clock genes was
abolished or extremely blunted in WAT and liver from LD 10 mice, indicating disruption of
clock function (Fig 3.1). In WAT of LD12 mice, the rhythmic expression, as determined by
one way ANOVA, of Per1 (F(4,38)=5.106);p=0.003;Fig 3.1A), Per2 (F(4,38)=28.22;
p<0.0001; Fig 3.1B), and Per3 (F(4,38)=27.13;p<0.0001; Fig 3.1C) all showed peak
expression at ZT12 (p<0.05) with a nadir of ZT0 in Per1 and Per3, a nadir of ZT6 in Per2.
Cry1 (F(4,37)=5.85;p=0.001; Fig 3.1D) and Cry2 (F(4,36)=5.394;p=0.002; Fig 3.1E) in
WAT showed peaks at ZT18 (p<0.05) with a nadir of ZT6 in Cry1 and ZT0 in Cry2. In
LD12 mice, Per1 (F(4,37)=15.23; p<0.0001; Fig 3.1F) and Per3(F(4,38)=18.77; p<.0001; Fig
3.1H) in the liver showed peaks at ZT12(p<0.05) with nadirs at ZT0. Per2 in the liver in
LD12 mice was rhythmic (F(4,35)=12.15; p<0.0001;Fig 3.1G) with an extended peak from
ZT12-ZT18(ZT0 vs. ZT12/18, p<0.05) and nadir at ZT0. Cry1 in the liver
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(F(4,39)=4.8;p=0.003; Fig 3.1J) showed a peak at ZT18 (p<0.05) and a nadir at ZT6. Clock
gene expression measured in the dorsal hippocampus revealed no effect of CD (Fig 3.2).
To better understand the underlying mechanisms of circadian clock disruption in WAT,
which may account for weight gain, shown to be significantly higher in LD 10 mice
compared to LD 12 mice as early as week 2 as previously shown,166 we analyzed circadian
variations in mRNAs of genes involved in WAT lipid metabolism. PPARγ was selected
from literature describing its direct relation to Per2, and for its central role in the control of
adipocyte gene expression and differentiation. PPARα is less adipogenic but is able to
induce significant differentiation in response to strong PPARα activators (Fig 3.3). 182,183
Although somewhat decreased at ZT12, there was no statistical difference in expression of
PPARα between groups; similarly there was no difference in PPARγ, although there appears
to be a slight phase advance in LD10 mice. Despite no differences here, there was an
increase in adipocyte size in LD10 compared to LD12 mice (t test, P=0.0309; Fig 3.4A-C).
To study the effects of shorter light cycles and subsequent decreased clock gene
expression on liver tissue, we measured the expression of genes involved in glucose
homeostasis. Hepatocyte nuclear factor 4α (HNF4α) and PParα were selected from
literature which suggest them to be regulated by Per2;182 they further act as transcriptional
factors that regulate glucose-6-phosphatase (G6P), a rate-limiting enzyme in
gluconeogenesis. mRNA expression was blunted in LD10 mice with no rhythmicity in
HNF4α, PPARα, or G6P as determined by one way ANOVA, compared to LD12 mice in
which HNF4α was rhythmic (F(4,19)=4.24;p=.017) with peak levels at ZT18 (p<.05) and a
nadir at ZT0 (Fig 3.5A).
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Figure 3.1 Circadian profile in liver and WAT of control and circadian disrupted mice. A shortened light cycle
of 10h light: 10 h dark, compared to the regular 12h light: 12 h dark paradigm resulted in blunted circadian

rhythms (n=6-8/group and time point). The ZT0 group is re-blotted as ZT24 for continuity. The active period is

indicated by the dark bar on the x-axis. Fold changes of gene expression (±SEM) in WAT (A-E) and liver (F-J)
in LD12( ) and LD10( ) were determined by qRT-PCR. Values represent the level of normalized gene
expression relative to the mean, overall normalized gene expression to ZT6. Significant peak levels of

expression in LD12 to LD10 * p<0.05,**p<0.01, and ***p<.001 by two way ANOVA and Bonferroni posttest.
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Figure 3.2 Clock gene expression in dorsal hippocampus of control and circadian disrupted
mice. A shortened light cycle of 10h light: 10 h dark, compared to the regular 12h light: 12 h
dark paradigm showed no significant difference between groups in either (A)Per1 or (B)
Cry1 mRNA expression in the dorsal hippocampus as determined by qRT-PCR, n=4/group
and time point. The ZT0 group is re-blotted as ZT24 for continuity. Fold changes of gene
expression (±SEM) ,values represent the level of normalized gene expression relative to the
mean, overall normalized gene expression to ZT6.

Figure 3.3 Transcripts involved in lipid metabolism in white adipose tissue (WAT) of
circadian disrupted (LD 10) and control (LD12) mice. Expressions of mRNAs encoding (A)
PParα and (B) PParγ. N=4/group for each observed time point. Values represent the level of
normalized gene expression relative to the mean, overall normalized gene expression to ZT6.
Results are expressed as means ± SEM. Two-way ANOVA was used to determine variance
with respect to time and groups, followed by Bonferroni's post hoc test.
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Figure 3.4 Histology of white adipose tissue (WAT) and liver sections in circadian disrupted
(LD 10) and control (LD12) mice. WAT samples embedded in paraffin were sectioned at 8
µm and stained with H&E. Representative samples from (B) LD12 and (C) LD10 mice
shown here at 10x. (A) 5 samples from LD 10 and LD 12 mice euthanized at ZT 6 were
analyzed for adipocyte length, 20 random droplets were measured per mouse. Fresh frozen
liver samples were sections at 14 µm and stained with Oil Red O. (E) LD10 mice have an
increased presence of lipid droplets compared to (D) LD12 mice. Representative samples
from LD10 and LD12 mice shown here at 10x.

Figure 3.5 Transcripts involved in lipid and glucose metabolism in the livers of circadian
disrupted (LD 10) and control (LD12) mice. (A) HNF4α showed blunted and decreased
expression in LD 10 mice. (B) PParα and (C) G6P have a slightly decreased rhythm in
LD10 mice but these values did not reach significance. N=4/group for each observed time
point. Values represent the level of normalized gene expression relative to the mean, overall
normalized gene expression to ZT6. Results are expressed as means ± SEM. Two-way
ANOVA was used to determine variance with respect to time and groups, followed by
Bonferroni's post hoc test.
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Figure 3.6 Chronic circadian disruption results in changes in the diurnal pattern of plasma
CORT levels. (A) Graph depicts total plasma CORT levels taken at 4 time intervals (n=910/group/time point). (B) Depicts circulating levels of CBG protein in plasma (n=35/group/timepoint). In each graph ZT0 is blotted again as ZT24 for continuity. While
circulating levels of CBG are great in LD10 mice, (D) Immunohistochemistry stain for CBG
protein and (C) cluster count from stain indicate a decreased presence in the liver, also
suggesting increased levels in circulation. *P<0.05, ***P<0.001 mark significant in LD12 vs.
LD10.

51

There was also a significant decrease in HNF4α expression between LD10 and LD12 at
ZT18 (p<.001). G6P also showed a rhythmic pattern (F(3,14)=3.778; p=.044) with a peak at
ZT18 (p<.05) and a nadir at ZT6 (Fig 3.5C). While LD10 levels were blunted, there was no
significant difference from LD12 in either G6P nor PPARα mRNA expression (Fig 3.5B).
In determining the effects of chronic circadian disruption on HPA-axis activity across the
day, levels of plasma CORT were measured at 4 time intervals. As expected LD12 mice
followed the diurnal pattern of total CORT plasma levels (F(4,47)=10.77;p<0.0001)) with
highest levels at ZT12, corresponding to lights out (p<0.05, Fig 3.6A ). LD10 resulted in a
blunted rhythm with no clear peak and significantly lower levels at ZT12 (p<0.01)
Circulating CBG protein levels also followed a daily pattern (F(2,24)=3.006; p=0.043) in
LD12 mice with a nadir at ZT12 (ZT0 vs. ZT12 t test, p=0.0316; Fig 3.6B). This level was
significantly higher in LD10 mice at ZT12 (t test p=0.0252). CBG levels, measured by
immunohistochemistry in livers of LD10 and LD12 mice, revealed a much greater level in
control mice (t test p<0.0001, Fig 3.6 C-D), suggestive of increased levels in circulation in
LD10 mice.
In order to determine the availability of free CORT at the tissue level, we also measured
the diurnal mRNA expression of the enzymes 11βHSD1/2 in the WAT and liver, as well as
the protein expression of these enzymes at ZT6 (Fig 3.7). In WAT there was no difference in
the expression of 11βHSD1 between LD10 and LD12, but 11βHSD2 showed a rhythmic
expression in LD12 mice (F(4,18)=6.04; p=0.005) with a peak at ZT12 (p<0.05) and was
significantly greater than LD10 at ZT12 (p<0.01; Fig 3.7B).

In the liver mRNA expression

of 11βHSD1 showed no rhythmicity in either group but two-way ANOVA pulled out a slight
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interaction between LD10 and L12 mice (F(4,65)=2.59;p=0.047, Fig 3.7C). In the liver there
was a slight rhythmic expression of 11βHSD2 in LD12 mice, but levels did not reach
significance (F(4,34)=2.465;p=0.065); however, peak expression in LD12 mice at ZT 6 was
greater (p=0.05) than in the LD10 condition (Fig 3.7D). LD10 mice showed a peak of
11βHSD2 mRNA (p<0.05).
To determine the extent of HPA-axis dysregulation, we measured CRH in the PVN and
amygdala. Analysis of in situ hybridization in the PVN revealed a main effect of light cycle
but no effect in rhythmicity. LD12 mice showed an increased mRNA expression of CRH
(F(1,74)=7.896;p=0.006) at ZT6 as revealed by posttests analysis (p<0.05; Fig 3.8A and C).
Analysis in the amygdala found a small interaction between groups
(F(4,34)=3.314;p=0.0214) and a main effect of time of day (F(4,34)=2.851;p=0.039; Fig
3.8B and D), as noted by increased expression at ZT18 in LD12 mice (p<0.05).
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Figure 3.7 Diurnal mRNA expression of 11β-hydroxysteroid dehydrogenase type 1 and 2 in
white adipose tissue (WAT) and liver. A shortened light cycle of 10h light: 10 h dark (LD10),
compared to the regular 12h light: 12 h dark (LD12) had no effect on (A) 11βHDS1 mRNA
expression in WAT or (C) liver, but the paradigm resulted in blunted circadian rhythms of
11βHDS2 in (B) WAT and a shift in the (D). (n=4-6/group and time point). The ZT0 group is
re-blotted as ZT24 for continuity. Fold changes of gene expression (±SEM) were determined
by qRT-PCR. Values represent the level of normalized gene expression relative to the mean,
overall normalized gene expression to ZT6. Significant peak levels of expression in LD12 to
LD10 * p<0.05 and**p<0.01by two way ANOVA and Bonferroni posttest.
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Figure 3.8 mRNA expression of CRH levels in the PVN and amygdala from circadian
disrupted mice. In situ hybridization of CRH revealed a decreased and shifted expression in
the (A) PVN and (B) amygdala of LD10 mice. n=6-9/group/time point, as determined by
densitometry and plotted as optical density. Representative expression in (C) PVN from
ZT6 and (D) amygdala from ZT18. * denotes P<0.05, **P<0.01.
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Discussion
In the current study we utilized the LD10 model of circadian disruption and showed that
beyond increased adiposity and circulating insulin and leptin levels, LD10 mice display
increased lipid content in their livers, suggesting the development of fatty liver, and
increased size of adipocytes. To reveal the impact of the circadian timing system on this
metabolic phenotype, we first looked at clock gene expression in the WAT, liver, and
hippocampus. While we showed diurnal variations in WAT and liver, there was no
significant effect of circadian disruption in the hippocampus. Data here is consistent with
findings in rats where adrenalectomy abolished the Per2 expression in the central nucleus of
the amygdala, but had no effect on rhythms in the basolateral amygdala and dentate gyrus.184
Changes in expression of peripheral genes as revealed here come as no surprise given the
observed metabolic abnormalities in CLOCK mutant mice,179 in a paramount study which
linked metabolic function to the molecular clock. In the current study, we went a step further
and demonstrated that environmental change can have a similar impact, a concept easily
translated into human life. More recent studies have shown the importance of clock
alignment in the periphery, particularly in adipose tissue.180,181
Given that we saw no difference in the hippocampus but strong effects in the periphery,
we turned to see if corticosterone (CORT), the primary corticosteroid in mice were playing a
role here. CORT has previously been shown to act as an entrainer for peripheral organs
because it is secreted in daily cycles, and its receptor is expressed in most cell types with the
exception of neurons in the SCN.143-144 Corticotropin-releasing hormone (CRH) is also
released in a pulsatile manner, and along with arginine vasopressin (AVP) in the
hypothalamus, drives the pulsatile release of CORT from the adrenal cortex. Increased
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CORT secretion at the circadian peak depends on increased HPA-axis activity and on
increased sensitivity of the adrenal cortex to adrenocorticotropic hormone (ACTH).185
Decreased or shifted CRH data presented here suggest, in conjunction with decreased
circulating CORT in LD10 mice, that the CD model represents some level of HPA-axis
dysregulation.
Beyond an arrhythmic and overall decreased level of CORT in disrupted mice, we also
noted an increase in corticosteroid-binding globulin (CBG), which is produced in the liver
and circulates in the plasma binding CORT with high affinity.186 CORT bound to CBG is
biologically inactive187,188 and, therefore, is important to measure to get an idea of the free
circulating CORT that is able to bind to receptors. Thus, in addition to decreased circulation
in total CORT, disrupted mice have significantly reduced free CORT.
CBG levels are known to be affected by season, stress, and time of day189-195 The time of
day finding in CBG was dependent on the diurnal nature of CORT.195 In this study it may be
the case that disruption not only leads to dysregulation of the HPA-axis as exhibited by
decreased CORT circulation, and decreased or delayed expression of CRH in the PVN, but
an overall misalignment in CORT regulation.
This hypothesis was strengthened by investigation of 11β-hydroxysteroid dehydrogenase
(11βHSD) type 1 and 2, the enzymes responsible for reducing cortisone to the active
hormone corticosterone and conversely inactivating corticosterone to cortisone, respectively.
These enzymes work at the tissue level to activate or deactivate CORT depending on the
tissue’s needs or in the case of the kidney tubules, where 11βHSD2 is highly expressed, to
enable aldosterone to reach the mineralocorticoid receptor by deactivating CORT. In our
study presented here, we showed no significant differences in 11βHSD1 in either the WAT
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or the liver, while there was a nice rhythmic expression of 11βHSD2 in LD12 mice, with a
peak in WAT that corresponded with an increase in circulating CORT levels suggesting that
11βHSD2 was working to decrease CORT availability in WAT at ZT12. This expression
was blunted in LD10 mice and while it is possible that we missed a peak in these mice due to
our sample times, overall 11βHSD2 levels were decreased. In the liver, 11βHSD2 was
shifted in the LD10 mice, while again this could be in relation to a peak that we missed in our
times of data collection, it speaks more to our hypothesis that the system of CORT regulation
is not in synchrony.
Increased circulating CORT is known to increase adiposity especially in the visceral area
through increased lipogenesis,86,87,104 but the role of blunted CORT on metabolism is less
clear. Given that arrhythmic CORT in LD10 mice led to arrhythmic expression of clock
genes, we examined Per2 interactions with nuclear receptor PPARα and PPARγ and nuclear
receptor target genes, including Hnf4α, and G6P, were altered in disrupted mice.182,196 In
WAT there was no significant difference in either PPARα or PPARγ although mRNA levels
showed a flatter rhythm. The same was the case in the liver where Hnf4α, G6Pc, and PPARγ
(the expression of these factors are greater in the liver than WAT)197 displayed a
significantly flatter rhythm in Hnf4α mRNA levels suggesting impairment of
gluconeogenesis in LD10 mice.
It remains to be determined how alterations in gene expression and CORT regulation,
which appear to have negative metabolic effects, align with feeding behavior. While we
have shown no difference in overall food intake, several studies have demonstrated the
importance of daily feeding time,198,199 which has shown to alter the liver metabolome, as
well as nutrient utilization and energy expenditure. 200,201 In CD mice misalignment in
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feeding behavior, energy metabolism, and substrate utilization could become worse overtime,
as the mice are unable to adjust to the light-cycle. Change in feeding behavior independent
of enzyme and receptor regulation could further modify rhythms, as again food availability
and food intake alone are sufficient to change rhythms. In this way, weight gain may be a
consequence of the body’s means to maintain allostasis.
How these findings translate to humans is an important area of research because such
effects could put chronically disrupted individuals at risk for developing metabolic and
cardiovascular problems. More recently the phenomenon of blunted and decreased daily
CORT release, referred here as hypocortisolism, has also been reported for patients suffering
from PTSD.51 More extensive research has also shown the presence of hypocortisolism in
body disorders such as burnout, chronic fatigue syndrome, fibromyalgia, chronic pelvic pain
and asthma, as well as in healthy individuals living under conditions of ongoing stress.50, 55
If circadian disruption is able to have a similar effect on CORT circulation, then the
phenomena of hypocortisolism may be more common place than once thought, given the
number of individuals who operate in conditions where circadian disruption is present (e.g.,
scientist running circadian experiments, doctors, nurses, and pilots to name a few). As with
individuals and animals with chronic stress, chronic circadian disruption could thereby have
a markedly altered regulation of the circadian and ultradian rhythms. The circadian rhythm
is flattened or lost leading to metabolic abnormalities as we see here, cognitive deficits,166
impaired inflammatory response as we noted in decreased Il-6 circulation after an LPS
challenge (unpublished data), suggesting an overall altered response to acute stressors.
The degree to which the noted metabolic disturbances reflect dysregulation of the clock,
dysregulation of CORT, or an interaction between these two systems also remains to be
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determined. Studies looking at the effects of chronic mild stress in both BALB/c mice and
C57BL/6 mice showed marked differences in terms of end point measurements in terms of
corticosterone levels, clock gene expression, and subsequent metabolic parameters. Future
work looking into these two mouse strains, which have been shown to have differential
responses to HPA-axis perturbations, could shed light on the extent CORT is having an effect
in this model of CD.202,203
In summary, chronic alterations in environmental lighting cues results in a loss of
rhythmicity and dysregulation of CORT secretion. The pattern of CORT activity is
associated with the loss of rhythmic clock gene expression in WAT and liver. In WAT the
direct relationship to circadian control and lipogenesis remains unclear, but CD appears to
alter glucose metabolism in the liver through decreased expression of Hnf4α and G6P.
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Chapter 4: Chronic glucocorticoid exposure alters metabolism and circadian rhythms
Abstract
Chronic glucocorticoid (GC) exposure, as often occurs under conditions of pervasive
stress, is accepted as one of the mediators of the obesity and metabolic syndrome epidemic
plaguing our nation; however, the molecular mechanisms connecting increased GCs to
metabolic dysregulation remains unclear. GC hormones, particularly corticosteroids (CORT)
also play a role in the regulation of circadian (daily) rhythms, particularly in some peripheral
tissues, as well as in the bed nucleus of the stria terminalis and central nucleus of the
amygdala in the brain. CORT effects on rhythms seem to be mediated through direct effects
on “clock genes” that regulate intrinsic timing at the cellular level. Given the effect of CORT
secretion and signaling on clock gene expression, an imbalance or disruption in CORT
signals could affect nutrient metabolism, storage, and feeding related hormone responses.
We have recently developed a non-invasive model of CORT administration that delivers
CORT through the drinking water of mice. This results in rapid and dramatic increases in
weight gain, increased adiposity, elevated plasma leptin, insulin and triglyceride levels, and
hyperphagia. In this study, we aimed to determine how chronic high levels of CORT impact
circadian rhythms, clock gene expression, and related changes in metabolism. Prolonged
treatment with CORT resulted in alteration of circadian rhythms as noted by body
temperature, activity levels, and decreased clock gene expression in both white adipose tissue
(WAT) and liver. Constant darkness also revealed the ability of increased circulating CORT
to decouple clock gene expression in WAT. Additional metabolic analysis in WAT and liver
revealed disruptions to lipid and glucose metabolism related pathways. As CORT mice
continue to gain weight in the absence of hyperphagia, these effects are likely independent of
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food intake. Thus, increased exposure to CORT can interfere with the circadian expression of
both core clock genes and metabolism-related genes, offering a mechanism that could
contribute to metabolic disorders in our modern 24/7, stressful society.

Rationale
Glucocorticoid (GC) hormones are thought to play a role in the regulation of clock genes
involved in the generation of circadian rhythms in peripheral tissues, as well as the bed
nucleus of the stria terminalis and central nucleus of the amygdala in the brain.184,145 Recent
studies have also shown circadian rhythmicity in glucocorticoid-related gene expression in
human adipose tissue, suggesting that intra-depot cortisol action can be modified in a
circadian fashion at the tissue level.204 Given that increased weight gain and decreased
circulation of CORT were associated with decreased expression of clock genes in the
periphery (as shown in Chapter 3), we wanted to explore how chronic administration of
CORT in the drinking water would affect circadian rhythms as measured through activity,
body temperature, clock gene expression and metabolism related genes.

Experimental design
The experiment was carried out with 2 cohorts of mice. In the first group, 48 mice were
obtained and placed on vehicle, 25 µg/mL or 100 µg/mL CORT. After 4 weeks of treatment,
mice were euthanized at Zeitgeber time (ZT, ZT12=lights OFF) 6, 12, or 18 (n=4-6/group, 2
cages were lost during experiment as the result of aggressive fighting). In the second cohort,
24 mice (n=4/group/time point) were surgically implanted with temperature and activity
telemeters. Their daily activity during the light dark cycle was monitored for the duration of
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the 4 week CORT treatment, with the last 72 hours in constant darkness (DD). Mice in this
cohort were euthanized at circadian time (CT, CT12 = start of daily activity) 12 or CT18
based on their free running period. Blood and tissue were collected at the end of the
experiment for processing.

Results
Mice chronically treated with CORT in the drinking water displayed biphasic activity as
suggested by actograms (Fig 4.1A-C) and tempograms (Supplemental Fig 4.1 A-C), where
there was a noticeable gap in the middle of the active cycle compared to control mice.
Overall activity levels were clearly decreased in CORT treated mice. One way ANOVA and
Tukey posthoc revealed decreased daytime activity in 100 µg/mL CORT treated mice
(F(2,26)=4.103, p=0.0293), and decreased nighttime activity in both 25 and 100 µg/mL
CORT treated mice (F(2,26)=105.3, p<0.0001; Fig 4.1F). A decreased or flattened
amplitude in circadian rhythm in CORT treated mice was also made evident by comparing
the magnitude of the change between daytime and nighttime activity levels
(F(1,40)=25.28;p<0.0001; Fig 4.1E). Bonferroni posthoc showed increased effect from days
1-8, to days 9-6 in CORT treated mice only (p<0.05). Although there were no change in
body temperature amplitudes from week-to-week, actual body temperature was decreased in
CORT treated mice (F(2,13)=18.78, p<0.0001; Supplemental Fig 4.1E), again suggesting a
flatter rhythm in CORT mice . Mice were placed in DD (constant darkness) for the final
three days of the experiment to determine affects on free running circadian rhythm. DD in
the actogram (Fig 4.1A-C) is noted by a decrease in Qp, an indicator of circadian robustness.
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Figure 4.1 Activity patterns of vehicle and CORT treated mice. Activity levels were recorded
in the light-dark cycle through the duration of the 4 week experiment with the use of
surgically implanted MiniMitters. (A) Vehicle mice showed normal activity patters in the
light-day cycle while both (B) 25 µg/mL and (C) 100µg/mL doses of CORT treatment
resulted in biphasic activity patterns. (E) Altered patterns in activity resulted in a decreased
“day-night” locomotor activity in CORT treated mice, indicating a flatter circadian rhythm,
as well as an (F) overall decrease in locomotor activity. There was no difference in (D)
activity period between groups as determined by free running behavior in constant darkness
during the last 3 days of the experiment. Bars with the same letter are non-statistically
different from one another as determined by two-way ANOVA and plotted ±SEM.
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There was no significant difference in circadian period between groups as measured through
activity and body temperature (Fig 4.1D and Supplemental 4.1D respectively).
Changes in activity levels and free running behavior suggested a change in circadian
behavior that was confirmed by analysis of clock gene expression in the WAT and liver (Fig
4.2). Specifically, in the WAT rhythmic expression of Per1 was detected (F(2,8)=10.12;
p=.0064) in vehicle treated mice with a gradual increase from ZT 6 to ZT 12 and a significant
decrease in expression at ZT 18 (p<.05; Fig 4.2A). Rhythmicity was blunted in 25µg/mL
CORT treated mice and severely flattened in the 100 µg/mL group. Posthoc tests revealed a
significant decrease in Per1 gene expression between vehicle and 100µg/mL CORT groups at
ZT 12 (p<.01). Vehicle treated mice showed a stronger circadian pattern of Per2 mRNA
expression (F (2,8)=24.43; p=.0004), with posthoc tests revealing a significant increase of
expression at ZT 12 (p<.05; Fig 4.2B). Again the 100 µg/mL CORT circadian rhythm was
completely blunted and significantly lower at ZT 12 (p<.01) compared to vehicle treated
mice. Plasma CORT levels were also measured and the typical diurnal pattern was noted in
the vehicle treated mice, with a peak at waking (ZT12 F(2,9)=54.05; p<.0001) and decline
through the day. In CORT treated mice, this rhythm was no longer determined by
endogenous secretion, as adrenal glads in these mice have completely atrophied. As such,
the endogenous rhythm in drinking drove plasma CORT levels.47 In both treated groups,
there was a gradual increase from ZT6 to ZT12 (25 µg/mL p=.014; 100 µg/mL p=.057);
however, unlike vehicle treated mice, CORT plasma levels continued to rise in CORT treated
mice through their active period as they drank water (Figure 4.2C). The increase from ZT12
to ZT18 is modest in the 25 µg/mL group (p=.044), and insignificant in the 100 µg/mL group
(p=.137). The overall levels of plasma CORT were increased in the 100 µg/mL group from
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ZT6 to ZT18 (F (2,11)=6.754; p=.012). At ZT18 these levels were significantly higher in
100 µg/mL mice compared to vehicle treated animals (p<.001).
Under DD conditions, increased mRNA expression of Per1 in WAT of 100 µg/mL CORT
animals suggested a possible decoupling from the endogenous rhythm as a result of increased
CORT intake (Fig 4.3). Analysis of WAT Per1 revealed a main effect of treatment
(F(2,16)=13.21; p<.001) and subsequent posthoc test showed a significant increase in 100
µg/mL treated mice compared to vehicle at CT18 (p<.001). Analysis of CORT drinking
behavior showed an effect of treatment (F(2, 17)=8.906; p=.002) and time of day
(F(1,17)=6.709; p=.019), and an interaction (F(2,17)=3.801;p=.0432). Bonferroni posttests
showed an increase of CORT in vehicle vs. high CORT mice at CT18 (p<.001). These levels
were lower in DD than under LD conditions, with a peak of 411 ng/mL in constant darkness
compared to 600 ng/mL in LD for the 100 µg/mL CORT mice. Similarly, peak levels were
around 160 ng/mL vs. 250 ng/mL for 25 µg/mL CORT treated mice, and 72 ng/mL vs. 151
ng/mL in VEH mice in DD vs. LD, respectively. Per2 expression showed a main effect of
time a day (F(1, 18)=19.15; p<.001), as expression increased from CT12 to CT18 in all
animals.
In the liver, under LD conditions we again observed rhythmic expression of Per1 mRNA
in vehicle treated mice (F(2,11)=5.827; p=.024), as well as a rhythm in Per2 mRNA
(F(2,10)=11.85; p=.004), with daytime difference between ZT6 and ZT12 (P<.05) in both
clock genes (Fig 4.4A and 4.4B). Expression was blunted in both CORT treated groups with
a decrease in expression of Per1 at ZT 12 (VEH vs. 25 µg/mL p<.05, VEH vs. 100 µg/mL
p<.001) and Per2 at ZT 12 (VEH vs. 25 µg/mL p<.001, VEH vs. 100 µg/mL p<.001) and ZT
18 (VEH vs. 100 µg/mL p<.05). In DD there was no difference between groups in Per1
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expression. Per2 showed a main effect of time of day (F(1,17)=25.48; p<.0001), and a slight
effect of treatment (F(2,17)=4.44; p=.028).
In order to determine how CORT treatment and altered circadian rhythms impact WAT
metabolism, we analyzed several genes known to play active rolls in the development of
obesity and insulin resistance in control and the 100 µg/mL CORT treated mice, by using
applied biosciences PCR pathway arrays, results described in Table 4.1 and 4.2. As an active
metabolic organ with constant feedback to appetite and food intake regulation to the brain,
we also used an array to study the impact in the hypothalamus (Table 4.3). Given a decrease
in expression, when comparing to the LD cycle, in all groups with no significant differences
between groups. *indicates P<0.05, ***P<0.001.

Figure 4.2 Exogenous glucocorticoid (CORT) exposure result in decreased expression in
clock genes under the light-dark cycle. White adipose tissue (WAT) from mice after 4 weeks
of VEH, 25 µg/mL or 100 µg/mL CORT treatment was collected at 3 times periods across
the light dark cycle and are shown here in zeitgeber time (ZT). Increasing doses of CORT
resulted in greater reductions in the mRNA expression of (A) Per1 and (B) Per2. Results
presented as fold changes and normalized to VEH ZT6. (C) Plasma CORT levels showed the
typical diurnal rhythm with VEH and increased through the active dark period with both
doses of CORT as they are exposed to the hormone through the day. ** indicates P<0.01,
*** P<0.001.
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Figure 4.3 Exogenous glucocorticoid (CORT) exposure result in differential expression in
clock genes under constant darkness. White adipose tissue (WAT) from mice after 4 weeks
of VEH, 25 µg/mL or 100 µg/mL CORT treatment were collected at the beginning or middle
of their active period and are shown here in circadian time (CT). The 100 µg/mL dose of
CORT resulted in an increased expression of (A) Per1 through the active period while
expression decreased in the 25 µg/mL group and remained flat in VEH mice. (B) Per2
showed increased expression through the active period with little difference between groups.
CORT results are presented as fold changes and normalized to VEH CT12. (C) While plasma
CORT levels were increased in CORT treated mice due to exposure in the drinking water,
levels in all groups were lower than under a light dark cycle. *** indicates P<0.001.
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Figure 4.4 Exogenous corticosterone (CORT) exposure result in decreased expression of
clock genes in both the light-dark cycle and under constant darkness. Liver samples were
collected following 4 weeks of VEH, 25 µg/mL or 100 µg/mL CORT treatment. For lightdark analysis, livers were collected at 3 time periods across the cycle and are shown here in
zeitgeber time (ZT). For constant dark analysis samples were collected at the beginning or
middle of their active period and are shown here in circadian time (CT). Under normal light
conditions, increasing doses of CORT led to decreased and less rhythmic (A) Per1 and (B)
Per2 expression. Under constant darkness levels of (C) Per1 and (D) Per2 showed a decrease
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Table 4.1 Insulin signaling pathway-related gene expression in gonadal fat pads (white
adipose tissue-WAT). Values represent fold change (±SEM; n=4/group) in corticosterone
treated mice compared to vehicle treated mice. Upregulation is noted in red, downregulation
noted by blue. *P<0.05.
Description

Gene Symbol

Thymoma viral proto-oncogene 1
Thymoma viral proto-oncogene 2
Thymoma viral proto-oncogene 3
FK506 binding protein 12-rapamycin associated
protein 1
Glucose-6-phosphatase, catalytic
Glucose-6-phosphatase, catalytic, 2
Growth factor receptor bound protein 2associated protein 1
Glucokinase
Glycerol-3-phosphate dehydrogenase 1
(soluble)
Growth factor receptor bound protein 2
Glycogen synthase kinase 3 beta
Hexokinase 2
Harvey rat sarcoma virus oncogene 1
Insulin-like growth factor I receptor
Insulin-like growth factor 2
Insulin-like growth factor binding protein 1
Insulin I
Insulin-like 3
Insulin receptor substrate 1
Insulin receptor substrate 2
Jun oncogene
V-Ki-ras2 Kirsten rat sarcoma viral oncogene
homolog
Low density lipoprotein receptor
Leptin
Mitogen-activated protein kinase kinase 1
Mitogen-activated protein kinase 1
Nitric oxide synthase 2, inducible
Neuropeptide Y

Akt1
Akt2
Akt3

70

Fold Change
vs. Control
(Vehicle WT)
CORT WT
-2.7435*
-2.6454*
-1.5594

Mtor
G6pc
G6pc2

-3.2344*
-1.4525
-1.6976

Gab1
Gck

-2.5865*
-1.0112

Gpd1
Grb2
Gsk3b
Hk2
Hras1
Igf1r
Igf2
Igfbp1
Ins1
Insl3
Irs1
Irs2
Jun

-1.0147
-2.2245*
-1.9467
-2.4259*
-1.6888*
-5.5828
-4.1655
-1.2363
-11.8433
-2.6272
-2.7721*
-3.6452
-2.5553

Kras
Ldlr
Lep
Map2k1
Mapk1
Nos2
Npy

-1.8006*
-1.1696
1.6234
2.7302
-1.6398
-2.4811
2.3522

Table 4.1 Continued
Phosphoenolpyruvate carboxykinase 2
(mitochondrial)
3-phosphoinositide dependent protein kinase-1
Phosphatidylinositol 3-kinase, catalytic, alpha
polypeptide
Phosphatidylinositol 3-kinase, catalytic, beta
polypeptide
Phosphatidylinositol 3-kinase, regulatory
subunit, polypeptide 1 (p85 alpha)
Phosphatidylinositol 3-kinase, regulatory
subunit, polypeptide 2 (p85 beta)
Peroxisome proliferator activated receptor
gamma
Protein phosphatase 1, catalytic subunit, alpha
isoform
Protein kinase C, gamma
Protein kinase C, iota
Protein kinase C, zeta
Prolactin
Protein tyrosine phosphatase, non-receptor type
1
Protein tyrosine phosphatase, receptor type, F
V-raf-leukemia viral oncogene 1
Resistin
Ribosomal protein S6 kinase polypeptide 1
Harvey rat sarcoma oncogene, subgroup R
Src homology 2 domain-containing
transforming protein C1
Solute carrier family 27 (fatty acid transporter),
member 4
Solute carrier family 2 (facilitated glucose
transporter), member 1
Sorbin and SH3 domain containing 1
Son of sevenless homolog 1 (Drosophila)
Sterol regulatory element binding transcription
factor 1

Pck2
Pdpk1

-1.3319
-2.145

Pik3ca

-2.3925*

Pik3cb

-3.4366*

Pik3r1

-2.047

Pik3r2

-2.5201*

Pparg

-2.0049

Ppp1ca
Prkcc
Prkci
Prkcz
Prl

-1.9979
-2.0118
-2.7625*
-3.3427*
-1.6976

Ptpn1
Ptprf
Raf1
Retn
Rps6ka1
Rras

-2.4683
-3.4967
-2.0223
-2.0118
-1.4201
-1.7183

Shc1

-2.4133*

Slc27a4

-2.0973

Slc2a1
Sorbs1
Sos1

-2.2673*
-1.4959
-1.7124*

Srebf1

-3.3601*

Values represent average fold change (±SEM; n=4/group) in response to corticosterone
treatment (100 µg/mL) mice compared to vehicle (1% ethanol) treated mice. Upregulation
with a fold change greater than 2 is noted in red, downregulation with a fold change less than
.5 noted by blue. All animals were euthanized at ZT6. *P<0.05.
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Table 4.2 Obesity-related gene expression in gonadal fat pads (white adipose tissue-WAT).
Description
Gene Symbol
Fold
Change vs
ControlVehicle WT
CORT WT
Adenylate cyclase activating
polypeptide 1
Adcyap1
0.6276
Adenylate cyclase activating
polypeptide 1 receptor 1
Adcyap1r1
8.1004*
Adiponectin, C1Q and collagen domain
containing
Adipoq
0.3271*
Adiponectin receptor 1
Adipor1
0.8959
Adiponectin receptor 2
Adipor2
0.3547*
Adrenergic receptor, alpha 2b
Adra2b
0.5205
Adrenergic receptor, beta 1
Adrb1
0.5502*
Agouti related protein
Agrp
0.4065*
Apolipoprotein A-IV
Apoa4
3.7877
Attractin
Atrn
0.698*
Brain derived neurotrophic factor
Bdnf
2.3316
Bombesin-like receptor 3
Brs3
0.8149
Complement component 3
C3
0.5657
Calcitonin/calcitonin-related
polypeptide, alpha
Calca
0.7638
Calcitonin receptor
Calcr
0.6276
CART prepropeptide
Cartpt
0.6276
Cholecystokinin
Cck
1.3299
Cholecystokinin A receptor
Cckar
0.0891
Colipase, pancreatic
Clps
0.6276
Cannabinoid receptor 1 (brain)
Cnr1
0.4724*
Ciliary neurotrophic factor receptor
Cntfr
0.2591*
Carboxypeptidase D
Cpd
0.8244
Carboxypeptidase E
Cpe
0.5696
Corticotropin releasing hormone
receptor 1
Crhr1
0.6276
Dopamine receptor D1A
Drd1a
0.3348
Dopamine receptor 2
Drd2
0.6276
Galanin
Gal
0.5979
Galanin receptor 1
Galr1
0.6276
Glucagon
Gcg
0.1014
Glucagon receptor
Gcgr
1.1132
Growth hormone
Gh
0.6276
Growth hormone receptor
Ghr
0.813
Ghrelin
Ghrl
0.6063*
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Table 4.2 Continued
Growth hormone secretagogue receptor
Glucagon-like peptide 1 receptor
Melanin-concentrating hormone
receptor 1
Gastrin releasing peptide
Gastrin releasing peptide receptor
Hypocretin
Hypocretin (orexin) receptor 1
Histamine receptor H1
5-hydroxytryptamine (serotonin)
receptor 2C
Islet amyloid polypeptide
Interleukin 1 alpha
Interleukin 1 beta
Interleukin 1 receptor, type I
Interleukin 6
Interleukin 6 receptor, alpha
Insulin I
Insulin II
Insulin receptor
Leptin
Leptin receptor
Melanocortin 3 receptor
Neuromedin B
Neuromedin B receptor
Neuromedin U
Neuromedin U receptor 1
Neuropeptide Y
Neuropeptide Y receptor Y1
Nuclear receptor subfamily 3, group C,
member 1
Neurotrophic tyrosine kinase, receptor,
type 2
Neurotensin
Neurotensin receptor 1
Opioid receptor, kappa 1
Opioid receptor, mu 1
Sigma non-opioid intracellular receptor
1
Pro-opiomelanocortin-alpha
Peroxisome proliferator activated
receptor alpha
Peroxisome proliferator activated
receptor gamma
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Ghsr
Glp1r

0.6932
0.6276

Mchr1
Grp
Grpr
Hcrt
Hcrtr1
Hrh1

1.3896
0.6276
0.6276
0.8301
0.7327
0.8282

Htr2c
Iapp
Il1a
Il1b
Il1r1
Il6
Il6ra
Ins1
Ins2
Insr
Lep
Lepr
Mc3r
Nmb
Nmbr
Nmu
Nmur1
Npy
Npy1r

0.6276
0.6276
0.6379
0.4868
0.8594
0.4542
0.7603
0.6276
0.6996
0.5193*
2.6172
0.3197*
0.6276
0.3758*
0.8093
0.6483
0.4959
1.6717
145.479

Nr3c1

0.4199*

Ntrk2
Nts
Ntsr1
Oprk1
Oprm1

0.563*
0.9189
0.6276
0.6233
0.3332*

Sigmar1
Pomc

1.2209
0.6948*

Ppara

0.3131*

Pparg

0.5592

Table 4.2 Continued
Peroxisome proliferative activated
receptor, gamma, coactivator 1 alpha
Prolactin releasing hormone receptor
Protein tyrosine phosphatase, nonreceptor type 1
Peptide YY
Receptor (calcitonin) activity modifying
protein 3
Sortilin 1
Somatostatin
Somatostatin receptor 2
Thyroid hormone receptor beta
Tumor necrosis factor
Thyrotropin releasing hormone
Urocortin
Uncoupling protein 1 (mitochondrial,
proton carrier)
Zinc finger protein 91

Ppargc1a
Prlhr

0.3572*
0.6276

Ptpn1
Pyy

0.7709
0.6276

Ramp3
Sort1
Sst
Sstr2
Thrb
Tnf
Trh
Ucn

1.022
0.6604
0.6276
0.7029
0.5169*
0.4627
0.7429
0.6276

Ucp1
Zfp91

0.6276
0.6742

Values represent average fold change (±SEM; n=4/group) in response to corticosterone
treatment (100 µg/mL) mice compared to vehicle (1% ethanol) treated mice. Upregulation
with a fold change greater than 2 is noted in red, downregulation with a fold change less than
.5 noted by blue. All animals were euthanized at ZT6. *P<0.05.
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Table 4.3 Obesity related gene expression in in the hypothalamus of corticosterone (CORT)
and vehicle treated mice.
Description

Gene
Symbol

Adenylate cyclase activating polypeptide 1
Adenylate cyclase activating polypeptide 1
receptor 1
Adiponectin receptor 1
Adiponectin receptor 2
Adrenergic receptor, alpha 2b
Adrenergic receptor, beta 1
Agouti related protein
Apolipoprotein A-IV
Brain derived neurotrophic factor

Adcyap1

Complement component 3
Calcitonin/calcitonin-related polypeptide,
alpha
CART prepropeptide
Cholecystokinin
Cholecystokinin A receptor
Cannabinoid receptor 1 (brain)

Adcyap1r1
Adipor1
Adipor2
Adra2b
Adrb1
Agrp
Apoa4

Fold
Change vs
1% WT
100 WT
1.1856
1.4132
-1.0938
1.4035
2.8992
-1.1014
13.823
4.5757

Bdnf
C3

1.5881
1.4231

Calca
Cartpt
Cck
Cckar

1.8886
1.9084
2.4044
-1.5397

Cnr1

-1.1629

Carboxypeptidase D
Cpd

-1.19

Galanin receptor 1
Glucagon
Glucagon receptor
Growth hormone
Growth hormone receptor
Growth hormone secretagogue receptor
Hypocretin
Hypocretin (orexin) receptor 1
5-hydroxytryptamine (serotonin) receptor 2C

Galr1
Gcg
Gcgr
Gh
Ghr

-1.2666
1.9894
1.9894
1.0393
1.6215

Ghsr
Hcrt
Hcrtr1

2.6494
-1.3159
1.1612

Htr2c

-1.4993**

Islet amyloid polypeptide
Iapp
Il1b
Il1r1

Interleukin 1 beta
Interleukin 1 receptor, type I
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-1.4006
4.0065
2.1347*

Table 4.3 Continued
Insulin I
Insulin II
Leptin receptor
Melanocortin 3 receptor
Neuromedin B
Neuropeptide Y
Neuropeptide Y receptor Y1
Neurotrophic tyrosine kinase, receptor, type 2
Neurotensin
Opioid receptor, mu 1
Pro-opiomelanocortin-alpha
Peroxisome proliferator activated receptor
alpha
Peroxisome proliferator activated receptor
gamma
Peptide YY
Peroxisome proliferative activated receptor,
gamma, coactivator 1 alpha
Receptor (calcitonin) activity modifying
protein 3
Somatostatin
Somatostatin receptor 2
Thyrotropin releasing hormone
Urocortin
Uncoupling protein 1 (mitochondrial, proton
carrier)

Ins1
Ins2
Lepr
Mc3r
Nmb
Npy
Npy1r
Ntrk2
Nts

1.9894
1.9894
2.3064*
1.8777
2.1845
2.3631
1.5699
1.3494
-2.0223*

Oprm1
Pomc

2.0739
7.5371

Ppara

1.2275

Pparg
Pyy

2.0739
7.6954

Ppargc1a

Ramp3
Sst
Sstr2
Trh
Ucn
Ucp1

-1.4499*

1.6309
1.2475
1.1308
-1.4685
1.9462
1.9894

Whole hypothalamus was collected by tissue punch from whole fresh frozen brain. Values
represent average fold change (±SEM; n=4/group) in response to corticosterone treatment
(100 µg/mL) mice compared to vehicle (1% ethanol) treated mice. Upregulation with a fold
change greater than 2 is noted in red, downregulation with a fold change less than .5 noted by
blue. All animals were euthanized at ZT6. *P<0.05 and **P<0.01.
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In order to determine how CORT treatment impact WAT metabolism, and if there was a
circadian component, we analyzed several genes known to play active rolls in the
development of obesity and insulin resistance in control and the 100 µg/mL CORT treated
mice, using SABiosciences RT2PCR pathway arrays, results described in Table 4.1 and 4.2.
As an active metabolic organ with constant feedback to appetite and food intake regulation to
the brain, we also used an array to study the impact in the hypothalamus (Table 4.3). Given a
decrease in PParα in the array (Table 2) and its known intersection with Per2, we analyzed
PParα to great detail across the light-dark cycle. As with Per2, CORT treatment resulted in
decreased expression of PParα most notably at ZT12 (F(2,16)=10.09, p=0.0015; Fig 4.5C),
which coincided with the peak of Per2 expression in VEH mice. HNF4α in the liver was
also analyzed given its interaction with Per2. In CORT treated mice, there was also
decreased expression at ZT18 (F(2, 12)=6.274, p0.0136; Fig 4.5F), which coincided with a
significant decrease of Per2 expression in100 µg/mL CORT treated mice.
Although circulating levels of CORT are increased in treated mice, it is possible through
actions of regulatory enzyme levels that the active level reaching receptors is not greatly
varied. In WAT, 11βHSD1 is increased at ZT6 (p<0.001) but decreased at ZT12 (p<0.01),
and ZT18 (not to significance) as determined by 2 way ANOVAs and Bonferroni posttest
(time of day (F(2, 16)=67.95, p<0.0001; Fig 4.5A). There is a slight decrease of 11βHSD2
in WAT at ZT12 but not to significance (Fig 4.5B). In the liver, CORT treated mice show an
increased in 11βHSD1 expression at the beginning of the dark cycle with decrease at ZT18,
but not significantly greater than controls (Fig 4.5D). 11βHSD2 expression in the liver of
VEH and control mice do not vary greatly at ZT6 or ZT12, but levels escalate greatly in VEH
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mice at ZT18 (p<0.01; Fig 4.5E) as determined by Bonferroni after a main effect in treatment
(F(1, 17)=7.447; p0.0143).
Given that all studies were conducted in whole adipose tissue we stained WAT sections
for F4/80, a membrane protein present in mature macrophages in mice. Staining revealed a
large population of macrophages in 100 µg/mL CORT treated mice (Supplemental Fig 4.2)
compared to VEH mice.
In CORT treated mice, increased circulating leptin and increased mRNA expression (t
test, p=0.016) of the leptin receptor in the hypothalamus in conjunction with abnormal
activity would suggest irregular feeding patters and food intake amounts that could account
for their metabolic abnormalities. However, when CORT treated mice were pair fed (food
intake was limited to that of control mice), they continued to gain a comparable amount of
weight to CORT treated mice fed ad lib, both reaching a significantly greater weight change
at week 4 compared to VEH ad lib fed mice (F(2,11)=6.678; p=0.0167; Fig 4.6), suggesting
that the obese phenotype was independent of food intake.
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Figure 4.5 Diurnal mRNA expression in white adipose tissue (WAT) and liver of control and
100µg/mL CORT treated mice. 4 weeks of chronic high doses of CORT treatment alters the
pattern and degree of expression of (A) 11βHSD type 1 and (B) type 2 in the WAT, as well
as in the liver (D-E, respectively). (C)PParα expression in WAT is decreased at ZT6 and
significantly so at ZT12 while HNF4α decreased through the day to significance at ZT18
(n=3-4/group and time point). Fold changes of gene expression (±SEM) were determined by
qRT-PCR. Values represent the level of normalized gene expression relative to the mean,
overall normalized gene expression to ZT6. Significant peak levels of expression in VEH to
100µg/mL CORT * P<0.05 and**P<0.01, **P<0.001, by two way ANOVA and Bonferroni
posttest.
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Figure 4.6 Clamped food intake in CORT treated mice does not prevent weight gain. CORT
treated mice were pair fed for the duration of treatment. Despite equivalent food intake to
VEH mice (n=4/group) pair fed CORT mice (restricted feeding) continued to gain weight
with comparable levels as CORT ad lib mice. * P<0.05.

80

Supplemental Figure 4.1 Body temperature rhythms of vehicle and CORT treated mice.
Body temperature was recorded in the light-dark cycle through the duration of the 4 week
experiment with the use of surgically implanted MiniMitters. (A) Vehicle mice showed
normal temperature rhythms in the light-day cycle while both (B) 25 µg/mL and (C)
100µg/mL doses of CORT treatment resulted in slight biphasic rhythms. (E) “Day minus
light” revealed a decreased body temperature amplitude in CORT treated mice emphasizing a
flatter rhythm in 25µg/mL and 100 µg/mL CORT mice. There was no difference in (D) body
temperature period between groups as determined by free running behavior in constant
darkness during the last 3 days of the experiment. Bars with the same letter are non
statistically different from one another as determined by two-way ANOVA and plotted
±SEM.
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Supplemental Figure 4.2 Chronic CORT treatment results in macrophage infiltration.
F4/80 stain of WAT reveals an inflammatory response and macrophage penetration after 4
weeks of chronic CORT treatment. Representative photos shown here from n=5 mice/group
killed at ZT6. Top photos show at 10x, bottom photos at 40x.
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Discussion
In this set of studies we showed that chronic CORT treatment resulted in an altered
pattern in daily activity with an increasingly biphasic pattern with one bout of activity at
lights off, a bout of rest, and a final bout of activity before lights on. This separation in
activity is clear in the 25 µg/mL group, but more pronounced in 100 µg/mL CORT treated
mice. In addition, there was an obvious decrease in the amplitude of circadian rhythmicity in
CORT treated animals, as measured by a smaller difference in day vs. night activity. When
mice were placed in DD, they retained a free-running circadian activity rhythm similar to that
of VEH mice. These changes in activity levels were accompanied by decreased clock gene
expression in both white adipose tissue (WAT) and liver. This effect of expression was
larger in 100 µg/mL CORT treated mice compared to the 25 µg/mL group. Constant
darkness revealed a possible decoupling effect of CORT in that we observed an increase in
Per1 mRNA expression in WAT despite the presence of light; this increase was not present
in VEH mice. Per2 mRNA expression did not vary greatly between groups in WAT, but
comparing expression levels with those in the light-dark cycle, we observed increased
expression in CORT animals. Again, this pattern of results suggests that, in the absence of
light cues, high circulating CORT can entrain clock gene rhythms in the WAT. Interestingly,
this effect of CORT was not present in the liver, and indeed expression of both Per1 and Per2
mRNA were decreased in all groups. CORT levels, even in CORT treated mice that received
CORT in their drinking water, showed decreased plasma CORT compared to the same time
points under the light-dark cycle. This decrease in expression in untreated mice is to be
expected given the decrease in rhythmic secretion from adrenals noted in constant dark
conditions4, but it is unclear how the drinking rhythm may be altered in DD in treated mice.
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Molecular studies have shown that occupied GC receptors bind to the glucocorticoidresponsive element (GRE) in the regulatory regions of many genes, thereby regulating target
gene transcription.205 A GRE is located in the promoter region of Per1 and is reportedly
involved in Per1 expression, which allows GCs to directly interact with Per1 as highlighted
in an in vivo study showing Per1 mRNA expression to be induced as the result of acute
stress.206 Therefore, upregulation of GCs induced by overactivation of the HPA axis might
directly affect the circadian expressions of core clock genes in the periphery. Increases in
circulating corticosterone levels and subsequent shifts in gene expression in mouse models of
chronic mild stress203 not only affirm the ability of GCs to entrain peripheral organs, but also
in the case of the later story, also link these changes to metabolic irregularities.
Increased circulation of GCs in the way of persistent stimulation of the HPA axis by
various stressors can cause metabolic disorders, such as insulin resistance, hypertension, and
dyslipidemia.47,149,207 These metabolic disturbances are also induced by dysregulation of the
clock system as noted in Chapter 3, and by others.146,208 It remains to be determined whether
modulation of the HPA axis leads to metabolic problems through the disruption of the clock
system, or if these systems influence the same metabolic pathways independently. Numerous
molecules, such as the PParα and PParγ, PGC-1α, and G6P, play crucial roles as mediating
metabolism and respond to modulations of both the core clock and GCs.146
Most studies exploring the interaction between the clock system and GC entrainment
focus on metabolism on the level of the liver. Given the suggested decoupling effect of
CORT during constant darkness as reported here, we explored in depth the mRNA
expression of various genes known to be affected in pathways of obesity and insulin
resistance, with attention given to PParα as it has been shown to control proadipogenic
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activity in WAT and modulated by Per2; we also made note of HNF-4α in the liver as it is
also modulated by Per2 and showed to be markedly affected by circadian disruption as
observed in Chapter 3.182,209 Analysis of PParα across the light-dark system in CORT treated
mice revealed a decrease consistent with decreased expression of Per2. This pattern was also
the case for HNF-4α expression in the liver, suggesting that altered expression of Per2 is
required for CORT induced perturbations of metabolism-related gene expression to some
degree in both the WAT and liver. In this way we show increased CORT acts together with
the clock system, to perturb the WAT and liver leading to the onset of metabolic
disturbances.
Since CORT levels can be varied on the tissue level through enzymatic regulation, we
examined levels of 11βHSD type1 and type2 in the liver and WAT. Previously it was noted
that CORT treatment resulted in increased protein expression of 11βHSD1 in the WAT but a
decrease in liver, but that was only measured at ZT4-5. In the current study we looked at 3
different time points and saw changes in expression in both the liver and WAT across the day
in both CORT and VEH treated mice. In WAT 11βHSD expression regulates CORT in a
manner consistent with WAT Per clock gene expression. In CORT treated mice, 11βHSD1
increased expression at ZT6, and subsequently further increased presence of active CORT,
resulted in the nadir of both Per1 and Per2 mRNA expression. Conversely, increased
expression of 11βHSD2 in VEH mice at ZT12 corresponds to the peak of Per2 mRNA
expression in WAT. Taken together 11βHSD and Per clock gene expression further suggest
a CORT induced suppression of clock genes in this model. In that regard, GR expression
needs to be measured to determine if levels in CORT treated mice are overall downregulated
at this point of treatment and the subsequent downregulation could possibly result in the
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decreased clock gene expression, which could be the case as suggested by a glucocorticoid
receptor resistance (GCR) model.210
Several recent studies have emphasized that rhythmic abnormalities affect energy
homeostasis, as well as glucose and lipid metabolism,179,211,212 and in turn excess energy in
the way of increased food intake through a high fat diet can also lead to rhythmic
abnormalities16, perhaps also through increases in CORT.136,199 While few studies have
looked at GC induced shifts in clock gene expression in WAT, recent studies have shown
that adipocyte-specific deletion of the core molecular clock component Arntl (also known as
Bmal1) results in obesity in mice, with a shift in the diurnal rhythm of food intake, a result
not seen in gene disruption in hepatocytes alone. 196,121 Additionally, it has been shown that
circadian modulation of lipolysis rates regulate the availability of lipid-derived energy during
the day, suggesting a role for WAT clocks in the regulation of energy homeostasis.181 Taking
these previous reports and our present results together, increased circulation of GCs through
HPA axis activation under chronic stress4 or in states of excess nutrition214 may contribute to
alterations in circadian clock gene expressions in the liver and WAT.
Beyond changes in clock genes and lipogenic factors, PCR array analysis in WAT also
revealed marked decreases in many genes involved in the insulin-signaling pathway, a
finding not surprising, given the increases in weight gain, adiposity, and increased levels of
insulin, leptin and triglycerides in circulation.47 Given that all analysis of WAT came from
full tissue, rather than adipocyte culture, and the ability of macrophages to infiltrate adipose
tissue and produce proinflammatory cytokines that alter organ function,215 their presence
should be kept in mind for future studies.
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As an active metabolic organ, WAT plays a large role in the fast-fed cycle and is able to
activate and deactivate anorectic and orexigenic neurons. For this reason we also ran a PCR
array in hypothalamic tissue. However, apart from neurotensin, a peptide that targets
anorexigenic neuropeptides, MSH and CART, we saw no significant changes in gene
expression.216,217 For this reason we ran a pair feeding study in order to clamp the food
intake of CORT treated mice. After 4 weeks of equivalent food intake to VEH mice, CORT
pair fed mice gained weight at a comparable level to CORT ad lib mice. This finding
suggest that calories are not the final determinate in weight gain in CORT treated mice and
could instead be the result of asynchrony of metabolic mediators.
In summary, to our knowledge, this is the first report to show chronic GCs exposure can
alter clock gene expression in both the WAT and liver. Thus overactivation of the HPA-axis
is likely to play an important role in the underlying mechanism of circadian induced obesity.
The dysregulation of clock gene expression and subsequent loss of rhythmicity in genes
regulating metabolism might trigger metabolic disturbances in states of increased GC
exposure such as chronic stress.
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Chapter 5: Cannabinoid CB1 Receptor deficient mice are resistant to metabolic
dysregulation following both circadian disruption and chronic glucocorticoid
administration
Abstract
In mammals, including humans, disruptions in circadian (daily) rhythms are related to
metabolic dysregulation, such as obesity and type II diabetes. The mechanisms by which
circadian disruption modulates metabolic dysregulation are not well characterized; however,
recent studies by our group suggest that consequences of glucocorticoid (GC) secretion and
regulation may be involved. In the current set of studies we demonstrate that male mice
exposed to a 10 h light: 10 h dark (LD10) circadian cycle or a constant high dose of
corticosterone (CORT) in the drinking water, both of which create profound dysregulation of
endogenous circadian processes including glucocorticoid regulation, and develop symptoms
of metabolic syndrome, as evidenced by increased body weight gain, elevated triglyceride
levels, hyperleptinemia and hyperinsulinemia. Interestingly, mice lacking the cannabinoid
CB1 receptor were protected against all of these changes in metabolic function, indicating
that endocannabinoid signaling is required for circadian disruption to promote obesity and
metabolic syndrome possibly through glucocorticoid regulation. These data build upon
previous findings that indicate the endocannabinoid system is required for diet-induced
obesity, but further suggest that this system plays a much broader role in the regulation of
metabolic processes, as well as acting as a mediator of changes in metabolic function in
response to an array of stimuli, and not just diet composition.
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Rationale
In mammals, circadian (daily) rhythms in physiology and behavior are driven by a
brain clock located in the suprachiasmatic nucleus (SCN) of the hypothalamus, and
synchronized to the environmental light/dark (LD) cycle.218 It is important to note that the
central clock regulates myriad “peripheral” oscillators in the rest of the brain, and periphery,
including organs such as the heart, lungs, and liver, through glucocorticoids, among potential
other entrainers as highlighted in Chapter 3 and 4. As such, it is thought the circadian clock
regulates physiology and behavior both by the central clock, and through diffusible
entraining signals that regulate local clocks in the periphery.
Our lab has modeled the metabolic effects associated with disruptions of the circadian
system in a noninvasive manner as described in Chapter 3, by chronically housing male mice
in 20-h light/dark (LD) cycles, incongruous with their endogenous ~24 hour circadian period.
In terms of metabolic effects, it was demonstrated that chronic circadian disruption (CD)
results in altered body temperature rhythms, increased weight gain, and elevated levels of
plasma insulin and leptin.166 These data are consistent with the increased rates of obesity and
metabolic syndrome in individuals with disrupted circadian cycles.176 Further in Chapters 3
and 4, disruption and subsequent metabolic dysfunction were found to occur in conjunction
with blunted rhythms of clock genes in the liver and WAT and circulating levels of CORT.
When CORT levels were increased, and plasma CORT rhythms altered, as shown in Chapter
4, mice continued to gain weight and showed clear changes in their circadian rhythms. In
both cases, the mechanisms by which this shift in metabolic function that occurred following
CD by light and chronic CORT, are not understood.
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Recent work has led us to hypothesize that the endocannabinoid (eCB) system may
play a role in CD and CORT induced metabolic dysregulation. The eCB system is a lipid
signaling system primarily composed of the endocannabinoids, anandamide (AEA) and 2arachidonylglycerol (2-AG), which exert their effects through activation of CB1 and CB2
cannabinoid receptors.219 Activation of the CB1 receptor results in increased appetite, insulin
resistance, and increased hepatic lipogenesis, suggesting involvement of the
endocannabinoid/CB1 receptor system in obesity and its metabolic consequences.121,167 These
findings are consistent with the distribution of CB1 receptors throughout neural feeding
centers, and in peripheral tissues such as the liver, pancreas and adipose.121,167 CB1 receptordeficient mice, or mice receiving treatment with CB1 receptor antagonists, are resistant to
diet-induced obesity and display improved metabolic measurements when subjected to highfat feeding.121 Similar findings have been reported in humans with the CB1 receptor
antagonist Rimonabant.150 Although the role of the eCB system is established in models of
diet-induced obesity, its role in other models of metabolic dysregulation has not been
explored. Apart from its role in energy homeostasis, the eCB system was a promising choice
since it has been shown to regulate the adaptive stress response, and eCBs are released upon
glucocorticoid release.150,113 Given that the eCB system within the periphery222 and limbic
and feeding centers in the brain223 exhibits circadian fluctuations, the objective of the present
study was to explore the role of eCB signaling in contributing to the metabolic profile of
mice exposed to CD in the way of disruption of light cues, as well as through chronic
exogenous CORT.
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Experiment design
Experiment 1
This portion of the study involved several cohorts of animals. For the CD through
shortened circadian day, 20 mice were initially studied, 5 CB1 receptor knockout (CB1R-/-)
mice placed under LD12 or LD10; and 5 WT mice places under LD12 or LD10 conditions
(n=5/group). After 8 weeks of shift a few mice died leaving n=3-5/group.

Experiment 2
The majority of studies in this chapter were run in the CORT drinking water model given
its shorter duration, which resulted in the loss of few CB1R-/- mice through the duration of a
protocol. In total 4 cohorts of mice (each ranging from 3-6/group and treatment) were run to
explore the interaction between the endocannabinoid system and circulating levels of CORT
on metabolism.
Results
Experiment 1
There was a significant interaction between circadian cycle and genotype on body weight
[F (21, 91) = 2.91, p < 0.0005; Fig. 5.1]. Post hoc analysis revealed wild-type mice exposed
to CD exhibited significant increases in body weight relative to both wild-type mice and
CB1R–/– mice on a 12:12 cycle at every week measured (p < 0.05 for every week). CB1R–/–
mice exposed to CD did not exhibit any increased weight gain, relative to 12:12 wild-type
mice (p > 0.05 for every week, except week 3). However, body weight of CB1R–/– mice

91

exposed to CD was also not significantly different than wild-type mice exposed to CD,
indicating that a loss of CB1 receptors only attenuated, but did not block, the effects of CD on
weight gain. There was also no significant difference in body weight at any time point
between wild-type and CB1R–/– mice on a 12:12 cycle.

Figure 5.1. Circadian disruption causes an increase in body weight gain that is attenuated in
CB1 receptor deficient mice. Disruption of circadian cycles, through housing wild-type (WT)
mice in a 10h:10h light/dark cycle (10:10) results in a progressive increase in weight gain,
relative to WT mice housed in a standard 12h:12h light/dark cycle (12:12). CB1 receptor
knockout mice (KO) exhibit an attenuation in the weight gain induced by circadian
disruption in a 10:10 light/dark cycle relative to WT mice undergoing circadian disruption. *
denotes a significant difference (p < 0.05) in 10:10 WT mice relative to 12:12 WT and KO
mice. 10:10 KO mice represented an intermediate phenotype as they were not significantly
different from either the 10:10 WT mice or the 12:12 WT or KO mice at any time point
(except at week 3 in which the 10:10 KO mice had significantly increased body weight
relative to the 12:12 WT mice). Data are displayed as mean +/- SEM; n = 4-5 / condition.
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Figure 5.2. Circadian disruption causes metabolic dysregulation, as evidenced by an
increase in circulating triglycerides, insulin and leptin, which is blocked in CB1 receptor
deficient mice. Disruption of circadian cycles, through housing wild-type (WT) mice in a
10h:10h light/dark cycle (10:10) results in an increase in circulating levels of triglycerides
(A), insulin (B) and leptin (C), but not glucose (D). CB1 receptor knockout mice (KO)
housed in a 10:10 cycle did not exhibit any changes in metabolic markers in the circulation,
indicating an integral role of the CB1 receptor in mediating metabolic dysregulation
following circadian disruption. * denotes significant differences between WT mice housed in
a 10:10 cycle relative to both WT and KO mice housed in 12h:12h light/dark cycle (12:12)
conditions and KO mice housed in 10:10 conditions. Data are displayed as mean +/- SEM; n
= 4-5 / condition.
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Analysis of metabolic markers in the blood, revealed a significant interaction between
genotype and circadian cycle on triglycerides [F (1, 19) = 8.32, p < 0.01; Fig. 5.2A] and
insulin [F (1, 19) = 4.53, p < 0.05; Fig. 5.2B] and a near significant interaction for these
variables on leptin [F (1, 19) = 3.08, p = 0.09; Fig. 5.2C]. A post-hoc Bonferroni analysis
revealed that all of these markers were elevated in CD exposed wild-type mice relative to all
other experimental conditions, including CB1R–/– mice exposed to CD (p < 0.05 for all
variables), indicating that CB1R-/- are resistant to CD induced changes in plasma metabolic
markers. There was no effect of any experimental manipulation on basal glucose levels [F (1,
13) = 1.42, p > 0.05; Fig. 5.2D].

Experiment 2
There was a significant interaction between treatment and genotype on body weight [F (1,
16) = 14.08, p = 0.0017; Fig. 5.3]. Post-hoc Bonferroni analysis revealed that weight was
increased in CORT treated WT mice relative to all other experimental conditions, including
CB1R–/– mice exposed to CORT. Body fat (F(1,16)=7.052;p=0.0173; Fig 5.3B) showed a
similar interaction and liver weight showed a main effect of CORT (F(1,10)=6.363;p=0.03;
Fig 5.3C) in WT mice (F(1,10)=8.05; p=0.018).
WT CORT mice were found to eat more each week. Specifically, analysis revealed a
main effect of CORT (F(3,12)=15.20;p=0.0002) with a significant difference at week 4
(p<0.05, Fig 5.4A). Similarly WT CORT mice drank increasingly more each week
(F(3,9)=9.014; p<0.0045) with a significant difference at week 4 (p<0.05; Fig 5.4B). This
increase in feeding in WT CORT mice was accompanied by a decrease in activity across the
day (Fig 5.5). This pattern of activity was also noted in circadian rhythm studies of VEH and
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CORT treated WT mice where the activity was split between the start and the end of the
active period. Focusing at activity across the plane and Z-axis (up and down movements; Fig
5.5A), this again seems to be the case. Total counts across the XY plane shows no difference
during the light (inactive) period but an interaction (F(1,11)=5.092, p=0.454) and main effect
of treatment (F(1,11)=13.05, p=0.0041) during the dark (active period; Fig 5.5B).
Combining activity through the day magnifies the interaction (F(1,11)=7.290, p=0.0207) and
effect of CORT (F(1,11)=10.39,p=0.0081). The interaction between CB1R global knockout
and CORT treatment is more clearly seen in Figure 5.5C where activity level was increased
in CORT treated knockout mice compared to WT (t(6)=2.785, p=0.0318). This effect was
maintained on the Z-Axis (t(6)=2.571, p=0.05). Given that VEH CB1R-/- mice exhibit less
activity compared to WT mice, and with a minimal increase in activity in the former on
CORT, activity likely plays a very small role in the overall weight change in mice.
In addition to weight gain and increased adiposity, a key component of the metabolic
syndrome is insulin resistance, which manifested here in the form of hyperinsulinemia (Fig
5.6 B; main effect of CORT (F(1,16)=151.9; p <0.0001)) and hyperglycemia (Fig 5.7 A;
interaction (F(1,10)=7.876; p=0.0186; posthoc analysis showed WT CORT exclusively to
have increased basal glucose (P<0.001). In addition, we observed hyperleptinemia (Fig 5.6
A; main effect of CORT (F(1,16)=307; p <0.0001), an indication of leptin resistance,
whereas the plasma level of adiponectin, an adipokine that promotes fatty acid oxidation, was
reduced as noted by 2 way ANOVA (Fig 5.6 C; main effect of CORT (F(1,11)=11.25;
p=0.0064). Insulin and leptin parameters were significantly reduced in CB1R-/- (main effect
of genotype (F(1,16)=39.47; p<0.0001, and (F(1,16)-32.95; p<0.0001), insulin and leptin,
respectively). While adiponectin levels were increased in CB1R-/- VEH treated mice as
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revealed by Bonferroni posttests, there was no significant difference in CORT treated CB1R/- mice. To investigate changes in the WAT, we measured adipocyte length using H&E stain
in WAT. We found increased adipocyte length in WT CORT mice (Fig 5.6E-H), reflects the
trend in plasma hormone levels. Analysis of adipocyte length (Fig 5.6D) reveals an
interaction (F(1,145)=41.42; p<0.0001), a main effect of treatment (1,145)=282.2;
p<0.0001), and a main effect of genotype (F(1,145)=34.72; P<0.0001). While these studies
were conducted in males, females showed a similar trend (Supplementary Fig 5.1).

Figure 5.3 CB1-/- mice are resistant to CORT induced weight gain. CB1 receptor global
knockout prevents significant (A) weight gain, (B) increase in adiposity, and (C) increase in
liver weight. N=4-5/group except liver weight N=3-5/group. Bars with the same letter do not
significantly vary from one another. *P<0.05, ***P<0.001.
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Figure 5.4 CORT treated CB1R-/- mice do not exhibit increased food and water intake.
CORT treated WT mice display hyperphagia (A) and increased water intake (B) not present
in CORT treated CB1R-/- mice (n=5/group). *P<0.05.

Figure 5.5 Spontaneous activity across the day. Ambulatory movement was measured on the
X and Z-Axis (movements up and down) for 4 days and averaged into 12 minute bins. (A)
Shows this activity across the day (dark box indicates the inactive-light period) without SEM
to make visualization easier. (B) Activity of X axis only split into light, dark and total. There
is no difference in activity in the light phase but decreased activity noted during the dark in
all groups compared to WT VEH. (C) Total activity of the X axis in groups treated with
CORT is decreased in WT mice. N=4/group; *p<0.5; bars with the same letter do not differ
from one another.
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Interestingly, there was no difference between groups in fasting glucose levels (Fig 5.7 B)
and when insulin resistance and insulin sensitivity were measured through an insulin
challenge, CB1R-/- mice were not able to prevent the decrease in insulin sensitivity induced
by CORT treatment (Fig 5.7 C and Fig 5.7 D, main effect of CORT (F(1,12)=15.54;
P=0.002)). However, looking at the islet cells (Supplementary Fig 5.3A), we see largely
intact cells in the case of the CB1R-/- animals and the breakdown of the cells in the case of
CORT WT mice. The anatomy here in conjunction with high circulating levels of insulin
and fasting glucose levels suggest an insulin resistance and the repository role of the islet
cells to hypersecrete insulin. However, looking at the condition of the cells, it is reasonable
to conjecture that the overnutrtion state is “slowly” damaging cells and most likely, in future,
they will unlikely be able to keep up with the demand, leading to impaired glucose tolerance
with mild increase in postprandial glucose concentrations and then to diabetes with overt
hyperglycemia.
CB1R-/- also markedly lowered circulating TG levels in CORT treated mice as noted by 2
way ANOVA, which revealed an interaction between groups (F(1,16)=15.41; p=0.0012), a
main effect of CORT (F(1,16)=73.65; p<0.0001), and a main effect of genotype
(F(1,16)=18.32; p=0.0006; Fig 5.8A). Liver TG content was also lowered in CB1R -/- CORT
mice in a similar fashion with an interaction between groups (F(1,12)=4.983; p=0.045)
despite a main effect of CORT (F(1,12)=65.74; p<0.001, Fig 5.11A). The decrease in liver
TG in CB1R-/- CORT mice (Fig 5.7E) compared to WT CORT mice (Fig 5.8D) can also be
noted by decreased presence of lipids by oil red o stain in liver tissue.
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Figure 5.6 Metabolic effects of CB1R-/- in CORT treated mice. Global knockout of the CB1
receptor counteract CORT induced increases in plasma (A) leptin, (B) insulin, and to a lesser
extent (C) adiponectin (n=3-5/group). (D) Adipocyte length as quantified by random
selection of adipocytes (n=4-5/group). Representative H&E stain images of epididymal WAT
tissue isolated from (E) WT VEH, (F) WT CORT, (G) CB1R-/- VEH, and (H) CB1R-/CORT, images taken at 10x. Bars sharing the same letter are not statistically different from
each other. **P<0.01.
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Figure 5.7 Glucose levels and insulin sensitivity in CORT treated mice. While (A) basal
glucose levels are reduced in CB1R-/- CORT treated mice, there is no difference in (B)
fasting levels. (C) Glucose levels measured pre and post injection of an insulin bolus showed
no effect of KO in CORT treated mice as measured over 120 minutes. (D) Area under the
curve (AUC) again shows no difference in insulin sensitivity in WT and CB1R-/- CORT
treated mice. N=3-5/group; **P<0.01,***P<0.001

100

CB1R-/- also reduced hepatocellular damage in CORT mice, as signified by a large
reduction of plasma levels of alanine aminotransferase (ALT). There was a significant
interaction between CORT treatment and genotype (F(1,11)=10.69; p=0.0075; Fig 5.9A) in
circulating levels of ALT. Bonferroni posttests revealed an increase in this parameter in WT
CORT mice compared to all other experimental conditions(P<0.001). Measurements of
alkaline phosphatase (ALP), also a determinant of liver health or disease as a means of bile
duct function, was found to have a main effect of genotype (F(1,11)=8.851;p=0.0126, Fig
5.9B). The extent of liver damage in CORT treated mice is further noted in H&E stained
liver sections where full-blown steatosis is apparent (Supplementary Fig 5.3B).
Given the increased amounts of water the CORT mice were drinking, we also looked at
parameters of kidney function as indicated by levels in blood plasma. Analysis showed no
difference between groups in total protein in plasma (Fig 5.9C), but did show a decreased
presence of phosphorus, in WT CORT mice compared to all other experimental groups as
indicated by an interaction (F(1,11)=7.947; p=0.0167; Fig 5.9D) and subsequent Bonferroni
posttests (p<0.001). TCO2 also showed an interaction (F(1,12)=5.838; p=0.0325; Fig 5.9 E)
with an increase in WT CORT mice compared to other experimental conditions (p<0.05).
Global knockout of CB1 receptor decreased circulating cholesterol levels as noted by an
interaction (F(1,10)=8.529; p=0.0153, Fig 5.9 F) and subsequent posttests showing an
increase in WT CORT mice compared to the other experimental conditions (p<0.01). WT
CORT mice have a slightly greater production and release of TG-rich VLDL, as measured by
Pluronic-407 injections (hour 4 WT VEH vs. WT CORT p=0.089; Fig 5.10B).
The effect of CB1R-/- on substrate utilization was analyzed by indirect calorimetry. After
3 weeks of treatment, mice were moved into individually monitored metabolic chambers

101

where they were allowed to acclimate over the weekend and were then monitored for 4-5
days. CB1R-/- mice on CORT showed a reduction in respiratory quotient (RQ, Fig 5.11 B),
resulting from an increase in fat oxidation (Fig 5.11 D) and decrease in carbohydrate
oxidation (Fig 5.11F). Thus, the decrease in body weight and reduced adiposity was likely
due to increased lipid oxidation.

Figure 5.8 Plasma triglycerides and liver lipid content are greatly reduced in CORT treated
CB1R-/- mice. (A) Triglycerides measured in plasma isolated from mice showed a significant
decrease in CB1R-/- mice, but not completely restored to the levels of VEH WT mice. Oil
red O staining revealed the development of non-alcoholic fatty liver (NAFLD) in (D) CORT
WT mice compared to the healthy livers of (B) VEH WT and (C) VEH KO. NAFLD was
prevented in (E) CORT CB1R mice. Representative liver stains shown at 10x. N=5/group.
Bars with the same letter do no statistically differ from one another.
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Figure 5.9 Blood chemistry profile. (A) ALT and (B) ALP circulating levels, indicators of
liver damage, are reduced in CORT treated CB1R-/- compared to other experimental
conditions. Global knockout also prevents changes in (C) total protein, (D) phosphorus, and
(E) TCO2 indicators of kidney damage, and CB1R-/- significantly reduced CORT induced
circulating cholesterol levels. N=4-5/group. *P<0.05, **P<0.01, ***P<0.0001.

Figure 5.10 Effect of CB1 R-/- hepatic triglycerides and VLDL production. (A) Hepatic
triglyceride content as determined by Folch (n=3-5/group), bars with the same letter are not
significantly different from each other. (B) VLDL-TG production was determined over 4
hours after Pluronic-407 injection. Values are expressed as relative changes compared with
respective controls. (n=3-4/group).
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Figure 5.11 Substrate selection as measured by indirect calorimetry. RQ in (A)VEH and (B) CORT treated WT and CB1R-

/- mice were assessed by a comprehensive animal metabolic monitoring system (CLAMS). Metabolic parameters were

measured over a 4 day period, and equivalent time points, and were averaged together, presented in bins of 12 minutes.

CB1R-/- induces reduction in RQ by decreasing (F) carbohydrate oxidation and increasing (D) fat oxidation in wild-type

mice on CORT. The shaded area represents inactive period. The data are expressed as mean values ± SEM, n=4/group.
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Table 5.1 Obesity related gene expression in gonadal fat pads (WAT).
Description

Gene
Symbol

Fold Change vs. ControlVehicle WT
CORT
WT

Adenylate cyclase
activating polypeptide 1
Adenylate cyclase
activating polypeptide 1
receptor 1
Adiponectin, C1Q and
collagen domain
containing
Adiponectin receptor 1
Adiponectin receptor 2
Adrenergic receptor,
alpha 2b
Adrenergic receptor, beta
1
Agouti related protein
Apolipoprotein A-IV
Attractin
Brain derived
neurotrophic factor
Bombesin-like receptor 3
Complement component
3
Calcitonin/calcitoninrelated polypeptide, alpha
Calcitonin receptor
CART prepropeptide
Cholecystokinin
Cholecystokinin A
receptor
Colipase, pancreatic
Cannabinoid receptor 1
(brain)
Ciliary neurotrophic
factor receptor
Carboxypeptidase D
Carboxypeptidase E

Adcyap1

0.6276

Vehicle
CB KO

1.1109

CORT
CB KO

0.4325*

Adcyap1r1 8.1004* 1.6161* 24.4879*

Adipoq
Adipor1
Adipor2

0.689

vs.
Vehicle
CBKO
CORT
CB KO

0.3893*

3.023 15.1527*

0.8207
2.558*
1.318

0.2058*
0.8302
0.2769*

0.6289
0.9267
0.7806

0.2507*
0.3245*
0.2101*

0.5205 3.3987*

0.672

1.291

0.1977*

1.9308
4.4588
1.6663
1.3747

0.6255
0.5816
0.5215
0.6498

1.1369
1.4308
0.1377
0.931

0.324*
0.1304*
0.3129
0.4727*

Bdnf
Brs3

2.3316 4.0116*
0.8149 1.2961

3.0592*
0.4325*

1.3121
0.5307

0.7626
0.3337*

C3

0.5657

1.923

0.67

1.1845

0.3484*

Calca
Calcr
Cartpt
Cck

0.7638
0.6276
0.6276
1.3299

1.0625
1.1109
1.1109
1.1961

0.5281*
0.4325*
0.4325*
0.7194

0.6914
0.689*
0.689
0.5409

0.4971*
0.3893*
0.3893*
0.6014

Cckar
Clps

0.0891
0.6276

0.1577
2.6651

0.0614
1.2001
0.0018*

0.689
1.9121

0.3893*
0.4503

Cnr1

0.4724*

0.004*

0.0038*

0.3893*

Cntfr
Cpd
Cpe

0.2591*
0.8244
0.5696

1.5157
1.8478
2.5024

1.2572
1.1435
0.7484

0.2149*
0.5102
0.1703*

Adra2b
Adrb1
Agrp
Apoa4
Atrn

0.3271*
0.8959
0.3547*

vs.
CORT
WT
CORT
CB KO

0.5502*
0.4065*
3.7877
0.698*
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0.3257*
0.9427
0.4263

Table 5.1 Continued
Corticotropin releasing
hormone receptor 1
Dopamine receptor D1A
Dopamine receptor 2
Galanin
Galanin receptor 1
Glucagon
Glucagon receptor
Growth hormone
Growth hormone
receptor
Ghrelin
Growth hormone
secretagogue receptor
Glucagon-like peptide 1
receptor
Melanin-concentrating
hormone receptor 1
Gastrin releasing peptide
Gastrin releasing peptide
receptor
Hypocretin
Hypocretin (orexin)
receptor 1
Histamine receptor H1
5-hydroxytryptamine
(serotonin) receptor 2C
Islet amyloid polypeptide
Interleukin 1 alpha
Interleukin 1 beta
Interleukin 1 receptor,
type I
Interleukin 6
Interleukin 6 receptor,
alpha
Insulin I
Insulin II
Insulin receptor
Leptin
Leptin receptor
Melanocortin 3 receptor
Neuromedin B
Neuromedin B receptor
Neuromedin U

Crhr1
Drd1a
Drd2
Gal
Galr1
Gcg
Gcgr
Gh

0.6276
0.3348
0.6276
0.5979
0.6276
0.1014
1.1132
0.6276

2.1202
1.1708
2.2294
5.11
1.1109
0.1588
2.5713
1.9747

Ghr
Ghrl

0.813
0.6063*

1.3503
5.5693

0.801
0.7679

0.9852
1.2666

0.5932
0.1379

Ghsr

0.6932

1.1109

0.4857*

0.7007

0.4372*

Glp1r

0.6276

1.6896

0.4362*

0.695

0.2582

Mchr1
Grp

1.3896
0.6276

2.9862
1.1109

7.0976
0.7608

5.1077
1.2122

2.3768
0.6849

Grpr
Hcrt

0.6276
0.8301

1.1947
1.3051

0.4325*
0.4325*

0.689
0.521

0.362*
0.3314*

Hcrtr1
Hrh1

0.7327
0.8282

1.6974
1.514*

1.0791
0.3203*

1.4727
0.3867

0.6357
0.2115*

Htr2c
Iapp
Il1a
Il1b

0.6276
0.6276
0.6379
0.4868

5.0252
2.1055
4.446
1.2205

0.4325*
2.5152
0.8061
0.1767

0.689*
4.0074
1.2637
0.3629

0.0861
1.1946
0.1813
0.1447

Il1r1
Il6

0.8594
0.4542

1.2585
1.3771

0.8197
0.7161

0.9538
1.5766

0.6513
0.52

0.7603 1.5052
0.6276 1.1109
0.6996 1.9611
0.5193* 1.4109
2.6172 0.9582
0.3197* 1.561*
0.6276 1.1109
0.3758* 1.6472*
0.8093 10.226
0.6483 1.6692

0.9855
0.4325*
3.988
0.6786
3.4878*
0.4187*
0.4325*
0.5994
1.0816
0.5736

1.2962
0.689
5.7002
1.3068
1.3327
1.3098
0.689
1.5949
1.3365
0.8848

0.6547
0.3893*
2.0335
0.481
3.6402*
0.2682*
0.3893*
0.3639*
0.1058
0.3436

Il6ra
Ins1
Ins2
Insr
Lep
Lepr
Mc3r
Nmb
Nmbr
Nmu
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0.4325*
0.689
0.6259 1.8695*
0.4325*
0.689
0.4948 0.8275
0.4325*
0.689
0.1554 1.5326
1.0841 0.9739
0.4325*
0.689

0.204
0.5346
0.194
0.0968
0.3893*
0.9787
0.4216*
0.219

Table 5.1 Continued
Neuromedin U receptor 1
Neuropeptide Y
Neuropeptide Y receptor
Y1
Nuclear receptor
subfamily 3, group C,
member 1
Neurotrophic tyrosine
kinase, receptor, type 2
Neurotensin
Neurotensin receptor 1
Opioid receptor, kappa 1
Opioid receptor, mu 1
Sigma non-opioid
intracellular receptor 1
Pro-opiomelanocortinalpha
Peroxisome proliferator
activated receptor alpha
Peroxisome proliferator
activated receptor gamma
Peroxisome proliferative
activated receptor,
gamma, coactivator 1
alpha
Prolactin releasing
hormone receptor
Protein tyrosine
phosphatase, nonreceptor type 1
Peptide YY
Receptor (calcitonin)
activity modifying
protein 3
Sortilin 1
Somatostatin
Somatostatin receptor 2
Thyroid hormone
receptor beta
Tumor necrosis factor
Thyrotropin releasing
hormone

Nmur1
Npy

0.4959
1.6717

8.2582
6.7466

0.2478*
4.8255

0.4998
2.8865

0.03
0.7152

Npy1r

145.479

1.5351

0.4697

0.0032

0.306*

Nr3c1

0.4199*

0.9532

0.2693*

0.6414

0.2825*

Ntrk2
Nts
Ntsr1
Oprk1
Oprm1

0.563*
1.078
0.9189 5.9759*
0.6276 3.4145
0.6233 1.1032
0.3332* 3.6448

0.4352*
0.681
0.4325*
0.4295*
0.2069*

0.773
0.7411
0.689
0.689
0.621

0.4037*
0.114*
0.1267
0.3893*
0.0568

Sigmar1

1.2209

1.0087

1.3722*

1.1239

1.3604

Pomc

0.6948*

1.8414

0.677

0.9745

0.3677

Ppara

0.3131*

1.265

0.4555*

1.455*

0.3601

Pparg

0.5592

1.1454

0.5424

0.97

0.4735*

0.3572* 1.5837*

0.488*

1.3662

0.3081*

Ppargc1a
Prlhr

0.6276

1.1421

0.4377*

0.6975

0.3833*

Ptpn1
Pyy

0.7709 1.9634*
0.6276 1.7311

0.5966
4.0718

0.7739
6.4875

0.3039*
2.3522

Ramp3
Sort1
Sst
Sstr2

1.022 19.3599
0.6604 1.5157*
0.6276 1.2782
0.7029 2.8812

4.3969
0.6897
0.5836
0.4774

4.3025
1.0444
0.9299
0.6792

0.2271
0.455*
0.4566*
0.1657*

0.5169* 1.4109
0.4627 1.8628*

0.618*
0.5411*

1.1955
1.1696

0.438*
0.2905*

0.4555*

0.6132

0.1739

Thrb
Tnf
Trh

0.7429

107

2.6193

Table 5.1 Continued
Urocortin
Ucn
0.6276 1.8489 0.4684* 0.7462
0.2533
Uncoupling protein 1
(mitochondrial, proton
carrier)
Ucp1
0.6276 1.9108 0.4325*
0.689
0.2263
Zinc finger protein 91
Zfp91
0.6742 1.9782* 0.6137* 0.9102 0.3102*
Values represent average fold change (±SEM; n=4/group) in response to corticosterone
treatment (100 µg/mL) mice compared to vehicle (1% ethanol) treated WT or CB1R-/- mice.
Upregulation with a fold change greater than 2 is noted in red, downregulation with a fold
change less than .5 noted by blue. *P<0.05.
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Table 5.2 Insulin pathway related gene expression in gonadal fat pads (WAT).
Description

Gene
Symbol

Fold Regulation vs. Control
(Vehicle WT)
CORT
WT

Thymoma viral protooncogene 1
Thymoma viral protooncogene 2
Thymoma viral protooncogene 3
CAP, adenylate
cyclase-associated
protein 1 (yeast)
FK506 binding protein
12-rapamycin
associated protein 1
Glucose-6phosphatase, catalytic
Glucose-6phosphatase, catalytic,
2
Growth factor receptor
bound protein 2associated protein 1
Glucokinase
Glycerol-3-phosphate
dehydrogenase 1
(soluble)
Growth factor receptor
bound protein 2
Growth factor receptor
bound protein 10
Glycogen synthase
kinase 3 beta
Hexokinase 2
Harvey rat sarcoma
virus oncogene 1
Insulin-like growth
factor I receptor

Vehicle
CB KO

CORT
CB KO

vs.
CORT
WT
CORT
CB KO

vs.
Vehicle
CBKO
CORT
CB KO

Akt2

2.7435*
2.6454*

Akt3

-1.5594

2.5359*

-1.0677

1.4605

-2.7076*

Cap1

-1.4325

2.0634*

-1.064

1.3463

-2.1954*

Mtor

3.2344*

1.5052*

-1.1247

2.8759*

-1.6929*

G6pc

-1.4525

1.359

-5.9566*

-4.1011

-8.0948*

G6pc2

-1.6976

-1.0534

-1.4738

1.1519

-1.3991

Gab1
Gck

2.5865*
-1.0112

1.6702
2.3335

-1.4866
11.0847

1.7399
11.2083

-2.4829*
4.7502

Akt1

Gpd1

1.5828*

-1.4236

1.9272

-2.2532*

1.0425

-2.2299*

1.1863

-2.3246*

1.633

2.2863

2.3198

1.4001

Grb2

-1.0147
2.2245*

-1.0335

-2.0914*

1.0636

-2.0237*

Grb10

1.1499

1.4768

1.1412

-1.0077

-1.2941

Gsk3b

1.0371

-1.7165

1.1341

-1.7802

1.0389

-1.3585

1.7857*

-1.4113*

Hras1

-1.9467
2.4259*
1.6888*

-1.2058

-1.2222

1.3818

-1.0136

Igf1r

-5.5828

1.5157

-2.4024

2.3238

-3.6414

Hk2
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Table 5.2 Continued
Insulin-like growth
factor 2
Insulin-like growth
factor binding protein
1
Insulin I
Insulin-like 3
Insulin receptor
substrate 1
Insulin receptor
substrate 2
Jun oncogene
V-Ki-ras2 Kirsten rat
sarcoma viral
oncogene homolog
Low density
lipoprotein receptor
Leptin
Mitogen-activated
protein kinase kinase 1
Mitogen-activated
protein kinase 1
Non-catalytic region
of tyrosine kinase
adaptor protein 1
Nitric oxide synthase
2, inducible
Neuropeptide Y
Phosphoenolpyruvate
carboxykinase 2
(mitochondrial)
3-phosphoinositide
dependent protein
kinase-1
Phosphatidylinositol
3-kinase, catalytic,
alpha polypeptide

Igf2

-4.1655

3.649*

-1.3305

3.1307

-4.8551*

Igfbp1

2.2307

1.1531

1.4255

-1.9346

-2.5624
23.0229

-17.7777
-1.6071

-1.5011
1.6347

-6.9379
-37.0012

Irs1

-1.2363
11.8433
-2.6272
2.7721*

1.3241

-1.9786

1.401

-2.6199*

Irs2
Jun

-3.6452
-2.5553

1.9119
1.5289

-2.2377
-1.2286

1.629
2.0799

-4.2782*
-1.8784*

Kras

1.8006*

1.1668

-1.6988*

1.06

-1.9821*

Ldlr
Lep

-1.1696
1.6234

-1.1038
1.3566

-1.1603
5.3629*

1.008
3.3035*

-1.0512
3.9531*

Map2k1

2.7302

5.8058

4.3334

1.5872

-1.3398

Mapk1

-1.6398

1.268

-1.4285

1.1479

-1.8113*

Nck1

-1.403*

1.2016

-1.6812*

-1.1983

-2.0202*

Nos2
Npy

-2.4811
2.3522

3.0209
3.5925

-1.2785
4.3334

1.9406
1.8423

-3.8624
1.2062

Pck2

-1.3319

1.9725*

1.1392

1.5173

-1.7315*

Pdpk1

-2.145

1.3827

-1.1888

1.8044*

-1.6438*

Pik3ca

2.3925*

1.5395

-1.6016

1.4938*

-2.4657*

Ins1
Insl3

Phosphatidylinositol
3-kinase, catalytic,
beta polypeptide
Phosphatidylinositol
3-kinase, regulatory

Pik3cb

3.4366*

1.1708

-2.3694*

1.4504

-2.7741*

Pik3r1

-2.047

2.0279

1.697

3.4738*

-1.195
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7DEOH&RQWLQXHG
subunit, polypeptide 1
(p85 alpha)
Phosphatidylinositol
3-kinase, regulatory
subunit, polypeptide 2
(p85 beta)
Pyruvate kinase liver
and red blood cell
Peroxisome
proliferator activated
receptor gamma
Protein phosphatase 1,
catalytic subunit, alpha
isoform
Protein kinase C,
gamma

2.5201*

1.7291*

-1.1826

2.131

-2.0449*

1.1301

2.8979

-1.3751

-1.554

-3.9848

Pparg

-2.0049

1.3013

-1.113

1.8013

-1.4484

Ppp1ca

-1.9979

1.4093

-1.0977

1.8201*

-1.547

Prkcc

5.0543*

1.0338

2.0799

-4.8889*

1.2924

-1.5205

1.8169

-1.965*

1.7839
-1.1607

-1.6268
-2.5482*

2.0548
-1.5011

-2.9019
-2.1954

Pik3r2
Pklr

Protein kinase C, iota

Prkci

Protein kinase C, zeta
Prolactin
Protein tyrosine
phosphatase, nonreceptor type 1
Protein tyrosine
phosphatase, receptor
type, F
V-raf-leukemia viral
oncogene 1
Resistin
Ribosomal protein S6
kinase polypeptide 1
Harvey rat sarcoma
oncogene, subgroup R
Related RAS viral (rras) oncogene
homolog 2
Serine (or cysteine)
peptidase inhibitor,
clade E, member 1
Src homology 2
domain-containing
transforming protein
C1
Solute carrier family
27 (fatty acid

Prkcz
Prl

-2.0118
2.7625*
3.3427*
-1.6976

Ptpn1

-2.4683

2.3054*

1.0446

2.5784

-2.2069*

Ptprf

-3.4967

-1.1587

-4.4444

-1.271

-3.8357

Raf1
Retn

-2.0223
-2.0118

1.1447
2.4158

-1.3054
2.0677

1.5492
4.1598*

-1.4943*
-1.1684

Rps6ka1

-1.4201

2.662

-1.8334

-1.291

-4.8804*

Rras

-1.7183

-1.2311

-1.7465

-1.0164

-1.4186

Rras2

-1.0651

-1.1607

-1.1623

-1.0913

-1.0014

Serpine1

-1.4006

1.4923

1.0038

1.4059

-1.4866

Shc1

2.4133*

1.4794

-1.6958

1.4231

-2.5088*

Slc27a4

-2.0973

1.2924

-1.1034

1.9007*

-1.426
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transporter), member 4
Solute carrier family 2
(facilitated glucose
transporter), member 1 Slc2a1
2.2673*
1.3851
-1.2012
1.8875
-1.6638
Sorbin and SH3
domain containing 1
Sorbs1
-1.4959
-1.0534 -2.2611*
-1.5115 -2.1465*
Son of sevenless
homolog 1
(Drosophila)
Sos1
1.7124*
1.3851
-1.5205
1.1262
-2.106*
Sterol regulatory
element binding
transcription factor 1
Srebf1
3.3601*
1.1871 -2.2493*
1.4938 -2.6703*
Values represent average fold change (±SEM; n=4/group) in response to corticosterone
treatment (100 µg/mL) mice compared to vehicle (1% ethanol) treated WT or CB1R-/- mice.
Upregulation with a fold change greater than 2 is noted in red, downregulation with a fold
change less than .5 noted by blue. *P<0.05.
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Analysis of mRNA expression in the liver and WAT further indicate a role of the CB1R in
regulating lipid oxidation and gluconeogenesis. Analysis of numerous genes in WAT
through the use of PCR arrays showed several subtle interactions between CORT treatment
and genotype with the most prominent related to leptin and the leptin receptor, hexokinase 2
and likely GLUT4, although it was not included in this array mTOR, Slc27a4, among others
regulating the insulin pathway (Table 5.1 and 5.2).
Analysis of Sterol regulatory element binding protein (SREBP)1c mRNA expression, a
transcription faction involved in fatty acid metabolism and de novo lipogenesis, and mRNAs
of lipogenic enzymes that are targets of SREBP-1c, fatty acid synthase (FAS) and acetylCoA carboxlyase (ACC), show a similar pattern of interaction with a main effect of CORT
(SREBP-1c F(1,14)=9.367; p=0.0085; Fig 5.12A), (FAS F(1,4)=8.272; p=0.045; Fig5.12B)
and a main effect of treatment in ACC1 F(1,11)=6.679; p=0.0254; Fig 5.12C). Posttests of
the former two genes showed decreased expression significant in WT mice but not CB1R-/mice (p<0.05).
Other models which exhibit significant weight gain, such as diet induced obesity, show
how increased expression of SREBP-1c and subsequent target genes. However, a decrease in
SREBP-1c in WAT in WT CORT mice as noted in Table 5.1, suggest a shift in the
deposition of triglycerides toward liver and muscle.242 The shift in lipogenic burden from fat
to liver coincides with a decrease in adipose tissue expression of SREBP-1c and an increase
in liver expression. A similar trend was noted in a time course analysis of SREBP-1c where
an increased expression of SREBP-1c is noted in WAT after 1 week of CORT treatment in
WT mice, though this level did not reach significance (Supplementary Fig 5.2D). However,
after 4 weeks of treatment, WT mice had significantly lower levels of SREBP-1c compared
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Figure 5.12 Effect of global CB1R knockout on liver mRNA expression of genes involved in
lipid metabolism. CORT treatment results in decreased expression of (A) SREBP-1C, (B)
FAS, and to a less degree ACC1. This reduction is not present in CB1R-/- CORT treated
mice. N=3-5/group, *P<0.05.

Figure 5.13 Expression of genes responsible for energy homeostasis and respiration in the
liver. Global knockout of the CB1R decreases the expression of (A) PGC1α, (B) NRF-1, and
(C) TFAM (n=4-5/group), ** P<0.01).
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to 1 week treated mice (p<0.05) and controls (p<0.01). While the time point of increase of
SREBP-1c was not noted in the liver (all time points of CORT treatment were significantly
lower than in VEH mice, p<0.01), lower levels are noted after 2 and 4 weeks of treatment
(Supplementary Fig 5.2A). A similar trend is noted in FAS expression in the liver
(Supplementary Fig 5.2B). In a separate cohort of animals, an intermediate group of CORT
treatment, 25 µg/mL, mice showed increased expression of SREBP-1c after 4 weeks of
treatment although the level did not reach significance compared to controls. Again, the 100
µg/mL group showed decreased expression compared to both controls and the 25 µg/mL
groups (p<0.05; Supplementary Fig 5.2D).
Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) is a
transcriptional coactivator that regulates genes involved in energy metabolism and
mitochondrial biogenesis, such as Nuclear respiratory factor 1, NRF-1, another transcription
factor that activates the expression of metabolic genes that regulate cellular growth, as well
as genes required for mitochondrial respiration. Both PGC-1α and NRF-1 showed
interactions (F(1,14)=5.093; p=0.0405; Fig 5.13A; and F((1,14)=7.46; p=0.0162; Fig 5.13 B
respectively). Bonferroni posttests revealed WT CORT treated mice to have increased levels
compared to all other experimental conditions (p<0.01). Finally we looked at TFAM as
another measure of mitochondrial function and number as an indication of respiration.
TFAM showed a comparable pattern of expression in all groups but none significantly
different from one another (Fig 5.13C).
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Supplementary Figure 5.1 Global knockout of the CB1R prevents the development of
metabolic syndrome in CORT treated mice. Female WT and CB1R-/- mice were placed on
VEH or CORT for 4 weeks. CB1R-/- prevented the large (A) weight change, (B) increased
adiposity, and elevated levels of (C) insulin, (E) leptin, and (F) triglycerides induced by
CORT treatment. (D) Spleen weights are decreased in both groups of CORT treated mice
showing a similar exposure to CORT. N=4-5/group, **P<0.01, ***P<0.001, bars that share
the same letter are not significantly different from one another.
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Supplementary Figure 5.2
Supplementary Figure 5.2 Time and dose course of SREBP1c expression. Quantitative RTPCR analysis of SREBP1c in (A) liver from 1-4 week 100 µg/mL CORT treated mice, (C)
liver from 25 and 100 µg/mL CORT treated mice, and (D)WAT from 1-4 week 100 µg/mL
CORT treated mice. (B) FAS expression in liver from 1-4 week 100 µg/mL CORT treated
mice. All expressed as fold change (±SEM) in relation to control group. Bars with the same
letters are not scientifically different from one another. ** notes P<0.01 as determined by one
way ANOVA.
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Supplementary Figure 5.3 CB1R-/- prevents CORT induced damage to the pancreas and
liver. H&E staining reveals damage to the (A) islet cells in the pancreases of CORT WT
mice, an effect not present in CORT CB1R-/- mice. Similarly CORT treated mice show signs
of (B) liver steatosis while CORT CB1R-/- mice are spared damage. Pancreas images taken at
40x, liver at 10x, representative samples from n=5/group.
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Discussion
Both increased and decreased CORT signaling, as demonstrated in our models of altered
light-dark cycle and CORT in the drinking water led to a disruption of circadian rhythms as
noted by decreased mRNA expression of molecular clock genes and altered activity level as
noted by tempograms and actograms, as noted in Chapter 4 and in previous publications.166
Here we looked to find a common mechanism of CORT regulation that may lead to the obese
phenotype in both mouse models.
The data generated herein provide insight into the potential mechanisms of CD-and
CORT-induced metabolic dysregulation, revealing that mice lacking cannabinoid CB1
receptors exhibited a blunted increase in body weight and a dramatic reduction of the
elevations in circulating insulin and leptin, and triglycerides following 8 weeks of CD. These
data are consistent with diet-based models of obesity and metabolic dysregulation, which
show that disruption of CB1 receptor signaling provides a significant degree of resistance to
metabolic change.167,224
The mechanisms by which CD engage the eCB system to modulate metabolic processes,
are still unknown. Endocannabinoid ligand content within feeding nuclei223, as well as the
circulation,222 are known to exhibit circadian fluctuations; however, the relationship of this
regulation to the control of metabolic processes is not known. In humans, sleep deprivation
results in an elevation in circulating levels of AEA,22 and in rodents, sleep deprivation
elevates central content of 2-AG.225 While sleep deprivation and CD are different forms of
circadian misalignment, these data provide evidence that disruption of normative circadian
cycles can cause a resultant elevation in eCB signaling. Sustained CD may result in a similar
tonic elevation in eCB signaling; however, this requires detailed analysis of normal circadian
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rhythms of eCB content and how it is altered by CD. Furthermore, both central and
peripheral CB1 receptor signaling can modulate metabolic function,121 thus determining if the
current effects that are mediated by central or peripheral mechanisms are of great importance,
particularly since peripherally restricted CB1 receptor antagonists are being developed to
treat and regulate obesity.226
In addition to these effects, a role for eCB signaling in the clock cannot be
disregarded. For instance, it is known that SCN neurons are sensitive to the effects of
eCBs.227 As such, sustained CD may alter eCB signaling within the SCN, having broad
ramifications for circadian regulation of many functions, including metabolic processes.
Given that the effects of CD are wide ranging and not exclusive to metabolic processes,166 it
is essential to determine if modulation of CB1 receptor function can alter all of the effects of
CD, or if its role is specific to metabolic dysregulation.
In experiment 2, looking at chronic high levels of CORT, given the ability of
glucocorticoids to rapidly mobilize eCB signaling, the eCB system seemed to be a plausible
target to mediate these glucocorticoid effects. The data produced in these groups of
experiments provide a detailed role of CB1 receptor modulation of CORT-induced metabolic
syndrome. In these studies, we revealed that mice lacking cannabinoid CB1 receptors were
resistant to CORT induced weight gain and gonadal fad pad and liver weights comparable to
control mice, at least when grossly measured. mRNA expression of leptin in the WAT of
treated mice showed an increase in CORT CB1R-/- mice compared to all other groups
suggesting that the hormone is functioning properly in these and leads to decreased food
intake compared to VEH CORT mice. Expression of several genes in the insulin pathway
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also showed upregulation in CB1R-/- compared to VEH CORT mice and thus possibly
improved insulin signaling.
Adiponectin levels were slightly increased in VEH WT mice and greatly increased in
VEH CB1R-/- mice, knockout of the receptor did little to improve levels in CORT treated
mice. mRNA expression of adiponectin again showed a decrease in both WT and CB1R-/CORT treated mice. AdipoR1 and AdipoR2 serve as receptors for the adiponectin, and their
reduction seems to be correlated with reduced adiponectin sensitivity; while AdipoR1
showed no change between control and CORT treated mice, with an elevation in VEH CB1R/-. AdipoR2 followed the trend of its hormone with a decrease in both CORT treated groups
compared to VEH mice. Differential expression here follows trends as seen by other groups
where AdipoR1 regulates AMP-activated protein kinase (AMPK) activation and AdipoR2
activates peroxisome proliferator-activated receptor (PPAR)-α signaling pathways.
Subsequently, we also observed decreased expression of the former in CORT treated mice.228
This leads us to propose that CB1R activity here does not seem to involve adiponectin
signaling.
Expression of resistin, like adiponectin, an adipose derived hormone, has been suggested
to link adiposity to insulin resistance.229 In this study mRNA expression of resistin in WAT
was decreased in WT CORT treated mice while increased in CORT CB1R-/- mice. Resistin
expression in WAT has been shown to be decreased in several mouse models of obesity
while levels in circulation are higher in the obese phenotype and increases in circulation have
been shown to play a vital role in the formation of insulin resistin,231,238 suggesting that the
increased expression of resistin in the WAT of CORT CB1R-/- should improve insulin
sensitivity. However, an insulin challenge revealed decreased insulin sensitivity in both
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CORT treated groups. To firmly evaluate the role of resistin in CORT mice, circulating
levels of the hormone need to be taken into account.
In the present study, we also demonstrated that global CB1R-/- improves dyslipidemia,
reverses hepatic damage and decreases cholesterol levels all induced by CORT treatments.
These effects are in part driven by increased food intake, but as demonstrated in Chapter 4,
an absence of increased caloric intake in CORT mice still resulted in weight gain comparable
to weight gain in adlib CORT treated mice. CB1R-/- here was shown to increase activity
levels in the otherwise inactive CORT mice, but in contrast to VEH treated mice these levels
are still significantly decreased. Results here would suggest that global CB1R-/- is the
combined result of centrally mediated decreases in caloric intake and a peripherally mediated
increase in energy expenditure as hypothesized by others in cases of diet induced
obesity.240,241 Indeed the respiratory quotient was decreased in CB1R-/- CORT mice as the
result of increased fatty acid oxidation and a decrease in carbohydrate oxidation.
In addition to eating more, WT CORT mice were also found to consume more water
(polydipsia) and have increased urination (polyuria), both signs of overt diabetes. A concern
here is that WT CORT mice might be exposed to more CORT over time, as it is in the
drinking water, and thus the polydipsia provides a positive feed forward loop leading to
larger effects not seen in CB1-/- mice since they were not drinking the same amounts of
water. However, both groups of mice showed excess levels of circulating CORT and splenic
atrophy, indicating that their exposure to CORT was very high, and likely equivalent.
Looking beyond adipocytes that appear to show an intermediate phenotype in CORT
CB1R-/- mice, a likely target of CORT in regard to metabolic action is the liver. CB1R-/reversed the CORT suppression of Srebp-1c and its target genes while simultaneously
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reducing expression of PGC-1α and its target genes. Results here point to a breakdown in
the fasting-refeeding cycle as seen in Srebp-1c deleted mice,242 where there is no longer an
appropriate regulated expression of critical lipogeneic genes such as FAS as shown in this
study.235,236 Here we see that increases in circulating levels are not sufficient to suppress
gluconeogenesis as evident by increases in PGC-1α and NRF-1,237 suggesting that the liver is
insulin resistant. When the liver becomes insulin resistant, it is still able to stimulate
lipogenesis, creating a vicious cycle that aggravates insulin resistance and ultimately
contributes to the onset of overt diabetes, as is the case in the CORT treated mice. The coexistence of hepatic insulin resistance (elevated gluconeogenesis) and sensitivity (elevated
lipogenesis) at gene expression level has been observed in rodent diabetic models.27
However, the mechanism of this co-existence of insulin sensitivity and resistance has not
been revealed until now.239
In CORT treated mice, elevated levels of PGC-1α indicate insulin resistance in the
gluconeogenic pathways. In the initial week of CORT treatment, Srebp-1c remains insulin
sensitive and thus fatty acid synthesis is accelerated and triglycerides accumulate in the liver.
The excess in triglycerides is secreted in VLDL, raising plasma triglyceride levels. However,
by week 4, we observed decreased expression of Srepb-1c, indicating a loss of insulin
resistance in this pathway as well, and further noted by extensive non-alcoholic
steatohepatitis (NASH). This decrease would suggest less fat accumulation, which we see if
treatment of CORT goes beyond 5 weeks when mice actually begin to lose weight and often
die. This decrease in Srepb-1c has recently been reported in the human condition of
NASH.248
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CB1R-/- mice remain insulin sensitive in both gluconeogenic and fatty synthesis pathways
in the liver, despite a decrease in sensitivity in adipose tissue and in circulation. Looking at
the level of the islet cell in the pancreas, the CB1R-/- prevents CORT induced damage or
decrease in cell volume. Protection here was noted despite predominant expression of CB2
receptor expression in the insulin secreting β cells. Both type 1 and type 2 receptors have
been described in glucagon secreting α cells.241 Inhibition of α cell signing in CB1R-/- mice
may aid in the maintained fast-fed cycles in CORT treated mice by stabilizing glucagon
levels.
Collectively, these data compellingly suggest that the eCB system may be involved in the
development of obesity from multiple etiologies, including diet, circadian dysregulation, and
hormonal imbalance. Taken together, these data provide the first evidence that the eCB
system is a contributor to metabolic dysregulation induced by disruption of circadian cycles
and hormonal regulation, and suggest that future research should continue to investigate the
wide-spanning role the eCB system may play in the genesis of multiple forms of metabolic
disorders. However, it should be noted that the synthesis and production of CORT as
induced by stress or in response to the rise and fall of the sun are independently controlled.18
While the eCB system has been thoroughly characterized in the regulation of CORT under
acute and chronic stress and acute and chronic glucocorticoid exposure,150 its role in the
diurnal release is unknown, making the results in that regard more difficult to interpret.
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Chapter 6: Characterization of endocannabinoid system signaling in glucocorticoid
treated mice
Abstract
Limbic and hypothalamic endocannabinoid (eCB) signaling is understood rather well in
rodents under conditions of chronic stress; however, studies investigating the impact of
prolonged exposure to glucocorticoid (GC) hormones have been limited by the concurrent
exposure to the stress of daily injections. The present study was designed to examine the
effects of a noninvasive approach to alter plasma corticosterone (CORT) on the eCB system
not only, centrally in the amygdala, hippocampus, and hypothalamus, but also in the
periphery in blood, liver, and white adipose tissue (WAT). More precisely, we explored the
effects of a chronic, ie, 4-week exposure to CORT dissolved in the drinking water of mice
(100 μg/ml) and measured cannabinoid CB1 receptor binding, eCB content, activity of the
eCB degrading enzyme fatty acid amide hydrolase (FAAH), and mRNA expression of both
the CB1 receptor and FAAH in both the hippocampus and amygdala. In the remaining tissue,
we looked only at eCB content, and mRNA expression of CB1 receptor, FAAH, N-acyl
phosphatidylethanolamine phospholipase D (NAPE-PLD), monoacylglycerol lipase
(MAGL), and diacylglycerol lipase, (DAGL). Our data demonstrate that protracted

exposure to GCs reduce CB1 receptor density and augmented anandamide (AEA) metabolism
within limbic structures. Signaling in the limbic brain region could contribute to shifts in
emotional behavior, especially increases in anxiety and depression-like behaviors, which
occur following sustained CORT exposure. Results from the hypothalamus and periphery
would suggest that the CORT induced metabolic drive is the result of increased synthesis and
decreased degradation of AEA in the liver, which likely spills over to blood circulation. In
conjunction with prior work, these findings suggest that increased AEA in the liver, and

125

possibly other sites through circulation, drives a shift in metabolic function that accelerates
carbohydrate metabolism and compromises fatty acid metabolism, resulting in the
development of fatty liver and fat stores in the adipose tissue.
Rationale
Glucocorticoids (GC) are the final mediators of the hypothalamic pituitary adrenal
(HPA) axis and play a crucial role in mounting the adaptive response to stress. Accumulating
evidence has demonstrated that GCs induce endocannabinoid (eCB) signaling and, in turn,
endocannabinoids regulate glucocorticoid secretion through both local and distal regulation
of HPA-axis activity.113-115 As described in the last chapter, the eCB system was originally
characterized as the neuronal system to which the psychoactive constituent of cannabis ∆9tetrahydrocannabinol (THC) interacted to exert its effects on physiology and behavior. The
system comprises of two subtypes: the cannabinoid type 1 (CB1) and type 2 (CB2) signaling
receptors.244,245 The system also comprises the endogenous ligands of both receptors,
anandamide (AEA) and 2-arachidonoylgycerol (2-AG), as well as the enzymes for ligand
biosynthesis and degradation, such as the fatty acid amide hydrolase (FAAH).116,117,248
Interestingly, following conditions of chronic stress eCB signaling appears to
breakdown, as chronic stress has been found to reduce both eCB content and receptor density
(reviewed in Gorzalka et al., 2008).249 However, the extent to which GCs contribute to the
effects of chronic stress centrally, in limbic system and hypothalamic eCB signaling, and
moreover in the periphery, is unclear. As such, the aim of the current study was to
characterize the effects of our non-invasive corticosterone (CORT) drinking water model on
the ability to modulate eCBs centrally in the hippocampus, amygdala, and hypothalamus and
peripherally in the blood, WAT and liver.
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Experimental design
This study was carried out using 2 cohorts of vehicle (VEH) and CORT treated animals. In
the first cohort n=7-8/group were euthanized and tissues were removed and processed for
eCB parameters. In the second cohort n=4-5 were euthanized and tissue was removed and
processed for mRNA expression.
Results
Once again, chronic exposure to CORT in the drinking water in the present study, resulted
in a significant increase in the concentration of plasma corticosterone measured in blood
obtained following four weeks of sustained CORT exposure [t (8) = 6.705, P <0.01;
Supplementary Fig 6.1)]. These data were consistent with our previous report that
demonstrates elevations in circulating CORT at all points of the circadian cycle with this
dosage.15 Additionally, mice which were exposed to CORT exhibited an increase in body
weight relative to control animals [t (6) = 4.50, P < 0.01; Supplementary Fig. 6.1B),
replicating our previous report that protracted exposure to CORT in the drinking water
produces an obese phenotype.47
In the amygdala, chronic CORT treatment resulted in a decrease in the binding site
density (Bmax) [t (4) = 2.812, P < .05; Fig. 6.1A], but no significant difference in the
dissociation constant (KD) [t (4) =0.84, P > .05; Fig. 6.1B] for [3H]-CP 55,940 compared to
those exposed to vehicle alone. Chronic exposure to CORT significantly decreased
amygdalar content of the eCB AEA [t (7) = 3.641, P < .01; Fig 6.1C]; however, there was no
change in concentration of 2-AG in mice treated with CORT compared to those receiving
vehicle [t (7) =0.3967, P >.05; Fig. 6.1D]. The fatty acid ethanolamides PEA [t (7) = 2.191,
P <.05; Fig 6.1F] and OEA [t (7) = 2.198, P<.05; Fig 6.1E] were also decreased in the
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amygdala of mice exposed to chronic CORT compared to vehicle. The Vmax for AEA
hydrolysis by membranes isolated from the amygdala of mice exposed to chronic CORT was
significantly increased compared to membranes from vehicle exposed mice [t (4) =2.858,
P<.05; Fig. 6.1G]. There was no significant difference in Km for AEA hydrolysis between
the two groups [t (4) =0.6917, P>.05; Fig. 6.1H].
In the hippocampus, membranes isolated from mice treated with chronic CORT exhibited
a significant decrease in [3H]-CP 55,940 binding site density [Bmax t (5) = 2.336, P <.05; Fig.
6.2A], without a significant change in the KD [t (5) =2.031, P>.05; Fig. 6.2B] compared to
the vehicle treated mice. Chronic CORT treatment resulted in a significant reduction in AEA
content [t (10)=3.534, P <.05; Fig. 6.2C], while there was a large increase in 2-AG content
[t(10)=4.979, P<.0001; Fig. 6.2D] in the hippocampus. As with AEA, PEA [t(10)=3.264,
P<.05; 6.2F] and OEA [t(10)=6.611, P<.0001; 6.2E] also show significant decrease in the
hippocampus as a result of chronic CORT treatment. Consistent with reductions in NAEs in
the hippocampus, there was an increase in the Vmax for AEA hydrolysis in hippocampal
membranes from CORT treated mice [t(4)=3.902, P<.05; Fig. 6.2H] and no change in Km
[t(4)= 1.905, P>.05; Fig. 6.2G] compared to vehicle treated mice.
To quantify FAAH and CB1 receptor expression under conditions of chronic CORT, we
used quantitative real time RT-PCR and mRNA extracted from the hippocampal and
amygdalar brain regions from CORT and vehicle treated mice. Treatment with CORT
resulted in no significant change compared to vehicle treated in mRNA for FAAH
(hippocampus t(6)=1.28, p>0.05; amygdala t(5)= 0.278, p >0.05) or the CB1 receptor
(hippocampus t(6)=0.783, p>0.05; amygdala t(7)= 0.286, p >0.05) (see Table 6.1).
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Figure 6.1 Effect of chronic corticosterone (CORT; 100 µg/mL ) on endocannabinoid
parameters in the amygdala. (A) The binding site density (Bmax) of the CB1 receptor was
reduced by CORT treatment; (B) however there was no effect on the binding affinity (Kd) of
the CB1 receptor. (C) CORT treatment reduced the tissue content of endocannabinoid
anadamide (AEA), but (D) had no effect on the endocannabinoid 2-AG. (G) Consistent with
the reduction in AEA content, CORT treatment increased the maximal hydrolytic activity (Vmax) of the enzyme for AEA degradation fatty acid amide hydrolase (FAAH); (H) but had
no effect on the binding affinity of AEA for FAAH. *Significantly different from control
(P<.05), **(P=.0024 and P=.008), ***(P=.0001) (n=7-8/group for endocannabinoid
quantification; n=4 for CB1 receptor binding parameters and enzyme activity.
129

Figure 6.2. Effect of chronic corticosterone (CORT; 100 µg/mL ) on endocannabinoid
parameters in the hippocampus. (A) The binding site density (Bmax) of the CB1 receptor was
reduced by CORT treatment; (B) however there was no effect on the binding affinity (Kd) of
the CB1 receptor. (C) CORT treatment reduced the tissue content of endocannabinoid
anadamide (AEA), but (D) increased the content of the other endocannabinoid 2-AG. (G)
Consistent with the reduction in AEA content, CORT treatment increased the maximal
hydrolytic activity (Vmax) of the enzyme for AEA degradation fatty acid amide hydrolase
(FAAH); (H) but had no effect on the binding affinity of AEA for FAAH. *Significantly
different from control (P<.05), ** (P=.003); (n=9-10/group for endocannabinoid
quantification, n=4 for CB1 receptor binding parameters and enzyme activity.
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Table 6.1 The effects of chronic corticosterone administration on gene expression of the
cannabinoid receptor and fatty acid amide hydrolase.
Vehicle Treated

CORT

Amygdala
CB1 receptor

1.08±0.35

1.25±0.53

FAAH

1.10±0.18

1.19±0.25

CB1 receptor

1.21±0.33

1.58±0.25

FAAH

1.22±0.19

1.86±0.59

Hippocampus

Twenty-eight day administration of corticosterone (CORT) in the drinking water had no
effect on the expression of mRNA for either the cannabinoid CB1 receptor or fatty acid
amide hydrolase (FAAH) within either the hippocampus or amygdala. Values denote means
±SEM and are expressed as fold changes of mRNA expression.
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Figure 6.3 Effect of chronic corticosterone (CORT; 100 µg/mL ) on endocannabinoids in the
hypothalamus. Chronic 4 week treatment of CORT compared to VEH mice, had no effect on
(A) AEA or (D) PEA but decreased (B) 2-AG and (C) OEA. * Notes significance of P<0.05,
**P<0.01, n=4-6/group.

Figure 6.4 Effect of chronic corticosterone (CORT; 100 µg/mL ) on endocannabinoids in
blood circulation. Chronic 4 week treatment of CORT compared to VEH mice, increased
circulating levels of (A) AEA, (B) 2-AG, (C) OEA, and (D) PEA. * Notes significance of
P<0.05; n=8-10/gro
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Figure 6.5 Effect of chronic corticosterone (CORT; 100 µg/mL ) on endocannabinoids in the
liver. Chronic 4 week treatment of CORT compared to VEH treated mice, increased (A)
AEA and (D) PEA content, but decreased content of (B) 2-AG, and (C) OEA. *Notes
significance of P<0.05, **P<0.01, ***P<0.001; n=8-10/group.

Figure 6.6 Effect of chronic corticosterone (CORT) on mRNA expression of
endocannabinoid parameters in liver. mRNA isolated from liver of VEH and CORT treated
mice showed increased expression of (A) CB1R, (C) MAGL, and (E) NAPE-PLD with
decreases in (B)FAAHand (D) DAGL. * Signifies P<0.05, **P<0.01, ***P<0.001, n=35/group.
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In the hypothalamus we measured eCB levels. There was no significant difference
between groups in AEA (t(6)=0.9194, p=0.3933) or PEA (t(6)=0.3870, p=0.7121) content.
However, significant decreases were noted in 2-AG(t(7)=2.457, p=0.0437) and OEA levels
(t(6)=2.796, p=0.0313).
Blood plasma isolated from mice treated with chronic CORT exhibited an increase in all
parameters measured with significance in AEA content [t (15)=2.294 P <0.05; Fig. 6.4A],
OEA [t(15)=2.159, P<0.05; 6.4C] and PEA [t(15)=2.458, P<0.05; 6.4D], 2-AG showed no
significant difference [t(15)=0.4822, P=0.6367; Fig 6.4B].
Liver samples from CORT treated mice demonstrated an increase in AEA content
[t(15)=3.267,P<0.01; Fig 6.5A] and PEA content [t(15)=2.422, P<0.05; Fig 6.5D]. These
increases were accompanied by increased expression of the CB1 receptor [t(5)=3.05,
P=0.0284; Fig 6.6A] and decreased mRNA expression of the AEA degrading enzyme,
FAAH [t(6)=3.756, P<0.01; Fig 6.6B] and a substantial increase in the biosynthetic AEA
enzyme, NAPE-PLD [t(8)=5.711, P<0.001; Fig 6.6E]. Decreases were noted in 2-AG
content [t(15)=7.019, P<0.001; Fig 6.5B] and OEA [t(15)=3.557, P<0.01; Fig 6.5C]. There
were no significant changes in either MAGL or DAGL mRNA expression, the enzymes
responsible for the degradation of 2-AG [t(5)=1.106, P=.3192; Fig 6.6C and t(6)=0.3895,
P=0.7103; Fig 6.6D respectively].
WAT exhibited decreases in all eCB measures with significance in AEA content
[t(16)=3.588, P<0.01; Fig 6.7A)] The reductions in eCBs were met with decreased mRNA
expression of the CB1 receptor [t(5)=3.899, P<0.05; Fig 6.8A] and mRNA expression of
FAAH [t(6)=2.523, p<0.05; Fig 6.8B]. Decreases were also noted in NAPE-PLD, MAGL,
and DAGL, but none reached significance.
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Figure 6.7 Effect of chronic corticosterone (CORT; 100 µg/mL ) on endocannabinoids in
white adipose tissue (WAT). Chronic 4 week treatment of CORT compared to VEH treated
mice, decreased WAT content of (A) AEA, (B) 2-AG, (C) OEA and (D) PEA. **Notes
significance of P<0.01; n=8-1-/group.

Figure 6.8 Effect of chronic corticosterone (CORT; 100 µg/mL on mRNA expression of
endocannabinoid parameters in white adipose tissue (WAT). mRNA isolated from WAT of
VEH and CORT treated mice showed decreased expression of (A) CB1R, (B)FAAH, (C)
MAGL, (D) DAGL, and (E) NAPE-PLD. * Signifies P<0.05, n=3-5/group.
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Supplementary Figure 6.1 Basal levels in treated mice. Chronic CORT treatment (100
µg/mL) results in (A) 10 fold elevation of plasma CORT (blood samples during light phase)
and (B) a significant increase in weight gain across the 28 days of CORT exposure. **
Signifies P < .005.
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Discussion
In this study we demonstrated that chronic CORT delivered via the drinking water
resulted in a significant decrease of CB1 receptor binding in the hippocampus and amygdala,
as well as a reduction of AEA within both of these limbic structures. The reduction of AEA
was met by an increase in FAAH activity, suggesting that glucocorticoids likely reduce AEA
through an increase in metabolic degradation as opposed to reductions in synthesis (although
this wasn’t directly tested and thus still remains a possibility). Additionally, chronic CORT
increased 2-AG in the hippocampus, but not the amygdala.
Similar to the effects of chronic stress,250-252 chronic CORT decreased CB1 receptor
density in the hippocampus. Chronic stress has not been found to affect CB1 receptor binding
in the amygdala of rats;253 however it was reduced in the present study, suggesting that CB1
receptor density in the amygdala is downregulated by CORT similarly to the effect in the
hippocampus. It is possible that CB1 receptor expression in the hippocampus is much more
sensitive to CORT and as a result is downregulated by the increase in CORT secretion
induced by chronic stress. This hypothesis is consistent with the fact that the hippocampus
exhibits a higher level of glucocorticoid receptors than the amygdala.254
The increase in circulating CORT produced by the current regimen is equivalent to
levels seen during exposure to stress (see (Karatsoreos et al., 2010)47 for temporal and diurnal
effects of this model on circulating levels of CORT); however, during exposure to stress the
increased levels of CORT are pulsatile and transient, and not sustained at a high level as they
are with the current CORT regimen. As a result, the described treatment unveiled a negative
regulation of CB1 receptor in the amygdala that was not seen following stress. This suggests
that CB1 receptor binding is negatively regulated in the amygdala, as well as the
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hippocampus, but it would appear that CB1 receptors within the hippocampus are more
sensitive to CORT exposure than those in the amygdala.
It has been shown that the reduction in CB1 receptor binding in the hippocampus
following chronic stress or CORT treatment was met by a reduction in CB1 receptor
protein,251,253 which is consistent with previous reports demonstrating that removal of CORT
through ADX increases CB1 mRNA in the striatum.256 In the current study however, CORT
did not downregulate CB1 receptor mRNA suggesting that the reduction in CB1 receptor
binding may not be due to a downregulation of gene transcription of the CB1 receptor by
glucocorticoids. It is possible that the downregulation of CB1 receptor mRNA may have
happened at an earlier phase following glucocorticoid exposure and that by 4 weeks this
effect has normalized as a compensatory response to the reductions in active receptor binding
sites, but this hypothesis requires temporal studies to track CB1 receptor mRNA across
phases of CORT exposure.
Chronic CORT dramatically reduced AEA content within both the hippocampus and
amygdala with an increase in AEA-mediated hydrolysis by FAAH, suggesting that CORT
increases FAAH activity, which results in a reduction in AEA content. In support of this
finding, two other fatty acid ethanolamides, which are substrates for FAAH, PEA and OEA,
are also both reduced by chronic CORT. This reduction in AEA and increase in FAAH
following chronic CORT directly mirrors the effects of chronic stress in both rats and mice,
257-259

suggesting that increases in CORT following chronic stress are likely the mediator of

changes in FAAH activity and AEA content. Similar to the changes in the CB1 receptor, this
change in FAAH activity does not appear to be due to an upregulation of FAAH mRNA
following CORT. This effect is not surprising given that glucocorticoids have been found to
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exert negative regulation over FAAH transcription through activation of a glucocorticoid
response element in the FAAH promoter, suggesting that glucocorticoid receptor activation
would downregulate FAAH expression.261 As such, a more parsimonious answer to this issue
would be that chronic CORT modulates post-translational modification of FAAH in a
manner that increases its hydrolytic activity. Ongoing research will seek to determine the
mechanisms underlying the regulation of FAAH activity by glucocorticoids.
Chronic CORT was found to increase 2-AG in the hippocampus, but not amygdala.
This finding is surprising as it is in direct contrast to the effects of CORT injections in the rat,
where chronic CORT (by injection) had no effect on 2-AG in the hippocampus but increased
it in the amygdala.253,261 Moreover, chronic restraint stress in mice has reliably been found to
increase 2-AG in both the amygdala and hippocampus where it has been hypothesized that 2AG synthesis is increased upon repeated restraint application and that this change contributes
to habituated HPA-axis response to repeated restraint stress.258,270 In the rat chronic stress
has been found to increase or have no effect on 2-AG in the amygdala (depending on the
nature of the stress, e.g. chronic restraint vs. chronic unpredictable stress), and either reduce
or have no effect on 2-AG in the hippocampus.250,251,257 Thus, unlike AEA, FAAH or CB1,
the regulation of 2-AG by glucocorticoids within limbic structures appears to be very
complex, and likely is dependent upon the time of tissue collection following stress or
glucocorticoid exposure as well as the fact that the bulk 2-AG measurements may not
represent what is occurring at the synapse. As such, this aspect requires further investigation.
However, given that 2-AG levels within the amygdala are reliably elevated by repeated
exposure to a homotypic stressor,257-259,270 it is likely that the difference in these effects from
those seen following CORT injections261 are due to the interactive nature of the injection
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stress and the CORT levels.
These data demonstrate that chronic CORT suppresses limbic CB1 receptor binding
and AEA signaling, while having variable effects on 2-AG. Given the role of limbic eCB
signaling in the regulation of emotional behavior,114,263 these data would suggest that
glucocorticoid-induced changes in limbic eCB signaling could contribute to shifts in
emotional behavior, especially increases in anxiety and depression like behaviors which
occur following sustained glucocorticoid exposure.264,265 More interestingly in conjunction
with our obese phenotype in these mice, alterations in limbic eCB signaling suggest possible
changes in emotional behavior that are related to hormonally mediated obesity phenotypes.
This could be particularly relevant for the growing rise of co-morbidity of mood and anxiety
disorders with the increasing obesity epidemic.266-268
In the hypothalamus we note no significant changes in either mRNA expression of
the CB1 receptor nor in AEA levels; however, there was a decrease in 2-AG. Generally,
feeding lowers, and fasting raises, hypothalamic, but not cerebellar, levels of 2-AG; however,
it should be noted that these results are from rats.269 Although measurements from the
current study are taken at a basal state we see reduction in hypothalamic 2-AG, which occurs
in response to satiation and is likely a homeostatic mechanism to prevent increases in food
intake. In the CORT animals, this is probably on overdrive, that is the energy balance
dysregulation is originating in the periphery and the observed changes in the hypothalamus
are a compensatory response that is at least trying to keep feeding at bay to prevent
unnecessary eating and facilitate the positive energy balance; however, as noted in previous
chapters, regulation is not sufficient to cap food intake in CORT treated mice.
Turning to the periphery, we found differential effects in the blood, liver, and WAT.
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In the liver we saw significant increases in AEA and PEA with decreases in 2-AG and OEA.
Changes in CORT induced eCB levels in the liver were met by increases in mRNA
expression of the CB1 receptor and NAPE-PLD but decreases in FAAH. There were no
changes in MAGL or DAGL. Results here would suggest an overabundance of AEA in the
liver as a result of increased NAPE-PLD.270 FAAH transcription is not at a sufficient level
for AEA degradation. Furthermore, FAAH is not only necessary for the breakdown of AEA,
but PEA and OEA as well, of which OEA levels are decreased in CORT treated mice
perhaps due to its substrate competition for FAAH (although this needs to be directly tested).
272,281

Spill over from the liver is likely to result in increased presence in the blood of AEA,

PEA, and OEA with no significant changes in 2-AG. Endocannabinoid parameters in WAT
reveal a decrease in AEA, but no changes in PEA, OEA, or 2-AG. mRNA expression of
FAAH was decreased as the expression of the CB1 receptor, but again there were no changes
in either MAGL or DAGL gene expression.
Endocannabinoid levels of WAT presented in this study from CORT treated mice vary
from mouse diet induced studies and from visceral fat from obese patients, both of which
show increases of 2-AG with no changes in AEA.281 However, while the eCB system is
rather well preserved evolutionarily,274 there seems to be no clear pattern of activity in
looking from mouse models or even among individuals. Circulating levels in obese females
with type 2 diabetes showed increases in both AEA and 2-AG in the blood while mRNA
expression in adipose tissue showed a reduction for both CB1 receptor and FAAH,275 but
studies in men looking to link circulating eCBs and cardiometabolic risk in male obese
subjects found a correlation between BMI and 2-AG, but not AEA276 suggesting that several
factors including hormonal cues can affect eCB dysregulation as noted by sex differences in
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eCBs in the amygdala.277 Perhaps these findings should come as no surprise given that sex
and even racial differences can affect both fat distribution and eCB levels.278,279 Findings in
the current study showing decreases in AEA, and decreased expressions of FAAH and CB1
receptor could shed light on cases of obesity induced by factors apart from food intake. A
growing number of social science studies and even animal models of social stress are
showing increases in weight gain as a result of a physiological stress.79-81 Interactions
between hormones and eCBs could offer insight into the obese phenotype in these models,
which are easily translated into the human condition.
Endocannabinoid measurements in the liver have been more consistent across studies.
Similar to CORT treated mice, liver of high-fat fed mice indicate that a high-fat diet
increases hepatic anandamide owing to a major reduction in its degradation by FAAH;
however, anandamide synthesis appears to be unchanged.287 Because the membrane levels of
the FAAH protein are not significantly altered, a high-fat diet may inhibit the activity rather
than the expression of FAAH or as suggested in the CORT model; increase of AEA might
also be accompanied by OEA resulting in a competition for FAAH deactivation as suggested
in the CORT model. The upregulation of hepatic CB1 receptor observed in mice on the highfat diet is similar to the reported upregulation of CB1 expression in CORT treated mice and
could involve similar underlying mechanisms. Clinically, increased eCB tone has also been
linked with the development of NAFLD.289
Induction of AEA is reported to decrease rather than increase fatty acid synthesis in rat
hepatocytes through a noncannabinoid mechanism mediated by arachidonic acid, as indicated
by the ability of the nonspecific FAAH inhibitor PMSF to block this effect.283 Thus, four
weeks of CORT treatment leads to increases in AEA, decreased mRNA expression of Srepb-
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1c, and the development of NASH as noted in Chapter 5, suggesting that increased AEA
decreases fatty acid synthesis in the liver. To confirm this hypothesis it would be ideal to
look at AEA levels after a week of CORT treatment when fact acid synthesis is more active.
The lipogenic response to CB1 receptor activation in isolated hepatocytes also argues
strongly for a direct hepatic effect under in vivo conditions, although it does not rule out an
additional, centrally mediated effect through neuronal or hormonal pathways. Inhibition of
this lipogenic response in CB1–/– mice both here and in case of high-fat diet, further confirm
the lipogenic role of hepatic CB1 receptor.287 The overall story here suggests that increased
CORT leads to increased NAPE-PLD in the liver, which then increases AEA synthesis. This
mechanism likely contributes to the development of not only CORT induced obesity and
subsequent increases in various metabolic parameters, but also fatty liver in control mice, as
indicated by the absence of both changes in CB1–/– mice on CORT.
In summary, we showed that chronic CORT treatment had differential effects on eCB
parameters both centrally and peripherally. Results presented here differ from those
presented by groups studying eCB regulation in cases of both chronic stress and from those
studying regulation under a high fat diet, suggesting a unique and fined tuned role of the eCB
system in regulating GC induced metabolic disturbances and the operation of multiple
regulatory factors on the eCB system. Inferences of eCB regulation of GC action come most
clearly from CB1R-/- mice as described in chapter 5 where the CORT induced metabolic
syndrome phenotype was prevented by global knockout of CB1 receptor; CB1R-/- mice also
indicate that a lack of CB1 receptor produces HPA-axis dysregulation.284 However, analysis
of regional concentrations of the eCB parameters sheds light into the central verses
peripheral mediation of the eCB in GC mediated metabolic syndrome. In the next chapter we
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make use of specific CB1 receptor inhibitors and liver specific knockout of the CB1 receptor
in order to further elucidate central verses peripheral effects. eCB levels in mice with a
normalized food
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Chapter 7: Determination of central versus peripheral endocannabinoid regulation
Abstract
We previously reported through the use of cannabinoid CB1 receptor deficient mice, the
role of endocannabinoid (eCB) signaling as a mediator in glucocorticoid (GC) mediated
metabolic syndrome. We have also shown that the detrimental metabolic effects of increased
exposure to corticosterone (CORT) occur independently from food intake. It has recently
been demonstrated that peripherally restricted CB1 receptor antagonist, AM6545, is sufficient
for weight-independent improvements in glucose homeostasis, fatty liver and plasma lipid
profile in mice with genetic or diet-induced obesity. The aim of the current study was twofold: first to replicate findings using pharmacological tools in the way of AM251, a global
CB1 receptor antagonist, and secondly to determine the role of eCB signaling in GCmediated obesity and mouse model of the metabolic syndrome independent of central feeding
effects by selectively targeting peripheral CB1 receptors. With the exception of circulating
triglyercide levels which were increased, AM251 treatment was able to prevent the negative
metabolic actions of CORT. Subsequent CORT induced increase in total body weight, the
weight of the abdominal/gonadal fat pads, and hyperphagia were substantially attenuated
with the peripheral antagonist AM6545, indicating that peripheral CB1 receptor activation
contributes to hormonal and metabolic abnormalities and continues to regulate appetitive
signals. In conjunction with prior studies, this data suggest that GC exposure produces an
elevation of tonic eCB signaling which promotes the development of metabolic syndrome,
through changes in feeding behavior in conjunction with peripheral metabolic processes.
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Rationale
In the previous chapters we have established a role for endocannabinoid (eCB) system
signaling in alternative models of metabolic syndrome. In mouse models where circadian
rhythms of clock genes and glucocorticoid (GC) signaling is blunted (Chapter 3) or in the
case of increased corticosterone (CORT) exposure with blunted clock gene expression
(Chapter 4), both were resistant to metabolic dysregulation by global knockout of the CB1
receptor. Both models also led to variations in eCB signaling (Chapter5 and Chapter 6). In
conjunction with eCB system measurements, it appears that at least in the CORT water
model, CORT increases NAPE-PLD in the liver resulting in increased AEA synthesis, which
spills into the circulation. This increased AEA in the liver, and possibly other sites reached
by the circulation, drives a shift in metabolic function that accelerates carbohydrate oxidation
and compromises fat metabolism, resulting in the development of fatty liver and fat stores in
the adipose tissue. These observations along with subtle changes in activity level in CORT
CB1R-/- mice (Chapter 5) and the maintained weight gain in pair-fed CORT mice (Chapter
4), suggest that eCBs and CB1 receptor regulate peripheral energy metabolism. While we are
aware that the weight effect is in part due to central changes as noted by decreased food
intake (Chapter 5) and CORT induced changes in eCB parameters in the limbic region
(Chapter 6), the aim here was to parse central and peripheral endocannabinoid regulation to
find the main site of interaction between GCs and the eCB system. In this way we first made
use of the global CB1 receptor antagonist, AM251 to replicate the effects of the global
knockout and identify any side effects of daily injection. We next made use of the newly
available and characterized peripheral specific CB1 receptor antagonist, AM6545.251
Given the success of the peripheral antagonist, we moved to look at the effects in a
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hepatocyte specific CB1R-/- mouse (LCB1R-/-). While the CORT induced phenotype is
blocked at every level in the CB1R global knockout, the role of adipose tissue is minor
compared with that of the liver.

Experiment design
Three different cohorts of animals were used to carry the following studies. In the first
group 26 mice were used in total, with 5 in both vehicle and CORT treated groups receiving
saline injections and 8 in both vehicle and CORT treated groups receiving the global
antagonist AM251. The second group receiving the peripheral antagonist AM6545 was run
as the AM251 study. In the final study making use of LCB1R-/- mice, 28 mice in total were
used, 6 WT on vehicle, 6 LCB1R-/- on vehicle, 8 WT on CORT, and 8 LCB1R-/- on CORT.

Results
There was a significant interaction between CORT and treatment of both AM251
(F(1,15)=5.102, p=0.0392) and AM6545 (F(1,20)=4.745, p=0.0416; Fig 7.1A) on weight
gain. Bonferroni posthoc revealed that the effect of CORT was only present in saline injected
mice (p<0.05). This weight loss can only partially be contributed to reduced adiposity as
gross measures in WAT, while decreased (Fig 7.1 E, 7.2B-E, 7.3B-E), are not completely
absent in mice treated with AM251 or AM6545. However, oil red o staining demonstrates
decreased presence of lipids in the livers of CORT treated mice with injections of either
AM251 (Fig 7.2 F-I) and AM6545 (Fig 7.3 F-I), suggesting that liver weights are also
decreased as with CB1R-/- CORT treated mice in Chapter 5.
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Figure 7.1 Metabolic effects of chronic treatment with AM251 and AM6545 in CORT treated
mice concurrently for 4 weeks. Both drugs delivered at 10/mg/kg/d, i.p, were able to reduce
(A) weight change, (E) adiposity, and (B) plasma leptin. AM251 was able to reduce (C)
plasma insulin while there was no change in mice treated with AM6545. Conversely,
AM6545 was able to reduce circulating (D) triglyceride levels while levels seemed to be
increased in AM251 treated mice. (F) Food intake was also decreased with both drugs but to
a larger extent with AM6545. Bars with the same letter are not statistically different from
one another. **indicates P<0.01 as determined by two-way ANOVA and Bonferroni
posthoc.
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Figure 7.2 Histology of liver and WAT in AM251 treated mice. (A) Adipocyte length as
quantified by random selection of adipocytes (n=5-8/group). Representative images of H&E
stain of WAT isolated from (B) Saline injected VEH, (C) AM251 injected VEH, (D) Saline
CORT and (E) AM251 CORT, images taken at 10x. Oil red O staining demonstrated the
ability of (I) AM251 to prevent the development of NAFLD as present in (H) saline injected
CORT treated mice and resembled healthy livers of (F) saline VEH and (C) AM251 VEH
mice. Representative liver stains shown at 10x. N=5-8/group. Bars with the same letter do
not statistically differ from one another.
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Patterns of circulating hormones exhibited intermediate effects in leptin and insulin in
CORT treated mice with AM251 treatment compared to control mice. Interestingly, AM251
CORT mice showed increased levels of circulating triglycerides (F(1,15)=78.13, p<0.001),
whereas this level was decreased with AM6545 injections (F(1,60)=8.170, p=0.0114). As
with AM251, AM645 also showed intermediate levels of insulin and leptin.
Specific knockout of the CB1 receptor in the liver (LCB1R-/-) was unable to either prevent
weight gain in CORT treated mice, or improve overall adipose levels, and circulating leptin
levels (Fig 7.4 A, B, and E respectively). Insulin levels in LCB1R-/- CORT treated mice
were statistically greater than in WT CORT mice (interaction F(1, 21)=4.717;p=0.0415, Fig
7.4F). Interestingly, despite no significant decrease in gross WAT weight, adipocyte size was
decreased in these mice (Fig 7.5 A-E). LCB1R-/- mice also showed an overall decrease in
liver weight, though not to the levels of control mice (interaction F(1,19)=4.755, p=0.042,
genotype F(1,19)=10.54, p=0.0042; Fig 7.4C). This data is consistent with the decreased
lipid content in LCB1R-/- CORT treated mice as noted by oil red o stain (Fig 7.5 G-J), and
decreased circulation of triglycerides (interaction F(1,23)=19.04; p=0.0002; genotype
F(1,23)=10.65, p=0.0034; Fig 7.4D). Decreased ALT levels, an indicator of decreased liver
damage in LCB1R-/- mice further validated the large effect of eCB signaling in the liver.
ALT levels were noted by an interaction between groups (F(1,22)=13.23; p=0.0015) with
posttest revealing that increased levels were present in WT CORT mice alone (p<0.01, Fig
7.5F)
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Figure 7.3 Histology of liver and WAT in AM6545 CORT treated mice. (A) Adipocyte length
as quantified by random selection of adipocytes (n=5-8/group). Representative images of
H&E staining of WAT isolated from (B) Saline injected VEH, (C) AM6545 injected VEH,
(D) Saline CORT and (E) AM6545 CORT, images taken at 10x. Oil red O staining
demonstrated the ability of (I) AM6545 to prevent the development of NAFLD as present in
(H) saline injected CORT treated mice and resembled healthy livers of (F) saline VEH and
(C) AM6545 VEH mice. Representative liver stains shown at 10x. N=5-8/group. Bars with
the same letter do not statistically differ from one another.
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Figure 7.4 Metabolic effects of chronic CORT treatment in LCB1R-/- mice. Specific
knockout of the CB1 receptor in hepatic cells did not prevent CORT induced increases in (A)
weight change, (B) adiposity, or (E) circulating leptin, and resulted in a slight increase of
circulating (F) insulin. However, hepatic cell knockout in CORT treated mice was able to
decrease overall (C) liver weight and circulating (D) triglycerides, n=6-8/group. Bars with
the same letter are not statistically different from one another as determined by two-way
ANOVA (±SEM). *P<0.05, ***P<0.001.
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Figure 7.5 Histology of liver and WAT in LCB1R knockout CORT treated mice. (A)
Adipocyte length as quantified by random selection of adipocytes (n=5-8/group), was
decreased in liver specific (LCB1KO) mice. Representative images of H&E staining of WAT
isolated from (B) WT VEH, (C) LCB1KO VEH, (D) WT CORT and (E) LCB1KO CORT,
images taken at 10x. Oil red O staining demonstrated the ability of (J) LCB1KO to prevent
the development of NAFLD as present in (I) saline injected CORT treated mice and
resembled healthy livers of (G) WT VEH and (H) LCB1KO VEH mice. Representative liver
stains shown at 10x. N=5-8/group. Bars with the same letter do no statistically differ from
one another. (F) ALT, an indicator of liver damage is also reduced in LCB1R KO mice.
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Discussion:
In this chapter, we confirmed findings in Chapter 5 that a global inhibition of eCB
signaling through the CB1 receptor prevents CORT induced metabolic anomalies with the
global CB1 receptor antagonist AM251 on all levels including weight gain, adiposity,
circulating levels of leptin and insulin, as well as prevent the development of NAFLD.
Additionally, AM251 resulted in an increase in circulating levels of triglycerides. It has been
suggested by others that increases in circulating triglycerides are the result of an increase in
clearance rate;286 however, we would need to measure VLDL particle and TG transport rates
to confidently say this was the case. Interestingly, concurrent treatment of AM251 and
CORT did not result in decreased food intake until the final week of treatment, unlike the
decreased intake that was noted in global knockout mice. It is also possible that food intake
was impaired in the first few days of treatment but regained to levels of untreated animals as
noted in studies of high fat diets, though the anorectic affect varies across studies.287,288
The primary aim of this paper was to separate the central and peripheral affects of CB1R
blockade. As such, and having seen no clear negative side effects of daily chronic injections,
we made use of the peripheral specific CB1 receptor antagonist AM6545. Concurrent
treatment with AM6545 and CORT resulted in an absence of weight gain and a decrease in
adiposity, and circulating levels of leptin, insulin, and triglycerides, although the latter were
not to the extent of levels in VEH mice. AM6545 also prevented the development of
NAFLD. Despite lack of AM6545 penetration into the brain,251 mice on the drug still
showed decreased food intake possibly through responses to fast-fed hormonal cues coming
from adipose tissue among other possible communication axes.289 Studies have suggested
that the orexigenic action of intestinal eCBs occurs via stimulation of CB1 receptor located in
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vagal afferent neurons, in particular, that CB1 receptors on afferent vagal neurons may be
involved in the transmission and processing of gut food-stimulated signals important in the
control of food intake and meal size.290,291 However, a more recent study has demonstrated
that neither vagal gut afferents, nor gut afferents traveling via the sympathetic nervous
system, are required for Rimonabant to inhibit food intake.292 If this is indeed the case, it will
be important to determine the exact location of the eCB control of residual feeding.
In conjunction with results from previous chapters, the ability of AM6545 to prevent
weight gain further suggested a strong role in liver eCB signaling as a large contributor to
metabolic abnormalities noted in WT CORT mice. To confirm this hypothesis, we made use
of hepatocyte specific knockout of the CB1R (LCB1R-/-). CORT treatment in LCB1R-/- mice
revealed a unique role of liver endocannabinoid signaling, whereby liver knockout was not
sufficient to prevent weight gain, adiposity or circulating leptin levels (results consistent with
the remaining adipose levels); however, knockout here did result in decreased levels of
circulating triglycerides and prevented the development of NAFLD. Unfortunately, we were
unable to monitor food intake in these mice as they were a gift from collaborators at the NIH
and had to remain in quarantine during the duration of the study.
In summary, using a peripherally-only active CB1 antagonist, we showed that the
endocannabinoid system is a mediator of CORT induced metabolic syndrome primarily
through peripheral mechanisms. Although findings strongly implicate hepatic CB1 receptors
in the development of hormonal induced obesity and related metabolic changes, they do not
exclude the possibility that endocannabinoids acting on CB1 receptors in the gut, adipose
tissue, or vagus nerve, or communication between these organs, which may occur through
neural pathways, may also exist. Further, residual weight and lipid clearance in the LCB1R-
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/- mice could also be the result of CB1R in the stellate cells of the liver which have been
shown to activate hepatic lipogenesis via paracrine system in mice chronically exposed to
ethanol as may be the case here as CORT is dissolved in 1% ethanol.293
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Chapter 8: Future Directions and Concluding Remarks
Future Directions
Studies presented in the previous chapters revealed that a disruption in external light cues
on circadian (daily) rhythms resulted in altered hypothalamic pituitary adrenal (HPA) axis
activity and a concurrent decrease in clock gene expression. Alternatively, an increase in
circulating corticosterones (CORT) also resulted in altered clock gene expression. Both
phenotypes altered metabolic regulation, resulting in increased weight gain, adiposity,
developed NAFLD, and showed imbalances in hormones secretion. While clock gene
expression likely plays a role in both mouse models through fluctuations of CORT, it is
difficult to see where the pathways interact, rather than work independently. However, the
endocannabinoid (eCB) system, which is well documented in the adaptive stress response
and is itself regulated by glucorticoid fluctuations and is further present in most peripheral
organs where it regulates energy homeostatis, proved to be vital in the pathologies noted in
our mouse models. Although analyzed in greater detail in the high CORT model, we
observed the ability of endocannabinoid inhibition through the CB1 receptor to prevent
weight gain and high hormonal levels in both circadian shifted (low CORT) and exogenously
delivered (high) CORT models.
In order to move forward with the circadian disrupted model, it would be ideal to
determine the precise mechanism of action regarding the decreased GC circulation noted in
the LD10 mice. Future experiments will seek to determine (1) if the noted down-regulation
was proceeded by an upregulation at an earlier time point as noted in other models of
hypocortisolism,50,59 (2) the down-regulation of specific receptors on different levels of the
axis (hypothalamus, pituitary, adrenals, target cells), (3) reduced biosynthesis or depletion at
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the various levels of the HPA axis yet to be measured (ACTH, adrenal corticosterone levels)
and/or (4) increased negative feedback sensitivity to GCs. Given that low levels of GCs can
lead to autoimmunity and inflammation as a result of compensatory hyperactivity of other
mediators, it would also be interesting to fully study the impact of an immune challenge in
this model of circadian disruption.
Additionally, we plan to look at the functional role of CORT in circadian shifted mice
through CORT replacement. We hypothesize here that restoration in CORT levels will
subsequently increase clock gene expression to the levels of control mice. As a preliminary
study, we decided to continue with our CORT drinking model and from week one gave mice
either water, VEH or CORT to drink while exposed to either a 24 hour day (12 hour light:12
hour dark) or a 20 hour day (10 hour light:10 hour dark).
Weekly measurements revealed a significant increase in weight change in CORT LD10
mice compared to VEH LD12 and water LD12 mice starting at week 3 as noted by two-way
ANOVA and subsequent posthoc test (p<0.05; Fig 8.1A). Percentage of body fat showed a
main effect of CORT treatment (F(1,50)=42.03, p<0.0001; Fig 8.1B). Unfortunately, VEH
treatment seemed to have a negative effect on weight gain and prevented LD10 mice from
gaining weight.
Metabolic parameters showed a similar additive effect when CORT treatment was paired
with a LD10 cyle. Analysis of treatments across the day showed an increase in insulin levels
at ZT12 in CORT LD12 mice compared to VEH LD12 and VEH LD10 mice (p<0.01; Fig
8.2A). CORT LD10 mice had greater levels at all measured time points. Leptin levels
exhibited increased levels in CORT LD12 and CORT LD10 mice compared to both VEH
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Figure 8.1 Simultaneous CORT treatment and altered light cycle have an additive effect on
weight gain and adiposity. Mice were given water, VEH (vehicle treatment of 1% ethanol in
water), or 25 µg/mL CORT (corticosterone dissolved in 1% ethanol) and placed on either a
12 hour light:12 hour dark or a 10 hour light: 10 hour dark light system. (A) Shifting alone
on a water solution significantly increased weight compared to LD12 mice given water
compared to VEH LD12 mice at every time point starting at week 3. (B) Overall adiposity
was increased in CORT treated mice in both lighting conditions. *P<0.05, **P<0.01,
***P<0.001; n=13-15/group.

Figure 8.2 Metabolic effect of simultaneous CORT treatment and altered light cycle. (A)
Plasma insulin was significantly increased in CORT treated mice at all time points in CORT
LD10 mice and at ZT 12 in CORT LD12 mice. (B) Plasma leptin was also increased in both
CORT treatments at ZT 6 and at ZT12 and 18 in CORT LD10 mice compared to VEH mice.
(C) Plasma triglycerdies in CORT LD10 mice are at comparable levels of VEH mice at all
time points but ZT 18 where they are significantly higher. *P<0.05, **P<0.01, ***P<0.001,
n=4-5/group and time point.
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groups at ZT6 and at ZT18 CORT LD10 mice had greater levels than all other experimental
groups (p<0.001; Fig 8.2B). Interestingly, CORT LD10 mice had levels of triglycerides
comparable to both VEH groups, and lower than CORT LD12 mice, at ZT 6 and ZT 12; but
had significantly higher levels than all other experimental groups at ZT 18 (p<0.001; Fig
8.2C).
While CORT treatment was unable to reverse the physiological effects of a disrupted light
cycle, treatment did appear to reestablish rhymicity in clock gene expression. This trend was
most clearly seen in Per1 (Fig 8.3B) and Per2 (Fig 8.3C) gene expression in WAT. Per1
expression of both VEH LD12 mice (F(2,12)=5.291;p=0.0271) and CORT LD10
(F(2,12)=5.181; p=0.0286) exhibited rhythmicty while expression in VEH LD10 and CORT
LD12 mice remained flat. This blunted expression in VEH LD10 and CORT LD12 resulted
in decreased expression at ZT12 compared to both VEH LD12 and CORT LD10 (p<0.01). A
similar trend was seen for Per2 gene expression with rhythmicity in VEH LD12
(F(2,12)=22.36; p<0.001; Fig 8.3C) and CORT LD10 (F(2.12)=5.35, p=0.0365). Rather than
a flat expression, VEH LD10 mice and CORT LD12 mice exhibited a rhythmic pattern of
Per2 gene expression (F(2,12)=13.51; p=0.0014) and F(2,13)=54.67; p<0.0001 respectively),
but instead of increased expression at ZT12 VEH LD10 had their nadir while CORT LD12
mice had an intermediate expression as increased expression is not noted until ZT18. This
differential expression between groups resulted in a difference in expression between VEH
LD12 and VEH LD10 at ZT 6 (p,0.05). At ZT12 VEH LD10 and CORT LD12 had
significantly lower expression (p<0.001) and higher expression at ZT18 (p<0.05) compared
to VEH LD12 and CORT LD10. CORT LD10 mice showed an intermediate expression in
mRNA expression of Per1 in the liver showing no significant difference from either VEH

160

LD12 or VEH LD10. VEH LD12 was, however, greater at all time points and significantly
so at ZT12 (p<0.05) compared to VEH LD10 mice. Expression patterns of Per2 mRNA in
the liver are a bit more complicated and does not seem to follow the trends noted in WAT.
Both VEH LD12 (F(2,10)=37.08, p<0.0001)and VEH LD10 (F(2,12)=4.58, p=0.0387)
showed a rhythmic expression pf Per2 gene expression (Fig 8.3E) but seemed to be in the
reverse of one another with increased expression in VEH LD12 at ZT18 and nadir at ZT6
while VEH LD10 had increased expression at ZT6 and a nadir at ZT12 with little increase at
ZT18.
This CORT replacement study needs to be repeated using a means of CORT
administration that does not require ethanol, but, preliminary results are promising with
elevations in CORT in the shifting mice corresponding to increased clock gene expression to
levels compariable to VEH non disrupted mice. How elavations in clock gene expression
translate to possible metabolic, cognitive decline, or behaviour,166 are yet to be fully
determined, but Chapter 3 and 4 would suggest that a misalignment in the expression of
enzyme and receptor systems could be to blaim. Development of a means to keep these
systems in sync could be vital in treating the metabolic syndrome.
Future studies also aim to characterize the possible unique role that the eCB system plays
in the circadian disrupted mice. It could be the case here that chronic disruption acts like a
chronic stressor. Prior studies have shown repeated activation of the HPA-axis by restraint
stress also demonstrates habituation as measured by a progressive decrease in plamsa
corticosterone with increasing numbers of restraint episodes.150 The eCB systems aid in this
response through increases of 2-AG in the hypothalamus.150 Given that we see no difference
in food intake in disrupted mice, activation of the system on this level does not seem to affect
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food intake, thus it remains to be determined how cross talk between the brain and the
periphery leads to metabolic changes in these mice.

Figure 8.3 Simultaneous CORT treatment and altered light cycle show a unique interaction
in circulating CORT levels and clock gene expression. (A) Plasma CORT is decreased in
VEH LD10 mice compared to VEH LD12 mice at all times points where as it is increased in
CORT LD 12 mice. CORT LD10 mice have significantly greater levels at ZT 6 and ZT 18.
In white adipose tissue (WAT), clock gene expression of (B) Per1 and (C) Per2 is decreased
in VEH LD10 mice and CORT LD12 mice but CORT LD10 mice exhibit similar expression
as VEH LD12 mice. A similar pattern of expression is noted in (D) Per1 mRNA in the liver
with CORT LD10 demonstrating an intermediate expression. All groups had reduced (E)
Per2 mRNA in the liver compared to VEH LD12 mice.
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Concluding Remarks
Environmental experience
Since stressful experiences do not exist in a vacuum, it is important to study their
existence in all environments and forms, as highlighted in this work though novel means to
alter HPA-axis activity. Disturbances in environmental lighting cues and exogenous CORT
in the drinking water disturbed endogenous CORT circulating levels and rhythm and led to
the dysregulation of circadian rhythms and eCB signaling. This effect was especially noted
in the periphery leading to impaired energy metabolism. CORT treatment did lead to
decreases of CB1R binding site density in both the hippocampus and amygdala and also
reduced AEA content and increased FAAH activity within both structures, suggesting that
emotional state can also play a role in the CORT induced phenotype and as increased GC
have been well linked to depression.8 Since the social environment impacts the body in large
part through the brain, future research should explore brain body crosstalk and how
emotional state can affect the periphery, including metabolism. One possibility, as touched
upon in previous sections, is the desynchronization between regulatory systems as the result
of circadian dysruption. Given the tightly and finely tuned regulation of the endocannabinoid
system on stress and the stress response, circadian rhythm disruption could result in eCB
signaling that acts to regulate CORT levels and prepare the system for mediating a response
to an acute stressor, while simultaneously producing a maladaptive response elsewhere. For
this reason, moving forward it is necessary to determine the precise mechanism of action
regarding the decreased GC circulation in circadian disrupted mice and the level of eCB
interaction.
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With this mindset, researchers and policy makers are beginning to pay more attention to
the “ecology of stress” because this concept is able to integrate both environmental and
biological mechanisms to explain health disparities. Residential chronic stress is of particular
interest because it is difficult or impossible to avoid; moreover, it is present on a regular
basis, as the residential environment is part of daily living. Again, it is these everyday
stressors- e.g. crowding, noise pollution, violence-that have been shown to have a greater
effect on long-term well being than the less frequent, but major class of stressors generally
referred to as life events.8 Neighborhood stress is also interesting because it goes beyond the
individual and can lead to the deterioration of the capacity of the population within a
neighborhood to resist the pathological effects of ambient stress. Social structures, such as
those found at the neighborhood level, determine at least in part, the exposure of individuals
to stressors, as well as stress-buffering resources. Stressors presented in such an environment
can include reduced or lack of access to opportunity or to the necessary means to achieve
ends, as well as structural reduction in available alternatives or choices.294
Hypercortisolism has been linked to cognitive decline, immunosuppression, obesity
and insulin resistance making it, theoretically, a key biological mechanism, linking
disadvantage to poor health.21 However, the experimental evidence linking chronic stress to
elevated cortisol has been mixed.14 Cortisol increases in response to acute stressors in
laboratory settings have been well reported, but there is inconsistent evidence concerning the
effects of long-term exposure to chronically stressful environments. Studies looking at
individuals at varying degrees of employment and the impact of job-demand and job-control
work stress on cortisol response on waking and throughout the day, found varying outcomes
for males and females depending on job demands versus job control and depending, as well,
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on levels of SES.295 Mainly, low job control was associated with elevated cortisol
throughout the day in men while job demands influenced cortisol over the day only in
women. The greatest cortisol output was recorded from lower SES women who experienced
high job demands. Low job control was more common in lower than higher SES men.
Cortisol responses to waking were affected by job demands but not job control. The impact
of high job demands varied with SES, leading to greater waking responses only in lower SES
participants.9 In contrast to these studies showing elevation in GC responses to stress, there
is growing literature documenting decreased GC output (hypocortisolism). This occurrence
was recently identified in the interaction between neighborhood social and physical
characteristics and patterns of diurnal cortisol secretion.57 In particular residents in
neighborhoods with high levels of perceived and observed stressors or low levels of social
support experience a flatter rate of cortisol decline throughout the day. Moreover, mean
cortisol levels were found to be lower in higher stress, lower support neighborhoods.57 This
study adds to the growing evidence of hypocortisolism among chronically stressed adult
populations and, further, challenges the current hypothesis that increased cortisol levels are
the sole mechanism linking social disadvantage to poor health.21, 251,296,297 The differences in
study results between hypercortisolism and hypocortisolism, highlight the need for proper
analyses of psychobiological pathways which must take into account variations in exposure
to chronic stressors, as well as differences in responses to stressors.
Similar to the neighborhood environment, the workplace is an interesting setting to
study chronic and repeated stressors. As with those in stress-producing neighborhoods,
lower SES individuals who have less mobility and control in their jobs have less ability to
avoid stressors; they also face continuing demands or health threats that can exacerbate the
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effects of stess.298 To date there has been a strong association between shift-work with an
increased risk of hypertension, metabolic syndrome, dyslipidaemia, diabetes mellitus and
vascular events.299-302 These effects remain strong when adjusted for SES; however, shift
workers, in general, are more likely to have worse SES than day workers. Alternatively
stated those from lower SES are more likely to work jobs with unstable shift assignments. In
this form of work, even a single overnight shift, is sufficient to alter health independent of
health behaviors.303-309
One possible link to shift work and poor health could be the well reported findings on
disruptions to circadian rhythms and impaired sleep and sleep quality as touched upon earlier
in this review.310 In order to study the impacts of sleep fragmentation on metabolic variables
Baud et al. developed a 14-day model of instrumental sleep fragmentation in mice, and
showed an impact on both brain-specific and general metabolism. Of particular interest the
group demonstrated an increase of food intake without change in body weight, development
of glucose intolerance, and perhaps most interesting an increase in the circadian peak of GCs
which may account for the observed metabolic effects.311 Such studies highlight the
usefulness of proper animal models to explore and map out mechanisms of the human
condition.

Final Summary
Research on social stress has grown in recent years with both social and bench scientists
considering its physiological and biochemical role in health outcomes. However, as the
literature has grown, the story has become more complex with many arguing that decreased
GC circulation in the case of chronic stress could be to blame rather than the widely held
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dogma of hypercortisolism. In order to fully understand the role of GC mediated health
issues, researchers must first clearly understand that there are varying levels of stress; and
moreover, that the system does not act in isolation. Thinking in terms of allostasis and
allostatic load, researchers can paint a broader picture that details a dynamic network of
biomarkers, themselves influenced by an individuals genetic make-up, developmental
history, and behavioral and psychological states.12
As detailed in the introduction chapter and work presented in this dissertation, advances
in translational animal and human research has led to several advancements in the world of
stress physiology and its role in the development of obesity and the metabolic syndrome. It
is clear that human studies cannot fully control for all social environments encountered,
especially those using retrospective analysis to measure risk factors over a lifetime. In
addition, many risk factors are correlated, such as social class, material resources,
neighborhood environment, and personal health behaviors and the potential for confounding,
both measured and unmeasured variables, is quite high. When attempting to separate the
effects of early life environment and later social status in human studies, researchers face the
challenge of including study participants in all combinations of exposure categories and risk.8
Using animal models in combination with human studies provides a novel opportunity to
understand how social experiences become biologically embedded across the life course.
Animal models provide a means to explore the questions raised by the epidemiologic work in
humans and further allow manipulation of selected experimental variables for the
investigation of psychosocial factors affecting vulnerability to stress exposure and HPA axis
response.58,312-314
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Prior animal and human studies on the role of endocannabinoid signaling on HPA axis
activity laid the foundation for my studies. My work in rodents would suggest that GCinduced changes in limbic endocannabinoid signaling, in the presence of chronic GC
exposure, could contribute to shifts in emotional behaviors, especially increases in anxiety
and depression-like behaviors. Further work looking at the role of endocannabinoid
signaling and the development of obesity and a metabolic syndrome phenotype, found the
predominant mechanistic response for metabolic dysregulation was peripheral. Nevertheless,
with the rise in co-morbidity of mood and anxiety disorders with the surge in the obesity,
changes in limbic endocannabinoid signaling could impact behavior and hormonal shifts that
result in an obese phenotype in an independent but meaningful way.124 Additional work
highlighted the role of endocannabinoid signaling in a mouse model of circadian disruption, a
model developed based on the human experience of shifted or shortened days based on work
shifts or inconsistent exposure to external light. While the precise mechanism of action is yet
to be determined, preliminary experiments, and work presented here, would suggest it
provides a compensatory response to moderate the blunted GC response in disrupted animals.
It would be of interest to see how endocannabinoid signaling maps out in the human body for
those experiencing circadian disruption as in shift workers or even those who have
fragmented sleep. Data presented here was the first evidence that the endocannabinoid
system may also be involved in the development of obesity from environmental
manipulations. In addition to this novel evidence, these studies are also the first to provide a
putative candidate system mediating the effects of circadian disruption on metabolic
function. As peripherally restricted CB1 receptor antagonists are gaining steam as a novel
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anti-obesity drug, these data suggest they may bear utility in treating metabolic syndrome and
obesity from multiple causes.
A better understanding of the interplay between the environmental experience and an
individual’s stress behavioral and physiological response provides the tools to study stress on
the level of the population, in the case of this review the role of the neighborhood and work
environments. Stress and adversity among low SES neighborhoods come in many forms and
varieties, including exposure to neighborhood violence, disorganized and dysfunctional
schools, signs of deteriorations (e.g. vacant lots, litter, graffiti), gangs, inadequate services,
discrimination, job insecurity, and lack of job control.315 Future work in this regard will be
focused upon unpacking these barriers, each of which can independently have numerous
effectors, on not only GC secretion but its regulatory components as well.
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